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GENERAL INTRODUCTION 
 
Venous thromboembolism (VTE) is a collective term for pathological thrombus 
formation and embolization in the venous system. Deep vein thrombosis of the leg 
and  pulmonary  embolism  represent  the  main  phenotypes  of  VTE.  The  overall 
incidence of VTE in developed countries is about 0.15% per year, varying from 
less than 0.005% in individuals younger than 15 years to as high as 0.5% at the age 
of  80.
1-3  More  than  a  century  ago,  Virchow  postulated  three  main  causes  of 
thrombosis: stasis of the blood, changes in the vessel wall, and changes in the 
composition of the blood.
4 Known risk factors for VTE fall in the first (stasis) and 
the third groups (blood composition), though nowadays a different classification is 
made into genetic and acquired risk factors.
5 Well established acquired risk factors 
for VTE include immobilization, surgery, major trauma, pregnancy, puerperium, 
malignancy,  hormonal  replacement  therapy  or  oral  contraceptives  and  long-
distance  travel  (i.e.,  >4  hours).
5  VTE  that  occurs  within  3  months  from  the 
abovementioned acquired risk factors is considered provoked or secondary VTE.
6 
In absence of these risk factors VTE is considered idiopathic or unprovoked. Well 
known  genetic  risk  factors  for  VTE  include  factor  V  Leiden,  prothrombin 
G20210A mutation and hereditary deficiencies of natural anticoagulant proteins 
(i.e., antithrombin, protein C or protein S).
5 However, in as many as 50% of VTE 
cases, none of these known risk factors are present.
3 Therefore, search for new risk 
factors of VTE is a matter of intensive ongoing research. 
 
It  is  widely  acknowledged  that  arterial  thromboembolism  (ATE),  comprising 
coronary heart disease, stroke or transient cerebral ischaemic attack, and peripheral 
artery disease is one of the leading causes of death and disability particularly in the 
developed countries.
7 ATE is mostly secondary to atherosclerosis, which is caused 
by various risk factors, such as hypertension, hyperlipidemia, diabetes, smoking, 
obesity,  microalbuminuria  and  metabolic  syndrome.
7  These  and  other  less 
prevalent  atherosclerosis  risk  factors  are  pathogenetically  interrelated  and 
frequently cluster in individuals. 
 
Association between atherosclerosis risk factors and VTE: 
Thromboembolic diseases of venous and arterial systems have been historically 
viewed  as  two  different  diseases  with  distinct  risk  factors.
8  This  notion  was 
challenged in the last decade since an increased incidence of atherosclerosis or 
ATE  had  been  observed  in  subjects  with  VTE,  especially  in  subjects  with  
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idiopathic VTE.
9-18 Moreover, an increasing amount of data indicates that classic 
atherosclerosis  risk  factors  (i.e.,  hypertension,  hyperlipidemia,  diabetes,  obesity, 
and smoking) may also predispose individuals to VTE, though results are some 
times inconsistent.
19-32 A recent meta-analysis that included a total of 21 studies,
19 
predominantly case-control studies, reported that obesity, hypertension, diabetes 
mellitus, high levels of triglycerides and low high-density lipoproteins were all 
significantly related  to  VTE.  However,  these  results  should be  interpreted with 
caution  as  for  most  of  the  evaluated  atherosclerosis  risk  factors  there  was 
considerable heterogeneity and the results of cohort studies were not adjusted for 
age.  Since  cardiovascular  risk  factors  such  as  hypertension,  lipid  levels,  and 
diabetes are strongly correlated with older age and older age in itself is a strong 
risk factor for VTE, crude associations between these atherosclerosis risk factors 
and VTE will be observed as epiphenomena or innocent bystanders, rather than as 
causative risk factors. Furthermore, smoking and elevated levels of total cholesterol 
did not reach statistical significance as predictors of VTE, in this meta-analysis,
19 
although a weak positive trend with odds ratios of 1.18 and 1.16 were observed, 
respectively. Dyslipidemia is especially interesting as a potential VTE risk factor, 
considering the results from the JUPITER trial (Justification for the Use of Statins 
in  Primary  Prevention:  An  Intervention  Trial  Evaluating  Rosuvastatin) 
demonstrating  significant  reduction  in  VTE  risk  in  the  intervention-arm  treated 
with rosuvastatin.
33 It has been hypothesized, however, that this risk reduction is 
not due to the cholesterol lowering effect of this drug, but secondary to pleiotropic 
effects of statins.
34 First, in the placebo-arm of JUPITER trial there was no clear 
evidence of higher VTE risk in subjects with higher lipid levels. Secondly, there 
was a lack of association between dyslipidemia and VTE in several recent large 
prospective cohort studies.
20,27 The association between smoking and VTE remains 
also controversial. Two recent large studies from Denmark showed a dose response 
relationship between smoking and VTE.
27,30 These studies concluded that the lack 
of association between smoking and VTE in other studies might be at least partially 
due  to  lack  of  precision  by  pooling  ex-smokers  with  current  smokers  or  non-
smokers, and lack of distinction between heavy and light smokers. Finally, of the 
mentioned atherosclerosis risk factors, obesity as measured by body mass index or 
by  waist-hip  ratio  is  the  only  atherosclerosis  risk  factor  that  was  consistently 
related with elevated risk of VTE.
19,24,25,27,29,31 
 
 
 Chapter 1 
  13 
Albuminuria, estimated glomerular filtration rate and risk of VTE: 
Microalbuminuria  (urinary  albumin  excretion  of  30-299  mg/24h), 
macroalbuminuria  (urinary  albumin  excretion  of  ≥300  mg/24h)  and  decreased 
estimated glomerular filtration rate (eGFR) are known risk factors for ATE 
35-39 and 
define  chronic  kidney  disease  (CKD)  according  to  the  2002  Kidney  Disease 
Outcomes Quality Initiative (K/DOQI) guidelines.
40 K/DOQI classified CKD in 5 
stages  as  presented  in  the  Table  with  the  estimated  prevalence  in  the  general 
population in the USA and the Netherlands. Estimates in the Netherlands are based 
on  data  from  the  Prevention  of  REnal  and  Vascular  ENd-stage  Disease 
(PREVEND) study.  
 
Whereas all stages of CKD are well recognized risk factors for ATE, its association 
with VTE is new. Stage 5 CKD, which is also called end-stage renal disease, is 
accompanied by uremic thrombopathy for which reason it was historically thought 
that  these  patients  may  have  lower  risk  of  VTE.  However,  recent  studies 
demonstrated an increased risk of VTE in stage 5 CKD patients.
43 The association 
between CKD stage 3-4 and VTE in the general population was first described by 
investigators  of  the  Longitudinal  Investigation  of  Thromboembolism  Etiology 
(LITE)  project,
44  using  the  Modification  of  Diet  in  Renal  Disease  (MDRD) 
equation.
45 The LITE project comprises the pooled data of the Atherosclerosis Risk 
Table. K/DOQI staging system of chronic kidney disease 
Stage  eGFR (ml/min/ 
1.73m
2) 
Albuminuria 
(>30 mg/24h) 
Estimated 
prevalence 
USA 
Estimated 
prevalence  
The Netherlands 
1  > 90  Mandatory  1.8 %  1.3 % 
2  60 - 89  Mandatory  3.2 %  3.8 % 
3  30 - 59  Not mandatory  7.7 %  5.3 % 
4  15 - 29  Not mandatory  0.4 %  0.1 % 
5  < 15 or RRT  Not mandatory  0.2 %  0.1 % 
Total        13.3 %  10.6 % 
eGFR denotes estimated glomerular filtration rate assessed by the Modification of Diet in 
Renal Disease (MDRD) Study formula and RRT denotes renal replacement therapy. For 
prevalence estimates in the USA see Coresh et al
41. JAMA. 2007 and for the estimates in 
the Netherlands, which are based on the PREVEND study data see De Zeeuw et al.
42 
Kidney Int. 2005.   
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in  Communities  (ARIC)  study  and  the  Cardiovascular  Health  Study  (CHS).
46,47 
Recently the same group assessed the VTE risk in CKD 3-4 in the ARIC cohort 
only,
46 using a cystatin C based and the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation.
48,49 Stage 3 to 4 CKD, based on eGFR cystatin 
C,  but  not  eGFR  CKD-EPI,  was  associated  with  an  approximately  1.6-fold 
increased risk of VTE.
50 These findings contrast with early follow-up of the LITE 
project.
44  The  authors  ascribed  this  to  potential  unknown  confounders  and 
differences in creatinine measurements as creatinine measures of different follow-
up  periods  were  used.  Stage  1  and  2  CKD  are  defined  by  normal  or  slightly 
decreased  eGFR  in  the  presence  of  additional  signs  of  kidney  damage.  In  the 
setting of epidemiological research these additional signs of kidney damage are 
based on the presence of albuminuria of ≥30 mg/24h. The association of stage 1 
and 2 CKD with VTE has not been investigated previously and has been described 
in this thesis for the first time (Table). The pathophysiological mechanisms of the 
association of albuminuria of ≥30 mg/24h with VTE are unknown.  In accordance 
with the Virchow triad, generalized endothelial dysfunction and the concomitant 
changes in the levels of several coagulation proteins including elevated levels of 
factor VIII and plasminogen activator inhibitor, may account for the higher risk of 
VTE in subjects with albuminuria of ≥30 mg/24h.
51-53 Moreover, given the new 
findings  of  a  positive  association  of  classic  atherosclerosis  risk  factors  (i.e.  
hypertension, hyperlipidemia, diabetes, obesity, and smoking) with VTE and the 
well  known  association  of  albuminuria  of  ≥30  mg/24h  with  the  classic 
atherosclerosis  risk  factors,  necessitates  appropriate  adjustment  for  classic 
atherosclerosis risk factors. 
 
Nephrotic syndrome and risk of both VTE and ATE: 
Overt proteinuria in patients with nephrotic syndrome is considered an established 
risk  factor  for  VTE,  whereas  its  association  with  ATE  is  relatively  less  well 
recognized.
54-56 Of note, in patients with diabetes, overt proteinuria is a well-known 
strong predictor for ATE.
57 The nephrotic syndrome is characterized by urinary 
protein  losses  in  excess  of  3.5  g/24h  in  association  with  hypoalbuminemia, 
hypercholesterolemia, and peripheral edema due to renal sodium retention. The 
nephrotic-range proteinuria (proteinuria ≥3.5 g/24h) is the main component of the 
nephrotic  syndrome,  and  its  association  with  the  remaining  components  of 
nephrotic syndrome is variable. Diabetic nephropathy is the most common cause of 
nephrotic-range proteinuria.
55 In non-diabetics several primary glomerular diseases 
such  as  membranous  glomerulopathy,  minimal  change  disease,  focal  segmental Chapter 1 
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glomerulosclerosis and membranoproliferative glomerulonephritis account for the 
great majority of cases of the nephrotic-range proteinuria.
55 In the remaining cases 
the  nephrotic-range  proteinuria  is  caused  by  a  wide  range  of  diseases  such  as 
systemic diseases (e.g. lupus erythematosus), infectious diseases, heredofamilial 
syndromes (e.g. Alport syndrome) and certain drugs.
55 Although reliable data are 
lacking, it is likely that the risk of both VTE and ATE may also vary according to 
the  underlying  lesion  accounting  for  the  nephrotic-range  proteinuria.  Examples 
include nephrotic syndrome due to diabetic nephropathy predisposing for ATE and 
membranous glomerulopathy predisposing for VTE. Low levels of antithrombin 
due to urinary loss and alterations in plasma levels of various proteins involved in 
coagulation  are  considered  to  be  the  main  predisposing  factors  for 
thromboembolism  in  patients  with  nephrotic-range  proteinuria.
56,58,59  Enhanced 
platelet aggregation, decreased fibrinolysis, hyperviscosity and hyperlipidemia are 
other  less  often  postulated  mechanisms  that  may  be  responsible  for  the 
prothrombotic  state  in  these  patients.
56,60-62  As  is  true  for  microalbuminuria, 
nephrotic-range  proteinuria  is  also  associated  with  prominent  endothelial 
dysfunction.
63  Experimental  data  support  a  role  for  hypoalbuminemia  in  the 
vascular dysfunction in nephrotic-range proteinuria.
64,65  
 
Hereditary thrombophilia and risk of both VTE and ATE: 
Hereditary thrombophilic deficiencies of the natural anticoagulant proteins (i.e., 
antithrombin, protein C and protein S) are considered the strongest hereditary risk 
factors  for  VTE;
5,66,67  however,  their  association  with  ATE  is  controversial.
68,69 
Whereas studies regarding these deficiencies and the risk of VTE are primarily 
conducted in thrombophilic families, the few available studies on ATE risk are 
mainly case-control studies in unrelated individuals. This study design may have 
led to inappropriate identification of hereditary deficiencies of protein S, protein C 
or antithrombin for the ATE end-point. Because acquired deficiencies of protein S, 
protein C or antithrombin are more prevalent than hereditary deficiencies of these 
proteins. Nevertheless, generally coagulation defects are considered more relevant 
for the pathogenesis of VTE as compared to ATE.
70,71  
 
Given the low prevalence of these thrombophilic defects (0.1–0.4% each in the 
general  population),  even  the  absolute  risks  of  VTE  in  individuals  with  these 
deficiencies are mainly based on retrospective data.
6,66,67 Though search for new 
hereditary  risk  factors  of  VTE  is  a  matter  of  ongoing  research,  some  experts 
question the clinical implications of screening for known hereditary risk factors.
72  
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Because  in  the  general  population  long-term  oral  anticoagulant  treatment  is 
associated with a major bleeding risk of about 2.8% per year,
73 which outweighs 
the risk of VTE, there is reluctance to advocate long-term primary prophylaxis in 
asymptomatic subjects with protein S, protein C or antithrombin deficiencies.
74 As 
about  50%  of  VTE  cases  are  provoked  by  acquired  risk  factors,  transient 
thromboprophylaxis  at  exposure  to  acquired  risk  factors  is  nowadays  the 
recommended  approach  for  primary  prevention  of  VTE,  even  in  non-deficient 
subjects.
75 Thus, the effect of screening asymptomatic relatives of patients with 
protein  S,  protein  C  or  antithrombin  deficiencies  and  recommendation  of 
subsequent preventative measures on VTE incidence has not been evaluated and 
was for the first time assessed in the current thesis. 
 
In summary, whether VTE and ATE are two different entities, or two different 
phenotypes  of  the  same  disease,  is  a  topic  that  currently  is  in  the  spotlight  of 
cardiovascular  research  and  this  topic  has  been  the  main  focus  of  research 
presented in the current thesis. 
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Outline of this thesis 
In the current thesis the association between VTE and ATE is studied by evaluating 
the  association  of  established  ATE  risk  factors  with  VTE  incidence  and  the 
association  of  deficiencies  of  the  natural  anticoagulant  proteins  with  ATE 
incidence. Moreover, renal disease is considered as a potential shared risk factor 
for both VTE and ATE, and pathophysiological mechanisms of the prothrombotic 
state in proteinuric patients are assessed.  
 
As depicted in the Figure, the association between nephrotic syndrome and ATE is 
relatively less well recognized as compared to the risk of VTE in non-diabetic 
patients with nephrotic-range proteinuria. Moreover, absolute risks of either VTE 
or  ATE  in  patients  with  nephrotic-range  proteinuria  have  not  been  assessed 
previously. In chapter 2 we assess the absolute risks of both VTE and ATE in a 
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Figure. Outline of this thesis. 
Solid  arrows  represent  well-established  association  between  the  risk  factors  and  the 
thromboembolic  endpoints  of  interest.  Dashed  arrows  represent  controversial  or  new 
associations  between  the  risk  factors  and the  endpoints that  are  evaluated  in  current 
thesis. The corresponding chapters of this thesis that address the depicted associations 
are presented.  
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retrospective  study  investigating  a  large  cohort  of  298  patients  with  nephrotic-
range proteinuria. Moreover, we attempt to identify predictive factors for incident 
ATE and VTE. The diagnosis of nephrotic-range proteinuria was defined as by 
proteinuria
 of ≥3.5 g/d, mainly derived from a 24-hour urine collection.
 Data on 
other  components  of  the  nephrotic  syndrome,  that  is,  hypoalbuminemia  (serum 
albumin <3.4 g/dL), hypercholesterolemia,
 hypertriglyceridemia and edema were 
retrieved from medical records, but were not mandatory.  
 
In  contrast  to  the  situation  with  nephrotic-range  proteinuria,  the  association  of 
microalbuminuria,  classic  atherosclerosis  risk  factors  and  decreased  eGFR  with 
ATE  is  well  established;  however,  its  association  with  VTE  is  not  assessed, 
inconsistent  or  warrants  confirmation,  respectively  (Figure).  In  chapter  3  we 
evaluate the association of these risk factors with the risk of VTE in participants of 
the PREVEND study, which is an ongoing community-based
 prospective cohort 
study. The PREVEND study was designed to investigate prospectively the natural 
course of albuminuria and its relation to renal and cardiovascular disease. In brief, 
during 1997-1998, all 85,421 inhabitants of the city of Groningen, the Netherlands, 
between the ages of 28 and 75 years old were sent a 1-page postal questionnaire 
regarding  demographics,  cardiovascular  morbidity,  use  of  medication,  and 
pregnancy, and a vial to collect a first morning void urine sample. A total of 40,856 
(47.8%) individuals responded, of whom a sample of 8,592 subjects enriched for 
higher  levels  of  albuminuria  completed  the  screening  protocol  and  formed  the 
baseline PREVEND cohort. In chapter 4 we assess the association of decreased 
eGFR with VTE incidence, using the K/DOQI classification for CKD, and study 
whether this association is independent of microalbuminuria status. 
 
Since  proteinuria  ranging  from  microalbuminuria  to  nephrotic-range  proteinuria 
turned out to be related to higher risk of thromboembolism, we opted to assess the 
exact  coagulation  disturbances  in  patients  with  overt  proteinuria  (chapter  5). 
Moreover,  we  also  evaluated  whether  antiproteinuric  treatment  with  losartan 
reverses the prothrombotic state in proteinuric patients. Of note, thus far the exact 
mechanism of the prothrombotic  state  in nephrotic syndrome is  unknown. It is 
assumed that the decrease in serum albumin, due to urinary loss, is sensed by the 
liver  that,  in  turn,  up-regulates  the  production  of  all  liver-synthesized  proteins, 
including various coagulation factors. Studies evaluating the impact of intervention 
in  the  renin-angiotensin  system,  which  is  nowadays  the  cornerstone  of Chapter 1 
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antiproteinuric  treatment,  on  coagulation  disturbances  in  patients  with  overt 
proteinuria have not been conducted previously. 
    
Hereditary  deficiencies  of  antithrombin,  protein  C  and  protein  S  are  well 
established strong hereditary risk factors for VTE, though their association with 
ATE is controversial (Figure). Any reported association between deficiencies of 
these  natural  anticoagulant  proteins  and  VTE  is  mainly  based  on  retrospective 
studies.  Thus,  whether  screening  and  subsequent  preventative  measures  in 
asymptomatic relatives of these patients is effective in VTE risk reduction has yet 
to be addressed. Due to the low prevalence of hereditary protein S, protein C and 
antithrombin deficiencies in the general population, family-cohort studies will be 
most  suitable  for  addressing  the  association  between  these  deficiencies  and 
thromboembolism. Therefore, we used the data from the DEficiencies of protein S, 
protein C and Antithrombin and the absolute Risk of ThromboEmbolism Study 
(DESCARTES)  that  contained  three  cohorts  of  families  with  hereditary 
deficiencies  of  either  protein  S,  protein  C  or  antithrombin.  Probands  were 
consecutive  patients  with  VTE  who  had  one  of  these  deficiencies.  First-degree 
relatives >15 years of age were identified by pedigree analysis. Detailed data on 
previous  episodes  of  VTE  and  ATE,  risk  factors  for  atherosclerosis  and 
anticoagulant treatment, were collected by using a standardized questionnaire and 
reviewing medical records. Blood samples were taken after clinical data had been 
collected. In chapter 6 we assess in a prospective analysis the risk of VTE and the 
impact of screening on VTE risk in relatives of antithrombin- protein C- or protein 
S-deficient  patients.    In  chapter  7  the  association  between  these  hereditary 
thrombophilic defects and incident ATE is assessed.  
 
Finally,  whereas  the  increased  risk  of  VTE  in  patients  with  previous  ATE,  in 
particular  in  patients  with  stroke,  is  well  recognized,  a  possibly  higher  risk  of 
incident ATE in subjects with a history of VTE is new and studies addressing the 
absolute risks of ATE after VTE have not been conducted, previously. In chapter 
8 we report the absolute risk of subsequent ATE after a VTE in the more than 
40.000 baseline participants of the PREVEND study. 
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ABSTRACT 
 
Background:  No  data  are  available  on  the  absolute  risk  of  either  venous 
thromboembolism  (VTE)  or  arterial  thromboembolism  (ATE)  in  patients  with 
nephrotic syndrome. Reported risks are based on multiple case reports and small 
studies with mostly short-term follow-up. We assessed the absolute risk of VTE 
and  ATE  in  a  large,  single-center,  retrospective  cohort  study  and  attempted  to 
identify predictive factors in these patients.  
 
Methods  and  Results:  A  total  of  298  consecutive  patients  with  nephrotic 
syndrome (59% men; mean age, 42±18 years) were enrolled. Mean follow-up was 
10±9 years. Nephrotic syndrome was defined by proteinuria ≥3.5 g/d, and patients 
were  classified  according  to  underlying  histological  lesions  accounting  for 
nephrotic  syndrome.  Objectively  verified  symptomatic  thromboembolic  events 
were the primary study outcome. Annual incidences of VTE and ATE were 1.02% 
(95% confidence interval, 0.68 to 1.46) and 1.48% (95% confidence interval, 1.07 
to 1.99), respectively. Over the first 6 months of follow-up, these rates were 9.85% 
and 5.52%, respectively. Proteinuria and serum albumin levels tended to be related 
to VTE; however, only the predictive value of the ratio of proteinuria to serum 
albumin was significant (hazard ratio, 5.6; 95% confidence interval, 1.2 to 26.2; 
P=0.03). In contrast, neither the degree of proteinuria nor serum albumin levels 
were related to ATE. Sex, age, hypertension, diabetes, smoking, prior ATE, and 
estimated glomerular filtration rate predicted ATE (P≤0.02).  
 
Conclusions:  This  study  verifies  high  absolute  risks  of  symptomatic  VTE  and 
ATE that were remarkably elevated within the first 6 months. Whereas the ratio of 
proteinuria to serum albumin predicted VTE, estimated glomerular filtration rate 
and multiple classic risk factors for atherosclerosis were predictors of ATE.  Chapter 2 
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INTRODUCTION 
 
The  first  observations  of  an  increased  risk  of  venous  (VTE)  and  arterial 
thromboembolism (ATE) in patients with nephrotic syndrome (NS) date back to 
>50  years  ago.
1,2  In  the  ensuing  half-century,  VTE  rates  ranging  from  2%  in 
children to as high as 42% in adults
3–6 and a relative risk of ATE ranging from 1 to 
5.5 have been reported in these patients.
7,8 Whereas NS resulting from membranous 
glomerulopathy  has  been  correlated  with  an  exceptionally  high  risk  of  VTE, 
especially renal vein thrombosis,
9,10 likewise correlations have not been described 
for ATE.
7,8 
 
The pathophysiological mechanisms of thromboembolism in patients with NS have 
yet to be unraveled. Nevertheless, alterations in plasma levels of proteins involved 
in coagulation and fibrinolysis, enhanced platelet aggregation, low plasma albumin, 
hyperviscosity, and hyperlipidemia, as well as treatment with corticosteroids and 
diuretics,  are  considered  predisposing  factors  for  the  development  of 
thromboembolic events.
5,6,10–16  
 
The reported risks of VTE and ATE in patients with NS are based on numerous 
case reports and small studies with mostly short-term follow-up and therefore are 
of  limited  accuracy.  Data  on  the  absolute  risk  of  either  VTE  or  ATE  are  not 
available. We conducted a single-center retrospective study to assess the absolute 
risk of symptomatic VTE and ATE in a large cohort of patients with NS. We also 
attempted to identify predictive factors. Thromboembolism in nephrotic syndrome 
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METHODS 
 
Study Patients 
Consecutive patients with NS, seen between January 1995 and December 2004 at 
our outpatient nephrology clinic, were retrospectively identified from computer-
stored hospital files. Patients who at time of study entry (February 2005) were ≥18 
years of age, had not been diagnosed with acute life-threatening diseases, and had 
been followed up for at least 6 months at our center were enrolled. The diagnosis of 
NS  was  confirmed  by  proteinuria  of  ≥3.5  g/d,  derived  from  a  24-hour  urine 
collection, or a protein-to-creatinine ratio (7 patients) calculated from a single urine 
sample.
17  Hypoalbuminemia  (serum  albumin  <3.4  g/dL),  hypercholesterolemia, 
and hypertriglyceridemia were recorded but were not a requisite for the diagnosis 
of NS.
18 On the basis of histology of a percutaneous renal biopsy or the clinical 
context, patients were classified as having membranous glomerulopathy, minimal 
change  disease,  focal  segmental  glomerulosclerosis,  membranoproliferative 
glomerulonephritis, diabetic nephropathy, and NS not otherwise specified.
18 
 
Medical  records  were  reviewed  for  symptomatic  thromboembolic  events  and 
exposure to risk factors for VTE and atherosclerosis, respectively. Risk factors for 
VTE included major surgery, trauma, malignancy, immobilization for >1 week, use 
of oral contraceptives, hormonal replacement therapy, and pregnancy. Risk factors 
for atherosclerosis, recorded at baseline (ie, diagnosis of NS), were hypertension, 
as defined by a systolic blood pressure of ≥140 mm Hg or ≥160 mm Hg in patients 
≥60 years of age or a diastolic blood pressure of ≥90 mm Hg measured on at least 2 
occasions  or  the  use  of  antihypertensive  drugs;  diabetes  mellitus
19,20;  cigarette 
smoking; and hyperlipidemia, defined by levels of total cholesterol >6.5 mmol/L 
(250 mg/dL) or triglycerides >2.5 mmol/L (220 mg/dL) or the use of lipid-lowering 
drugs. The diagnosis of a multisystem disease was documented. End-stage renal 
disease was defined by application of regular dialysis. 
 
Proteinuria, serum albumin, cholesterol, triglycerides, and creatinine were recorded 
at baseline. In adults, the glomerular filtration rate (GFR) was estimated (eGFR) 
with  a  validated  prediction  formula
21:  eGFR=30,849  x  (serum  creatinine)
-1.154  x 
(age)
-0.203 x (0.742 if female) x (1.212 if black), where eGFR is measured in mL/ 
min/1.73m
2 and age is in years. In children (<18 years of age), creatinine clearance 
was taken as measure for renal function. Chapter 2 
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Diagnosis of Thromboembolic Events 
Only objectively verified symptomatic thromboembolic events were considered. 
Deep  vein  thrombosis  (DVT)  was  confirmed  by  compression  ultrasound; 
pulmonary  embolism,  by  ventilation  and  perfusion  lung  scanning  or  spiral 
computed  tomography;  renal  vein  thrombosis,  by  venography  or  Doppler 
ultrasound; and mesenteric vein thrombosis, by computed tomography scanning. 
Unstable angina pectoris and Q-wave and non–Q-wave myocardial infarction were 
confirmed  by  typical  ECG  features,  elevated  levels  of  cardiac  enzymes, 
radionuclide imaging techniques, or coronary angiography. Ischemic stroke was 
documented by computed tomography scanning or magnetic resonance imaging; 
peripheral artery disease was documented by intraarterial or magnetic resonance 
angiography. Cerebral transient ischemic attack required neurological symptoms 
and  signs  lasting  <24  hours.
22  Amaurosis  fugax  was  established  when  sudden 
monocular blindness lasted <24 hours. 
 
Statistical Analysis 
We  calculated  annual  incidences  of  VTE  and  ATE  by  dividing  the  number  of 
events by the total number of observation years. The observation time for each 
patient was defined as the period from the diagnosis of NS until the first episode of 
thromboembolism, a censoring event (end-stage renal disease or death), or end of 
study. When calculating the incidence rates of VTE, we ignored the occurrence of 
ATE  and  vice  versa.  The  95%  confidence  intervals  (CIs)  around  the  annual 
incidences were assessed with the Poisson distribution assumption. 
 
Kaplan-Meier
23 methods were used for survival plots. To evaluate the effects of 
baseline  characteristics  on  VTE-  and  ATE-free  survival,  we  used  the  Cox 
proportional-hazards model with a single covariate.
24 Results were expressed as 
hazard ratios with 95% CIs and probability values. 
 
Continuous variables are presented as mean±SD and categorical data as numbers 
and frequencies. For continuous data, differences were evaluated by the Student t 
test, Mann-Whitney U test, Kruskal-Wallis test, or univariate ANOVA, depending 
on  the  normality  of  the  data  and  levels  of  the  outcome  variable.  Categorical 
variables  were  compared  with  chi-square  or  Fisher’s  exact  test.  Statistical 
significance was considered at a 2-tailed value of P<0.05. Statistical analyses were Thromboembolism in nephrotic syndrome 
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performed with SPSS software version 14.0 (SPSS Inc, Chicago, Ill, USA) and 
SAS software, version 9.1 (SAS Institute Inc, Cary, NC, USA). 
 
RESULTS 
 
Patients 
Table 1 shows the clinical characteristics at diagnosis of NS of the total study 
population  of  298  patients  and  subgroups  according  to  the  underlying 
nephropathies.  Whereas  all  cases  classified  as  membranous  glomerulopathy, 
minimal  change  disease,  focal  segmental  glomerulosclerosis,  and 
membranoproliferative  glomerulonephritis  were  confirmed  by  renal  biopsy;  the 
diagnoses of diabetic nephropathy and NS not otherwise specified were 28% and 
46% based on renal biopsy, respectively. NS in the not-otherwise-specified group 
was due to systemic diseases (19%), infections (8%), heredofamilial diseases (8%), 
clinically suspected primary glomerular diseases that were not confirmed by biopsy 
(19%), biopsy-proven cases of IgA nephropathy (17%), and miscellaneous diseases 
(28%). 
 
Overall, the mean±SD age was 42±18 years; 59% of patients were male; 10% were 
<18  years  of  age;  61%  had  hypertension,  92%  had  hyperlipidemia,  14%  had 
diabetes, and 10% had a prior thromboembolic event at diagnosis of NS; and 50% 
reported ever having smoked. For individual patients, the mean observation period 
was 10±8 years for VTE and 10±9 years for ATE. The observation period differed 
among  subgroups  (P<0.001).  Compared  with  patients  with  nondiabetic 
nephropathies,  patients  with  diabetic  nephropathy  were  older  (P=0.005),  had  a 
higher prevalence of hypertension (P<0.001) and prior ATE (P=0.005), and had 
lower  eGFR  (P<0.001),  less  proteinuria  (P=0.003),  and  higher  serum  albumin 
levels  (P=0.02).  Among  patients  with  nondiabetic  nephropathies,  age,  serum 
cholesterol, serum albumin, proteinuria, and eGFR varied significantly (P=0.003) 
according to the type of nephropathy. 
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Table 1. Characteristics of the Study Population 
Variable  Total  MG  MCD  FSGS  MPGN  DN  NOS 
Baseline characteristic               
Patients, n (%)  298 (100) 72 (24)  49 (16)  36 (12)  26 (9)  32 (11)  83 (28) 
  Male sex, n (%)  177 (59)  49 (68)  27 (55)  21 (58)  9 (35)  18 (56)  53 (64) 
Age, y  42±18  45±17  36±18  39±18  31±16  50±13  43±19 
Hypertension, n (%)  182 (61)  43 (60)  23 (47)  16 (44)  15 (58)  30 (94)  55 (66) 
Diabetes, n (%)  42 (14)  3 (4)  0 (0)  3 (8)  1 (4)  32 (100)  3 (4) 
Hyperlipidemia, n (%)*  221(92)  64 (98)  47 (100)  29 (97)  20 (95)  21 (91)  40 (73) 
Prior VTE, n (%)  3 (1)  1 (1)  0 (0)  0 (0)  0 (0)  0 (0)  2 (2) 
Prior ATE, n (%)  28 (9)  9 (13)  2 (4)  2 (6)  0 (0)  8 (25)  7 (8) 
Ever smoked, n (%)*  116 (50)  33 (59)  13 (37)  14 (50)  11 (44)  20 (67)  25 (42) 
MSD, n (%)  28 (9)  2 (3)  2 (4)  0 (0)  5 (19)  0 (0)  19 (23) 
Laboratory 
measurements† 
             
  Proteinuria, g/day  8.1±5.2  9.7±6.5  9.2±5.4  10.2±5.9  6.5±2.6  6.0±2.5  6.4±3.6 
  eGFR, ml/min/1.73m
2  59±28  71±23  78±32  58±23  70±27  36±18  46±25 
  Albumin, g/L  28±8  26±7  24±7  29±10  28±9  33±8  31±9 
  Cholesterol, mmol/L  9.0±3.5  9.9±3.0  10.6±4.0  9.3±2.9  8.4±2.9  7.4±2.8  7.4±3.5 
  Triglycerides, mmol/L  3.0±2.1  3.3±2.3  2.3±1.3  3.1±1.8  2.4±1.4  4.1±4.1  3.0±1.2 
Follow-up                
  VTE observation 
  period, y 
10±8  10±8  13±11  10±7  15±10  5±5  7±6 
  ATE observation 
  period, y 
10±9  11±8  13±11  11±7  15±10  5±4  7±7 
  ESRD, n (%)  39 (13)  5 (7)  1 (2)  7 (19)  6 (23)  6 (19)  14 (17) 
  Death, n (%)  15 (5)  4 (6)  2 (4)  2 (6)  0 (0)  3 (9)  4 (5) 
MG  indicates  membranous  glomerulopathy;  MCD,  minimal  change  disease;  FSGS,  focal 
segmental  glomerular  sclerosis;  MPGN,  membranoproliferative  glomerulonephritis;  DN, 
diabetic nephropathy; NOS, nephrotic syndrome not otherwise specified; MSD, multisystem 
disease; and ESRD, end-stage renal disease. Values are mean±SD when appropriate. To convert 
values  for  cholesterol  to  milligrams  per  deciliters,  divide  by  0.0259;  to  convert  values  for 
triglycerides to milligrams per deciliters, divide by 0.0113. 
*Hyperlipidemia and smoking status were unknown for 57 and 64 patients, respectively. 
†Proteinuria, eGFR, serum albumin, serum cholesterol, and serum triglycerides measurements 
were available for 272, 251, 184, 142, and 117 patients, respectively. 
 
Thromboembolic Events 
Twenty-nine patients had at least 1 episode of VTE during the observation period, 
corresponding to an annual incidence of 1.02% (95% CI, 0.68 to 1.46) (Table 2). 
The median observation period until VTE was 0.9 years (interquartile range, 17.3 
years).  The  most  commonly  encountered  first  VTE  was  pulmonary  embolism 
(38%), followed by DVT (34%), combined pulmonary embolism and DVT (10%), Thromboembolism in nephrotic syndrome 
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combined  pulmonary  embolism  and  renal  vein  thrombosis  (10%),  renal  vein 
thrombosis (3%), and mesenteric vein thrombosis (3%). None of these patients had 
VTE before they received a diagnosis of NS. No fatal VTE was observed. At the 
onset of VTE, only 6 patients (21%) were exposed to another risk factor for VTE 
(immobilization,  n=2;  malignancy,  n=2;  surgery,  n=1;  and  use  of  oral 
contraceptives,  n=1].  The  annual  incidence  of  VTE,  calculated  over  the  first  6 
months of observation time, was 9.85% (95% CI, 5.38 to 16.52). 
 
Table 2. Risk of thromboembolism by type of nephropathies 
Variable   Total 
(n = 298) 
MG 
(n = 72) 
MCD 
(n = 49) 
FSGS 
(n = 36) 
MPGN 
(n = 26 ) 
DN 
(n = 32) 
NOS 
(n = 83) 
VTE                
No. events  29  10  4  5  5  1  4 
Observation 
period, y  
2857  716  645  362  378  171  585 
Annual 
Incidence  
(95%CI)-% 
1.02 
(0.68–1.46)
1.40 
(0.67–2.57)
0.62 
(0.17–1.59)
1.38 
(0.45–3.22)
1.32 
(0.43–3.09)
0.58 
(0.01–3.26) 
0.68 
(0.19–1.75) 
ATE                
No. events  43  10  2  6  2  11  12 
Observation 
period, y 
2904  762  656  390  396  148  551 
Annual 
Incidence  
(95%CI)-% 
1.48 
(1.07–1.99)
1.31 
(0.63–2.41)
0.30 
(0.04–1.10)
1.54 
(0.56–3.35)
0.51 
(0.06–1.82)
7.43 
(3.71–13.3) 
2.18 
(1.13–3.80) 
Abbreviations as in Table 1 
 
Forty-three patients had ≥1 ATE during the observation period, resulting in an 
annual  incidence  of  1.48%  (95%  CI,  1.07  to  1.99)  (Table  2).  The  median 
observation period until ATE was 3.5 years (interquartile range, 7.3 years). The 
most commonly observed first ATE was myocardial infarction (44%), followed by 
unstable angina pectoris (14%), peripheral artery disease (14%), ischemic stroke 
(11.5%), cerebral transient ischemic attack (11.5%), amaurosis fugax (2%), and 
aorta thrombosis (2%). Three of these events (7%) were fatal. Fifteen of the 43 
patients  (35%)  had  already  experienced  ATE  before  the  diagnosis  of  NS.  The 
annual incidence of ATE, calculated over the first 6 months of observation time, 
was 5.52% (95% CI, 2.38 to 10.87). The annual incidence in nondiabetic patients 
without prior ATE was 0.82% (95% CI, 0.52 to 1.25) compared with 7.08% (95% 
CI, 3.77 to 12.10) in diabetics, including patients with prior ATE. Only 4 patients Chapter 2 
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had both ATE and VTE. The annual incidence of any thromboembolic event (ATE, 
VTE, or both) was 2.50% (95% CI, 1.94 to 3.18). Annual incidences for different 
types of thromboembolism are depicted in Figure 1. 
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Figure 1. Annual incidences per types of thromboembolism among the total cohort. Some 
patients are listed in 2 or 3 categories; therefore, the total of these categories exceeds 29 
incidents of VTE and 43 of ATE. Solid circles denote annual incidences of VTE (black) 
and ATE risk (grey), with the corresponding 95% CIs represented by the vertical bars. 
Dotted  lines  represent  the  estimated  age-  and  sex-weighted  annual  incidences  in  the 
general population (i.e., Worcester DVT study for VTE and the Framingham study for 
ATE).
25,26 
PE indicates pulmonary embolism; RVT, renal vein thrombosis; CAD, coronary artery 
disease (unstable angina pectoris or myocardial infarction); CVD, cerebrovascular disease 
(ischemic  stroke  or  transient  ischemic  attack);  and  PAD,  peripheral  artery  disease. 
*Annual incidence in the general population is unknown. 
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The probability of VTE-free survival was 69% and of ATE-free survival was 73% 
over  25  years  of  observation  time  (Figure  2).  The  highest  risk  of  VTE  was 
observed within the first 6 months and between 20 and 25 years. The likelihood of 
any event-free survival was 52%. 
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Figure 2. Kaplan-Meier estimates of the probability of VTE-, ATE-, and any (VTE, ATE, 
or both) event-free survival. 
 
Predisposing Factors 
Figure 3 shows the association of various variables at baseline with the risk of 
VTE and ATE. Overall, the extent of proteinuria tended to be associated with VTE. 
Statistical significance was reached at a level of ≥8.2 g/d (hazard ratio, 5.2; 95% 
CI, 1.1 to 23.0; P=0.03). Serum albumin showed an inverse relationship with VTE, 
although  not  significant  (P=0.41).  The  ratio  of  proteinuria  to  serum  albumin, 
analyzed as a continuous variable, was a more accurate predictor of VTE (hazard Chapter 2 
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ratio, 5.6; 95% CI, 1.2 to 26.2; P=0.03). The ratio of proteinuria to serum albumin 
was more sensitive and more specific than either proteinuria or serum albumin 
(data not shown). In contrast, neither the degree of proteinuria nor the level of 
serum albumin predicted ATE. Sex, age, hypertension, diabetes, smoking, prior 
ATE, and eGFR were significantly associated with ATE. 
 
1.0, reference
Variable
> 55
ATE
HR (95% CI)
2.2 (1.1 - 4.5)
no. patients/
no. studied
35 - 54
< 35
P value
177/298 Sex, male
Age, y
VTE
HR (95% CI)
0.64 1.2 (0.6 - 2.6) 0.02
28/298 0.47
0.003
< 0.001
0.7 (0.2 - 2.1)
< 0.001
4.8 (2.4 - 9.5)
7.9 (2.7 - 23.5) 102/298
28/298
14.2 (4.7 - 42.4) 79/298
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0.46
 
Figure 3. Proportional-hazards analysis of association with the time to the first VTE and 
ATE among the total cohort. Solid squares denote the hazard ratios of VTE (black) and 
ATE  (red),  with  the  corresponding  95%  CIs  represented  by  the  horizontal  bars.  HR 
indicates hazard ratio; MSD, multisystem disease; NE, not estimatable; and P/A ratio, ratio 
of proteinuria to serum albumin. Thromboembolism in nephrotic syndrome 
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DISCUSSION 
 
This study shows a high risk of VTE and ATE in patients with NS. Absolute risks 
of VTE (1.02% per year) and ATE (1.48% per year) were each about 8 times 
higher in these patients than the estimated age- and sex-weighted annual incidences 
in the general population (the Worcester DVT study, 0.12%; and the Framingham 
study, 0.18%, respectively).
25,26 Risks of both VTE and ATE were particularly high 
within  the  first  6  months  of  NS  (annual  incidences,  9.85%  and  5.52%, 
respectively).  Survival  analysis  showed  that  over  25  years  of  observation,  the 
probability  of  a  thromboembolic  event  was  48%,  with  the  risk  of  VTE  being 
approximately equal to the risk of ATE. Whereas the risk of VTE was roughly 
similar among the different groups of NS, the risk of ATE was remarkably high in 
patients  with  diabetic  nephropathy  compared  with  patients  with  nondiabetic 
nephropathies. For the first time, we report that the ratio of proteinuria to serum 
albumin predicts VTE and that multiple classic risk factors for atherosclerosis are 
associated  with  ATE  in  patients  with  NS,  including  sex,  age,  hypertension, 
diabetes, smoking, prior ATE, and eGFR. 
 
Our finding of the increased risk of VTE is in agreement with previous reports. In 
our study, 10% of patients experienced symptomatic VTE, confirmed by objective 
techniques,  during  a  total  observation  period  of  2857  years.  Annual  incidences 
were not provided in previous studies. Not considering the observation period, the 
incidence rate of VTE in adults with NS ranged from 8% to 42%, with an overall 
incidence of 23%.
5 However, risk estimates in those studies were based on small 
numbers of patients and asymptomatic cases of renal vein thrombosis in particular; 
it often was not clear whether thrombosis at other sites was objectively verified and 
whether  consecutive  patients  were  evaluated.
4,5,27,28  Renal  vein  thrombosis 
especially has received attention with an overall incidence rate of 28%, ranging 
from 22% to 42%.
10 However, the high rates of renal vein thrombosis in previous 
reports reflect the vigor of the investigators; 90% of renal vein thromboses were 
demonstrated in clinically asymptomatic patients.
9 Whereas the ratio of pulmonary 
embolism to DVT in the general population is approximately 1:2,
25 it was 1.3:1 in 
our study. Our finding of the high risk of pulmonary embolism could be explained 
by an apparently large proportion of asymptomatic renal vein thrombosis. 
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Although there has been controversy in the past about the association of NS and 
ATE,
29  an  increased  risk  of  coronary  events  has  been  documented  in  a 
retrospective, controlled study in 142 patients with NS.
8 After adjustment for age, 
sex, hypertension, and smoking, the relative risk of myocardial infarction in these 
patients was 5.5, and its annual incidence was 1.49%. Our absolute risk estimates 
were lower when we confined our analysis to nondiabetic patients without prior 
ATE (0.82% versus 1.49%), as Ordonez et al
8 did. This difference might reflect our 
longer follow-up because annual incidences of ATE over a comparable follow-up 
were 2.71% in the total cohort and 1.20% in nondiabetic patients without prior 
ATE in our study. The somewhat lower risk in our patients could be ascribed to 
application of statins (51% patients) and renin-angiotensin system inhibitors (81% 
patients) because these drugs were not available during the period in which patients 
in the study of Ordonez et al
8 were followed up. The beneficial effect of these 
drugs is supported by a 3-fold-lower annual incidence of end-stage renal disease in 
our patients (1.4% versus 4.3%). Furthermore, our patients were on average 6 years 
younger (38 versus 44 years). Given that the risk estimates by Ordonez et al
8 were 
based on only 11 episodes of myocardial infarction, their study size was less than 
half of ours, and the fact that they documented only coronary events, we presume 
that our estimates reflect a more accurate assessment of the absolute ATE risk 
conferred  by  NS.  In  addition,  we  established  that  compared  with  the  general 
population,
26 the risks of cerebrovascular events and peripheral artery disease were 
elevated  about  the  same  extent  as  the  risk  of  coronary  artery  disease  in  these 
patients. 
 
The  association  between  serum  albumin  levels  and  VTE  has  previously  been 
suggested,
13 although others failed to confirm this finding.
4,9,10 We demonstrated 
that the ratio of proteinuria to serum albumin was a stronger predictor because it is 
probably a better reflector of the severity of NS than serum albumin levels or the 
magnitude of proteinuria alone. It is remarkable that ATE was not shown to be 
related to either proteinuria or serum albumin because an almost linear association 
with  the  occurrence  of  ATE  has  been  established  for  non-nephrotic  range 
proteinuria  (<3.5  g/d)  and  even  microalbuminuria.
30,31  Our  finding  could  be 
ascribed to the imbalance of multiple other risk factors for ATE among different 
nephropathies. Whereas the incidence of ATE was shown to be higher in patients 
with  diabetic  nephropathy  or  not  otherwise  specified  NS  compared  with  other 
nephropathies,  these  patients  had  less  proteinuria  and  higher  serum  albumin. Thromboembolism in nephrotic syndrome 
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However, they were older; had higher prevalence of hypertension, prior ATE, and 
diabetes;  and  had  lower  eGFR.  On  the  other  hand,  minimal  change  disease  is 
considered  a  relatively  mild  disorder  because  it  reacts  more  promptly  to 
treatment.
32 Although the extent of proteinuria at presentation of this disorder was 
high, other risk factors were less prevalent. 
 
The  historical  dichotomy  of  venous  and  arterial  diseases  as  2  different  patho-
physiological  entities  with  distinct  risk  factors  has  recently  been  challenged 
because an increased risk of ATE was observed in patients with VTE.
33,34 Our data 
do not support such a relationship between VTE and ATE. Moreover, the findings 
that VTE was related to proteinuria and serum albumin (i.e., ratio of proteinuria to 
serum albumin) and that ATE but not VTE was associated with eGFR and multiple 
classic risk factors for atherosclerosis might indicate different pathophysiological 
mechanisms of VTE and ATE in these patients. 
 
Over the first 6 months of observation time, we demonstrated a markedly elevated 
risk of about 140 times for VTE (annual incidence, 9.85%) and 50 times for ATE 
(annual incidence, 5.52%) compared with the general population (age- and sex-
weighted annual incidences of 0.07% and 0.11%, respectively).
25,26 Therefore, one 
might consider primary thromboprophylaxis during this period. Further prospective 
studies are warranted to assess whether the decline in risk of thromboembolism 
during follow-up is related to the treatment of NS. 
 
The main limitation of this study is its retrospective design. Consequently, baseline 
laboratory  data  were  not  available  in  all  patients.  It  could  be  argued  that 
asymptomatic VTE especially may have been missed because patients were not 
routinely screened and clinical diagnosis of VTE is unreliable. This would have 
resulted  in  an  underestimated  risk  of  VTE.  However,  the  clinical  relevance  of 
asymptomatic VTE is a matter of debate. Referral bias may have been introduced 
by the setting of a university hospital. Selection bias seems less likely because 
consecutive patients were analyzed. Although our study is the largest evaluating 
thromboembolic events in patients with NS, CIs around the risk ratios were wide, 
indicating  a  limited  power.  We  considered  multivariable  analysis  for  ATE. 
However, because of the large number of predictive factors and small number of 
events, the multivariable model was over-fitted and the power was severely limited 
to detect moderate effects. Consequently, these data were not included. Chapter 2 
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In summary, this study delineates high absolute risks of symptomatic VTE and 
ATE  that  were  excessively  elevated  within  the  first  6  months.  Whereas  the 
magnitude of proteinuria and serum albumin levels were related to VTE, eGFR and 
multiple classic risk factors for atherosclerosis predicted ATE. 
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ABSTRACT 
 
Context: Microalbuminuria (albuminuria 30-300 mg per 24-hour urine collection) 
is  a  well-known  risk  marker  for  arterial  thromboembolism.  It  is  assumed  that 
microalbuminuria  reflects  generalized  endothelial  dysfunction.  Hence,  micro-
albuminuria may also predispose for venous thromboembolism (VTE). 
Objective: To assess whether microalbuminuria is associated with VTE. 
Design, Setting, and Participants: Prevention of Renal and Vascular End-stage 
Disease  (PREVEND)  study,  an  ongoing  community-based  prospective  cohort 
study initiated in 1997. All inhabitants of Groningen, the Netherlands, aged 28 
through 75 years (n=85 421) were sent a postal questionnaire and a vial to collect a 
first morning urine sample for measurement of urinary albumin concentration. Of 
those  who  responded  (40  856),  a  cohort  (8592  participants)  including  more 
participants  with  higher  levels  of  urinary  albumin  concentration  completed 
screening at an outpatient clinic. Screening data were collected on urinary albumin 
excretion (UAE) and risk factors for cardiovascular and renal disease. 
Main Outcome Measure: Symptomatic and objectively verified VTE (ie, deep 
vein thrombosis, pulmonary embolism, or both) between study initiation and June 
1, 2007. 
Results: Of 8574 evaluable participants (mean [SD] age, 49 [13] years; 50% men), 
129 experienced VTE during a mean (SD) follow-up period of 8.6 (1.8) years, 
corresponding to overall annual incidence of 0.14% (95% confidence interval [CI], 
0.11%-0.19%).  Annual  incidences  were  0.12%,  0.20%,  0.40%,  and  0.56%  in 
participants with UAE of less than 15 (n=6013), 15-29 (n=1283), 30-300 (n=1144), 
and greater than 300 (n=134) mg per 24-hour urine collection, respectively (P for 
trend  <0.001).  When  adjusted  for  age,  cancer,  use  of  oral  contraceptives,  and 
atherosclerosis risk factors, hazard ratios associated with UAE levels of 15-29, 30-
300, and greater than 300 mg/24 h were 1.40 (95% CI, 0.86-2.35), 2.20 (95% CI, 
1.44-3.36), and 2.82 (95% CI, 1.21-6.61), respectively, compared with participants 
with UAE of less than 15 mg/24 h (global P=0.001). Adjusted hazard ratio for 
microalbuminuria vs normoalbuminuria (UAE<30 mg/24 h) was 2.00 (95% CI, 
1.34-2.98; P<0.001). Microalbuminuria-related number needed to harm was 388 
per year. 
Conclusion: Microalbuminuria is independently associated with an increased risk 
for VTE. Chapter 3 
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INTRODUCTION 
 
The overall incidence of venous thromboembolism (VTE) in developed countries is 
about 0.15% per year, varying from less than 0.005% in individuals younger than 
15 years to as high as 0.5% at 80 years.
1-3 More than a century ago, Virchow 
postulated 3 main causes of thrombosis: stasis of the blood, changes in the vessel 
wall, and changes in the composition of the blood.
4 Known risk factors for VTE 
fall in the first (stasis) and the third groups (blood composition).
5 However, in as 
many as 50% of VTE cases, none of the known risk factors are present.
1 
 
Arterial  thromboembolism  has  historically  been  viewed  as  a  different  patho-
physiological entity with distinct risk factors. However, this dichotomy between 
VTE  and  arterial  thromboembolism  has  recently  been  questioned  since  an 
increased risk of arterial thromboembolism and atherosclerosis had been reported 
in patients with prior VTE.
6,7 Moreover, an increasing amount of data indicate that 
classic  atherosclerosis  risk  factors  (ie,  hypertension,  hyperlipidemia,  diabetes, 
obesity, and smoking) may also predispose individuals to VTE.
8 This emerging 
concept may indicate the involvement of vessel wall changes in the pathogenesis of 
VTE.
9 
 
Classic  atherosclerosis  risk  factors  are  also  strongly  correlated  with 
microalbuminuria (albuminuria of 30-300 mg/d), which is itself an established risk 
marker  for  arterial  thromboembolism.
10,11  Microalbuminuria  is  assumed  to  be  a 
sensitive  marker  for  generalized  endothelial  dysfunction  that  is,  among  others, 
associated with changes in the levels of several coagulation proteins.
12-19 The effect 
of coagulation disorders is more evident in the pathogenesis of VTE than in the 
pathogenesis of arterial thromboembolism. Hence, in theory, a link between micro-
albuminuria and VTE is likely; however, research addressing this issue has yet to 
be  conducted.  We  performed  a  study  to  assess  whether  microalbuminuria  is 
associated with VTE in a population-based cohort study. Albuminuria and venous thromboembolism 
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METHODS 
 
Study Population and Design 
This study was conducted on participants in the Prevention of Renal and Vascular 
End-stage  Disease  (PREVEND)  study.  The  PREVEND  study  was  designed  to 
investigate prospectively the natural course of albuminuria and its relation to renal 
and cardiovascular disease in a large cohort drawn from the general population. 
Details of the study protocol have been published elsewhere
10,20 and can be found 
at http://www.prevend.org.  In brief, during 1997-1998, all 85 421 inhabitants of 
the city of Groningen, the Netherlands, between the ages of 28 and 75 years old 
were sent a 1-page postal questionnaire regarding demographics, cardiovascular 
morbidity, use of medication, and pregnancy, and a vial to collect a first morning 
void urine sample. A total of 40 856 (47.8%) individuals responded (Figure 1). 
Since the link between cardiovascular or renal disease and microalbuminuria in 
individuals  with  insulin-dependent  diabetes  mellitus  was  well  established,  and 
pregnant females may present with temporary microalbuminuria, these individuals 
were  excluded  from  the  PREVEND  study.  After  the  additional  exclusion  of 
individuals who were unable or unwilling to participate in the study, a total of 6000 
individuals  with  a  urinary  albumin  concentration  of  10  mg/L  or  greater  and  a 
random control sample of individuals with a urinary albumin concentration of less 
than 10 mg/L (n=2592) completed the screening protocol and formed the baseline 
PREVEND  cohort  (n=8592).  These  participants  twice  visited  an  outpatient 
department  where  demographic,  anthropometric,  and  cardiovascular  risk  factors 
were assessed. For the current analysis, 18 participants were excluded because of 
missing data on 24-hour urinary albumin excretion (UAE), leaving a total of 8574 
participants. The PREVEND study has been approved by the local medical ethics 
committee and is conducted in accordance with the guidelines of the Declaration of 
Helsinki. Written informed consent was obtained from all participants. 
 
Laboratory Measurements and Definitions 
Fasting blood samples were obtained during the morning in all participants. Serum 
creatinine, total cholesterol, and plasma glucose were measured by dry chemistry 
(Eastman Kodak, Rochester, New York). High-density lipoprotein cholesterol was 
measured with a homogeneous method (direct HDL, Aeroset TM System, Abbott 
Laboratories, Abbott Park, Illinois). Triglycerides were measured enzymatically. 
High-sensitivity C-reactive protein was determined by nephelometry (BN II, Dade 
Behring,  Marburg,  Germany).  Plasma  antigen  levels  of  tissue  plasminogen Chapter 3 
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  85 421 Invited by mailed questionnaire for spot urine test 
44 565 Did not respond 
40 856 Responded to questionnaire 
30 890 Had UAC <10 mg/L  9 966 Had UAC ≥10 mg/L 
22 492 Eligible to participate  7 768 Eligible to participate 
3 395 Randomly selected 
2 592 Completed the 
screening protocol 
6 000 Completed the  
screening protocol 
8 592 Completed baseline screening (1997-1998) 
18 Excluded (24-hour urine 
     collection missing) 
11 Had UAC <10 mg/L 
7 Had UAC ≥10 mg/L 
8 574 Included in primary analysis 
2198 Excluded: 
1800 Did not consent 
60 Pregnant 
167 Insulin-dependent 
171 Other 
8398 Excluded: 
7332 Did not consent 
223 Pregnant 
212 Insulin-dependent 
631 Other 
1 768 Declined to participate  803 Declined to participate 
activator  and  plasminogen  activator  inhibitor  type-1  were  measured  using  an 
ELISA kit from Technoclone Gmbh (Vienna, Austria). Participants collected two 
24-hour urine samples, in which urinary albumin concentration was determined by 
nephelometry with a threshold of 2.3 mg/L and intra- and inter-assay coefficients 
of  variation  of  less  than  2.2%  and  less  than  2.6%,  respectively  (Dade  Behring 
Diagnostic, Marburg, Germany). 
Figure 1. Participant Selection for the PREVEND Study Cohort 
 
Urinary albumin concentration (UAC) was assessed in a first morning void urine sample 
and measured in milligrams per liter. The number of randomly selected participants was 
arbitrarily set at 3395 to obtain a total cohort size of approximately 10 000 accounting for 
a 15% nonparticipation rate. Albuminuria and venous thromboembolism 
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Hypertension was defined as systolic blood pressure of 140 mm Hg or greater or 
diastolic blood pressure of 90 mm Hg or greater, or the use of antihypertensive 
drugs. Diabetes was defined as a fasting glucose level of 126 mg/dL or greater 
(≥7.0 mmol/L), nonfasting plasma glucose level of 200 mg/dL or greater (≥11.1 
mmol/L), or the use of oral antidiabetic drugs. Hypercholesterolemia was defined 
as a total serum cholesterol concentration of 250 mg/dL or greater (≥6.5 mmol/L), 
or in the case of a previous myocardial infarction (MI) or stroke a concentration of 
193  mg/dL  or  greater  (≥5.0  mmol/L),  or  the  use  of  lipid-lowering  drugs.  The 
metabolic syndrome was defined according to the Adult Treatment Panel III of the 
National Cholesterol Education Program.
21 Body mass index (BMI) was calculated 
as weight in kilograms divided by height in meters squared. Estimated glomerular 
filtration  rate  (eGFR)  was  estimated  using  the  Modification  of  Diet  in  Renal 
Disease study equation, taking into account sex, age, race, and serum creatinine 
level.
22 Low-density lipoprotein cholesterol was estimated using the Friedewald 
formula.
23 The UAE was measured as the mean of two 24-hour urine collections 
and was classified according to clinical classes: low-normal (<15 mg/24-hour urine 
collection),  high-normal  (15-29  mg/24-hour  urine  collection),  microalbuminuria 
(30-300 mg/24-hour urine collection), and  macroalbuminuria (>300 mg/24-hour 
urine collection).
10 
 
Identification and Validation of Venous Thromboembolic Events 
We used the regional anticoagulation clinic database to identify participants of the 
PREVEND study who developed VTE between January 1, 1997, and June 1, 2007. 
This  clinic  monitors  the  anticoagulant  therapy  of  all  patients  in  the  city  of 
Groningen and in a well-defined geographical area proximal to the city. For fatal 
VTE cases, we searched the national registry of death certificates (Central Bureau 
of Statistics, The Hague/Heerlen, the Netherlands) and, as an additional check of 
the anticoagulant clinic database, we searched the database of the national registry 
of  hospital  discharge  diagnoses  (Prismant,  Utrecht,  the  Netherlands).  Patients’ 
medical records were reviewed for all participants of the PREVEND study who 
had  VTE  according  to  any  of  the  aforementioned  databases.  The  investigators 
(B.K.M. and N.J.G.M.V.) who collected these clinical data were blinded for the 
UAE  status  of  these  participants.  Only  objectively  verified  symptomatic 
thromboembolic events were considered. Deep vein thrombosis was confirmed by 
compression ultrasound; and pulmonary embolism, by ventilation/perfusion lung 
scanning,  spiral  computed  tomography,  or  at  autopsy.  VTE  was  considered 
provoked if it had occurred at or within 3 months after having acquired risk factors Chapter 3 
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including major surgery, trauma, immobilization for more than 7 days, oral contra-
ceptives,  hormone  therapy,  pregnancy,  malignant  disease,  or  miscellaneous  (ie, 
long-distance  travel  for  longer  than  4  hours,  active  infectious  disease,  paresis/ 
paralysis of the leg, or heart failure). In the absence of these acquired risk factors, 
VTE was considered unprovoked. 
 
Statistical Analysis 
We assessed adjusted annual incidences of VTE for the enrichment of our cohort 
with  participants  with  higher  UAE,  using  survey  probability  weights.
24  The 
observation time for each patient was defined as the period from the testing of 
albuminuria  (1997-1998)  until  the  first  episode  of  VTE  or  a  censoring  event 
(withdrawal from the study, moving out of the city, death, or end of the study). The 
95% confidence intervals (CIs) were computed by a Jackknife approach assuming 
a Poisson distribution, and the P value for the test of trend was calculated via the 
Mantel-Haenszel method.  
 
To evaluate the effects of baseline characteristics on VTE-free survival, we used 
univariate and sex- and age-adjusted Cox proportional hazards models. A multi-
variate model was developed that considered known VTE risk factors (i.e., age, 
malignancies, BMI, and use of oral contraceptives) as well as cardiovascular risk 
factors that yielded a P<0.15 from the univariate model. Results were expressed as 
hazard ratios (HRs) with 95% CIs and P values. 
 
Continuous  variables  are  presented  as  mean  (SD)  or  as  medians  with  the 
interquartile range (IQR) for skewed data. Categorical data are presented as counts 
and  frequencies.  For  continuous  data,  differences  were  evaluated  by  Kruskal-
Wallis test or 1-way analysis of variance, depending on the normality of the data. 
Categorical variables were compared with Chi-square test of association. Statistical 
significance was considered as a 2-tailed P <0.05. All statistical analyses were 
performed using STATA software version 10.0 (Stata-Corp LP, College Station, 
Texas). Albuminuria and venous thromboembolism 
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RESULTS 
 
Study Population 
Individuals who responded (40 856) were more often women (54.4% vs 45.4%) 
and older (mean age 51.9 vs 46.4 years) than those who did not (Figure 1). The 
randomly selected group of 2592 participants with urinary albumin concentration 
of  less  than  10  mg/L  was  representative  of  the  30  890  eligible  responding 
individuals with urinary albumin concentration of less than 10 mg/L, as previously 
reported.
25 
 
The Table represents baseline clinical characteristics of the analyzed study cohort 
of 8574 participants stratified into subgroups of UAE. Of the overall cohort, 70% 
(6013), 15% (1283), 13% (1144), and 1.6% (134) of participants had UAE of less 
than 15, 15-29, 30-300, and greater than 300 mg per 24 hour urine collection, 
respectively.  The  prevalence  of  male  sex,  hypertension,  hyperlipidemia,  current 
smoking  status,  diabetes,  metabolic  syndrome,  history  of  myocaridal  infarction, 
stroke, malignancy, and use of oral contraceptives were all higher in participants 
with increased levels of UAE (P<0.05). Similarly, age, BMI, total cholesterol, low-
density  lipoprotein  cholesterol,  triglycerides,  C-reactive  protein,  tissue 
plasminogen activator, and plasminogen activator inhibitor-1 levels were positively 
associated with UAE (P<0.001). High-density lipoprotein cholesterol levels were 
inversely associated with UAE (P<0.001). 
 
Urinary Albumin Excretion and Venous Thromboembolism 
Overall, 129 participants developed at least 1 VTE during a mean (SD) observation 
period  of  8.6  (1.8)  years,  corresponding  to  survey  design–adjusted  annual 
incidence of 0.14% (95% CI, 0.11%-0.19%), ranging from 0.12% (95% CI, 0.09%-
0.17%)  in  participants  with  UAE  of  less  than  15  mg/24  h  to  0.56%  (95%  CI, 
0.26%-1.47%) in participants with UAE of greater than 300 mg/24 h (Figure 2). 
These annual incidences were 0.40% (95% CI, 0.26%-0.65%) in microalbuminuric 
vs 0.12% (0.10%-0.17%) in normoalbuminuric participants (UAE<30 mg/24 hour 
urine collection). The drop-out rate due to study withdrawal and migration out of 
the city was 16% (1388) and was comparable between subgroups of UAE (P=.17). 
For these individuals, the available mean (SD) observation period was 6.5 (1.8) 
years.  
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The most commonly encountered first VTE was deep vein thrombosis (73, 57%), 
followed by pulmonary embolism (44, 34%), and combined deep vein thrombosis 
and pulmonary embolism (12, 9%). Types of VTE (pulmonary embolism vs deep 
vein thrombosis) did not differ among subgroups of UAE (P=.23). Of pulmonary 
embolism cases, 4 out of 56 (7%) were fatal. Of participants with VTE during 
follow-up,  24  (19%)  had  prior  VTE  and  that  rate  was  similar  among  different 
subgroups of UAE (P=.47). At onset of VTE, 63 participants (49%) were exposed 
to an acquired risk factor for VTE: 20 (32%) had a malignancy, 14 (22%) had 
surgery or trauma, 8 (13%) had a combined malignancy and surgery, 8 (13%) used 
oral contraceptives, 4 (6%) were immobilized, and 9 (14%) had other acquired risk 
factors. 
 
Figure 2. Adjusted Annual Incidences of Venous Thromboembolism in Relation 
to Urinary Albumin Excretion by Clinical Class 
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The annual incidences are adjusted for the enrichment of the cohort with participants with 
higher urinary albumin excretion using the survey probability weights. Chapter 3 
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Figure 3 shows the association of various variables at baseline with the unadjusted 
and  sex-  and  age-adjusted  risk  of  VTE.  In  the  univariate  analyses,  multiple 
variables were associated with VTE. After adjustment for sex and age, only UAE, 
BMI,  premenopausal  use  of  oral  contraceptives,  and  plasminogen  activator 
inhibitor type-1 levels  were significantly related to VTE. The  multivariate Cox 
model included the following variables: UAE, established VTE risk factors (ie, 
age,  malignancies,  BMI,  and  use  of  oral  contraceptives),  hypertension,  current 
smoking,  history  of  myocardial  infarction,  eGFR,  C-reactive  protein,
26  and 
plasminogen activator inhibitor-1. In this model, UAE of 15-29, 30-300 and greater 
than 300 mg per 24-hour urine collection had HRs of 1.40 (95% CI, 0.86-2.35; 
P=.14), 2.20 (95% CI, 1.44-3.36; P<0.001) and 2.82 (95% CI, 1.21-6.61; P=.02), 
respectively, as compared with participants with UAE of less than 15 mg per 24 
hour urine collection (global P=0.001). When UAE was entered as a dichotomous 
variable, that is, microalbuminuria vs normoalbuminuria (<30 mg/24 hour urine 
collection) in the multivariate Cox model, microalbuminuria conferred an HR of 
2.00  (95%  CI,  1.34-2.98;  P<0.001).  This  adjusted  HR  conferred  by 
microalbuminuria was 1.93 (95% CI, 1.24-3.03; P=0.004) if participants with prior 
VTE  were  excluded  from  the  analysis.  Of  the  mentioned  variables  in  the 
multivariate  model,  age  and  eGFR  were  entered  as  continuous variables.  Since 
metabolic syndrome is a cluster of other cardiovascular risk factors
21 and tissue 
plasminogen  activator  complexes  with  plasminogen  activator  inhibitor  type-1, 
these 2 variables were not included in the multivariate model so as to minimize 
collinearity. 
 
During  8  years  of  follow-up,  3%  of  microalbuminuric  participants  and  1%  of 
normoalbuminuric  participants  developed  VTE  (Figure  4).  As  compared  with 
participants with normoalbuminuria, the microalbuminuria related number needed 
to harm was 388 per year. 
 
When we confined our analysis to participants with unprovoked VTE, UAE of 15-
29, 30-300 and ≥300 mg per 24-hour urine collection conferred HRs (adjusted for 
age, malignancies, BMI, and use of oral contraceptives) of 1.07 (95% CI, 0.48-
2.35),  3.03  (1.71-5.38),  and  4.97  (1.87-13.18),  respectively,  as  compared  with 
participants  with  UAE  of  less  than  15  mg  per  24-hour urine  collection  (global 
P<0.001). Hazard ratios were 1.74 (95% CI, 0.94-3.24), 1.50 (0.77-2.92), and 0.98 
(0.13-7.22), respectively, for provoked VTE (global P=0.31). Albuminuria and venous thromboembolism 
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Figure 3. Univariate and Sex- and Age-Adjusted Proportional Hazards Analysis of 
Association With the First Venous Thromboembolism 
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eGFR  indicates  estimated  glomerular  filtration  rate
22;  MI,  myocardial  infarction;  UAE, 
urinary  albumin  excretion;  VTE,  venous  thromboembolism.  To  convert  values  for 
cholesterol,  HDL,  and  LDL  to  mmol/L,  multiply  by  0.0259;  to  convert  values  for 
triglycerides to mmol/L, multiply by 0.0113; to convert CRP to nmol/L multiply by 9.524. 
Solid squares denote univariate hazard ratios of VTE (black) and solid diamonds sex- and 
age-adjusted hazard ratios of VTE (grey), with the corresponding 95% CIs represented by 
the horizontal bars. 
a Sex- and age-adjusted hazard ratios (HRs) with corresponding 95% confidence intervals 
(95% CIs). Sex was adjusted for age only and age for sex only. Use of oral contraceptives 
was also adjusted for age only. 
b Body mass index (BMI [calculated as weight in kilograms divided by height in meters 
squared]), metabolic syndrome, cholesterol, high-density lipoprotein (HDL), low-density 
lipoprotein (LDL), and triglycerides were classified according to the Adult Treatment Panel 
III of the National Cholesterol Education Program.
21 Chapter 3 
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c C-reactive protein (CRP) was classified according to the Centers for Disease Control and 
Prevention and the American Heart Association.
26 
d  Since  normal  ranges of  tissue  plasminogen  activator  (tPA)  and plasminogen  activator 
inhibitor-1 (PAI-1) in the general population are unknown, we dichotomized these variables 
using their medians as cutoffs. 
 
When  UAE  measured  in  24-hour  urine  collection  was  substituted  by  urinary 
albumin  concentration  measured  in  a  spot  urine  sample,  the  adjusted  HR  for 
microalbuminuria (ie, urinary albumin concentration 20-200 mg/L) was the same, 
that is, 1.95 (95% CI, 1.34-2.83; P<0.001) as compared with normoalbuminuria (ie, 
urinary albumin concentration <20 mg/L). When the multivariate Cox model was 
also adjusted for the enrichment of the study cohort with participants with higher 
UAE,  using  survey  probability  weights,
27  the  corresponding  HR  for 
microalbuminuria measured in 24-hour urine collection was 2.33 (95%CI, 1.34-
4.05; P = 0.003), as compared with normoalbuminuria. 
 
Figure 4. Cumulative Incidence of Venous Thromboembolism 
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MA denotes microalbuminuria (i.e., UAE 30-300 mg/24-hr); NA, normoalbuminuria 
(i.e., UAE<30 mg/24-hr). 
 Albuminuria and venous thromboembolism 
 
  58 
As previously reported for UAE and arterial thromboembolism,
11,28 we found a 
gradual relationship between UAE and VTE in the normal ranges of UAE (<30 
mg/24 h): adjusted HRs of UAE 10-19 and 20-29 mg per 24-hour urine collection 
were 1.31 (95% CI, 0.81-2.11) and 1.86 (95% CI, 1.00-3.43), as compared with 
UAE  of  less  than  10  mg  per  24-hour  urine  collection.  Finally,  there  was  no 
interaction between UAE and eGFR (P=0.67) Chapter 3 
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COMMENT 
 
This study explored the relationship between microalbuminuria and VTE. A clear 
gradual relationship was found between levels of UAE and the incidence of VTE, 
even in the normal range of UAE. Besides UAE, multiple classic atherosclerosis 
risk factors were related to VTE in univariate analyses. However, after adjustment 
for sex and age, only UAE, BMI, premenopausal use of oral contraceptives, and 
plasminogen activator inhibitor type-1 levels were related to VTE. In a multivariate 
model, UAE remained an independent predictor of VTE. About half of the VTE 
cases  were  unprovoked.  Moreover,  higher  levels  of  UAE  were  particularly 
associated with unprovoked VTE. 
 
Several studies addressed the link between atherosclerosis risk factors and VTE.
8,29-
33  Our  results  on  atherosclerosis  risk  factors  are  consistent  with  a  comparable 
community-based prospective cohort study
33 in which only BMI and diabetes were 
related to VTE; after adjustment for age, sex, and race. In our study, diabetes was 
not related to VTE; however, our results could not be generalized to all diabetics 
since individuals with insulin-dependent diabetes were excluded.
10,20 In a recent 
meta-analysis,
8 obesity, hypertension, diabetes, and higher triglyceride levels were 
positively  associated  with  VTE,  whereas  higher  high-density  cholesterol  levels 
were  inversely  related  to  VTE,  and  smoking  and  total  cholesterol  were  not 
significantly related to increased risk of VTE. However, there was a significant 
heterogeneity among studies evaluated in this meta-analysis.
8 Moreover, most of 
the  analyzed  studies  were  not  primarily  conducted  to  assess  the  link  between 
atherosclerosis risk factors and VTE, some were limited to only 1 sex, and the 
results  from  cohort  studies  were  not  adjusted  for  age.  In  our  study,  metabolic 
syndrome,
21 a cluster of cardiovascular risk factors, was not related to elevated risk 
of VTE after sex and age adjustment. In several studies, metabolic syndrome was 
associated with an approximately 2-fold increased risk of VTE.
34 However, this 
link might be due to the association between individual features of the metabolic 
syndrome and VTE.
35 
 
The  value  of  microalbuminuria  as  an  independent  predictor  of  arterial 
thromboembolism has been demonstrated in individuals with diabetes as well as in 
those without.
10,11,36,37 In our previous publication,
10 microalbuminuria was related 
to an adjusted relative risk of 1.29 (95% CI, 1.04-1.60) and 1.58 (1.10-2.26) for MI Albuminuria and venous thromboembolism 
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and stroke, respectively, as compared with participants with normoalbuminuria. In 
the HOPE study,
11 adjusted HRs for MI, stroke, or cerebrovascular death were 1.75 
(95% CI,1.49-2.05) and 1.42 (1.18-1.71) in the placebo and intervention group, 
respectively. In comparison, in the current analysis microalbuminuria conferred an 
adjusted  HR  of  2.00  (95%  CI,  1.34-2.98)  for  VTE,  as  compared  with 
normoalbuminuria.  Moreover,  nephrotic-range  proteinuria  is  a  well-known  risk 
factor  for  VTE  and  predisposes  at  least  as  often  to  VTE  as  arterial 
thromboembolism.
38  The  high  risk  of  VTE  in  individuals  with  nephrotic-range 
proteinuria  is  assumed  to  be  secondary  to  loss  of  anticoagulant  proteins.  In 
individuals  with  microalbuminuria,  this  is  unlikely  to  be  a  direct  cause;  more 
likely,  the  increased  risk  of  VTE  is  secondary  to  endothelial  injury  and/or  the 
related changes in the levels of procoagulant proteins.
9,12-19 
 
The fact that microalbuminuria has a high prevalence in the general population 
(7.2%)  suggests  that  on  the  population  level,  microalbuminuria  may  be  an 
important risk factor for VTE.
39 Moreover, in contrast to most of the established 
VTE  risk  factors,  microalbuminuria  could  be  treated  by  non-anticoagulant 
medication (eg, renin-angiotensin system inhibitors). Future studies are needed to 
evaluate the effect of these drugs on the risk of VTE. 
 
Our study has some potential limitations that should be addressed. The incidence of 
VTE  in  our  cohort  may  be  underestimated  as  VTE  cases  were  retrospectively 
identified.  However,  as  compared  with  other  prospective  studies,  the  annual 
incidence of 0.14% is rather elevated given the very high incidence of VTE in 
individuals older than 75 years, whereas our cohort was confined to individuals 
aged 28 to 75 years. Furthermore, VTE was not adjudicated by an independent 
committee. Nevertheless, since only symptomatic and objectively verified events 
were  considered,  misclassification  seems  unlikely.  Enrichment  with  participants 
with higher UAE is unlikely to have influenced our risk estimates (ie, HRs), as 
these estimates did not significantly change after accounting for the study design. 
Since we used predefined cutoff values for UAE, spectrum bias is unlikely despite 
the differences in sex and age between individuals who responded and those who 
did not. Due to lack of sufficient statistical power, as only 134 participants were 
known with malignant disease, malignancy was not associated with VTE after age 
and sex adjustment. Data on the use of oral contraceptives could not be generalized 
as participants younger than 28 years were not enrolled. Chapter 3 
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Despite these limitations, this is the first study assessing a link between micro-
albuminuria  and  VTE.  Moreover,  the  PREVEND  cohort  is  unique  in  its  large 
population-based  prospective  setting  in  which  UAE  is  assessed  in  two  24-hour 
urine  samples,  which  is  considered  the  criterion  standard  for  measuring  UAE. 
Although criterion standard is desirable for the proof of concept, in the clinical 
setting microalbuminuria is generally assessed in a spot urine sample. When we 
used the microalbuminuria definition for a spot urine sample (ie, urinary albumin 
concentration of 20-200 mg/L), results were the same. 
 
In  conclusion,  microalbuminuria  is  an  independent  risk  factor  for  VTE.  The 
relative risk of VTE associated with microalbuminuria is comparable to previously 
reported risk of MI or stroke in individuals with microalbuminuria. 
 
Additional  Contributions:  We  thank  Frits  R.  Rosendaal,  MD,  PhD,  Department  of 
Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands; and 
Martin H. Prins, MD, PhD, Department of Clinical Epidemiology and Medical Technology 
Assessment, Academic Hospital, Maastricht, the Netherlands, for clinical and statistical 
advice. Neither individual received compensation for the contributions. Dr van der Meer 
recently died following a sudden illness. We thank Hanneke C. Kluin-Nelemans, MD, PhD, 
Department  of  Hematology,  University  Medical  Center  Groningen,  Groningen,  the 
Netherlands, for providing help to guide the paper during revision after Dr van der Meer’s 
death. 
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ABSTRACT 
 
Background: End-stage renal disease has been associated with venous thrombosis 
(VT). However, the risk of VT in early stages of chronic kidney disease (CKD) has 
not yet been investigated. The aim of this study was to investigate whether CKD 
patients with stage 1-3 are at increased risk of VT. 
 
Methods: 8 495 subjects were included in a prospective cohort study, in which 
renal  function  and  albuminuria  was  assessed,  starting  in  1997-1998,  and  were 
followed for the occurrence of VT until June 1, 2007. CKD patients were staged 
according to the Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines 
based on 24-hour urine albumin excretions and estimated glomerular filtration rates 
(GFR). Objectively verified symptomatic VT was considered as endpoint. 
 
Results: Of the 8 495 subjects, 243 had stage 1 CKD, 856 stage 2, and 491 stage 3. 
During a median follow-up period of 9.2 years, 128 individuals developed VT. The 
hazard ratios (HRs) for CKD stages 1, 2, and 3 were respectively 2.2 (95% CI 0.9-
5.1), 1.9 (95% CI 1.1-3.1), and 1.6 (95% CI 0.9-2.8) relative to those without CKD 
after  adjustment  for  age,  sex,  BMI,  hypertension,  diabetes,  malignancy,  and 
hsCRP. Subjects with CKD stage 3 and albuminuria (≥30 mg per day) had an 
adjusted HR of 3.0 and subjects with stage 3 without albuminuria had an adjusted 
HR of 1.0. 
 
Conclusions:  CKD stage 1, 2, and CKD stage 3 in presence of albuminuria are 
risk factors for VT. The risk of VT is more related to albuminuria than to impaired 
GFR. 
 
 
   Chapter 4
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Introduction 
 
Patients with severe chronic kidney disease (CKD) have both an increased risk of 
arterial cardiovascular disease as well as for venous thrombosis (VT). The Kidney 
Disease Outcome Quality Initiative (K/DOQI) guidelines defined CKD as either 
kidney damage (albuminuria ≥30 mg per day) or decreased kidney function and 
categorized CKD in five stages [1;2]. The prevalence of CKD in the US is now 
13% and is increasing, predominantly as a result of the type II diabetes epidemic 
[3].  
 
The increased risk of arterial cardiovascular disease in CKD has been known for a 
long time and has been studied extensively for different CKD stages [4-8]. Recent 
studies have also shown an association between overt CKD and VT [9;10]. A study 
of  the  PREVEND  cohort  showed  that  the  presence  of  micro-albuminuria 
(albuminuria 30-300 mg per day) was a risk factor for VT [9]. Another study of the 
LITE cohort showed that patients with a glomerular filtration rate (GFR) between 
15  and  60  ml/min  (CKD  stage  3-4)  had  a  two-fold  increased  risk  of  VT  as 
compared  to  subjects  with  a  normal  kidney  function  (GFR  >90  ml/min)  [10]. 
However,  information  on  albuminuria  was  not  available  in  this  study.  To  our 
knowledge, there is no study on the risk of VT in the different CKD stages taking 
into account albuminuria which is a prerequisite for staging CKD and for defining 
patients without CKD.  
 
Therefore, we investigated whether patients with CKD stage 1, 2, and 3 had an 
increased risk of VT in a large population-based cohort, and set out to determine 
absolute and relative risks for various stages of CKD. Chronic kidney disease and venous thromboembolism 
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METHODS 
 
Study design and population 
For  this  study,  we  used  data  of  the  Prevention  of  Renal  and  Vascular  Disease 
(PREVEND)  study.  The  PREVEND  study  was  designed  to  investigate  the 
association  between  albuminuria  and  renal  and  cardiovascular  outcomes  in  the 
general population. Details of the study have been published elsewhere [11-13] and 
can be found at http://www.prevend.org. The study outline is presented in Figure 
1. In summary, all inhabitants of the city of Groningen, the Netherlands, aged 28-
75 years (n= 85 421) were invited to send a morning urine sample to screen for 
albuminuria.  Of  these  subjects,  40  856  responded.  From  these  responders,  the 
PREVEND cohort was selected aiming for a cohort enriched for the presence of 
albuminuria.  Pregnant  women  and  subjects  with  insulin-dependent  diabetes 
mellitus  were  excluded.  All  participants  with  an  urinary  albumin  concentration 
(UAC) of ≥10 mg/L were invited (N=9 966), of whom 6 000 subjects participated. 
Furthermore, a randomly selected cohort group of 2 592 subjects selected from 30 
890 respondents with UAC of <10 mg/L participated. These 8 592 subjects formed 
the baseline PREVEND cohort. These participants twice visited an outpatient clinic 
for  measurements  concerning  their  health.  For  the  current  study,  subjects  were 
excluded  because  of  missing  data  on  24-hour  urinary  albumin  excretion  or 
creatinine (n=86). Furthermore, subjects with CKD stage 4 (n=8) or stage 5 (n=3) 
were excluded of whom one had a VT event, leaving 8 495 subjects for the present 
analysis.  The  PREVEND  study  has  been  approved  by  the  local  medical  ethics 
committee and is conducted in accordance with the guidelines of the Declaration of 
Helsinki. 
 
Measurements and definitions  
Serum  creatinine,  total  cholesterol,  and  plasma  glucose  were  measured  by  dry 
chemistry  (Eastman  Kodak,  Rochester,  New  York).  High-sensitivity  C-reactive 
protein (hsCRP) was determined by nephelometry (BN II, Dade Behring, Marburg, 
Germany).  Participants collected two 24-hour urine samples, in which UAC was 
determined  by  nephelometry  (BN  II,  Dade  Behring,  Marburg,  Germany).  The 
amount  of  albuminuria  was  measured  as  the  mean  of  the  two  24-hour  urine 
samples.   Chapter 4
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  85 421 Invited by mailed questionnaire for spot urine test 
44 565 Did not respond 
40 856 Responded to questionnaire 
30 890 Had UAC <10 mg/L  9 966 Had UAC ≥10 mg/L 
22 492 Eligible to participate  7 768 Eligible to participate 
3 395 Randomly selected 
2 592 Completed the 
screening protocol 
6 000 Completed the  
screening protocol 
8 592 Completed baseline screening (1997-1998) 
 97 Excluded             
86 Missing creatinine or 24-
hour urine collection  
8 CKD stage 4  
3 CKD stage 5   
8 495 Included in primary analysis 
2198 Excluded: 
1800 Did not consent 
60 Pregnant 
167 Insulin-dependent 
171 Other 
8398 Excluded: 
7332 Did not consent 
223 Pregnant 
212 Insulin-dependent 
631 Other 
1 768 Declined to participate  803 Declined to participate 
 
Figure 1. Outline of the PREVEND study. 
CKD indicates chronic kidney disease; UAC, urinary albumin concentration. 
 
Hypertension was defined as systolic blood pressure of ≥140 mm Hg, diastolic 
blood pressure of ≥90 mm Hg, or the use of antihypertensive drugs. Diabetes was 
defined as a fasting glucose level of ≥126 mg/dL, nonfasting plasma glucose levels 
of ≥200 mg/dL, or the use of oral antidiabetic drugs. Hypercholesterolemia was 
defined as a total serum cholesterol concentration ≥250 mg/dL, or in case of a 
previous myocardial infarction or stroke a concentration of ≥193 mg/dL, or the use 
of  lipid-lowering  drugs.  Body  mass  index  (BMI)  was  calculated  as  weight  in Chronic kidney disease and venous thromboembolism 
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kilograms  divided  by  height  in  meters  squared.  GFR  was  estimated  by  the 
Modification of Diet in Renal Disease (MDRD) study equation [14] taking into 
account sex, age, race, and serum creatinine level. In an additional analysis, the 
newly  developed  but  less  often  used  Chronic  Kidney  Disease  Epidemiology 
Collaboration  (CKD-EPI)  study  equation  [15]  was  used  to  estimate  eGFR  to 
compare  these  results  with  the  results  of  the  MDRD-equation.  The  CKD-EPI 
equation  has  been  shown  to  outperform  the  MDRD  equation  in  estimating  the 
eGFR above the 60 ml/min [15]. 
 
Chronic kidney disease 
CKD was staged according to the K/DOQI guidelines [1;2]. CKD stage 1 was 
defined as eGFR >90 ml/min and albuminuria (urinary albumin excretion ≥30 mg 
per 24-hour urine collection), CKD stage 2 as eGFR between 60 and 90 ml/min 
and albuminuria, and CKD stage 3 as eGFR between 30 and 60 ml/min. 
 
Venous thrombosis  
The regional anticoagulation clinic database was used to identify participants who 
developed  VT  between  January  1997  and  June  2007.  In  the  Netherlands,  all 
outpatient  treatment  with  vitamin  K  antagonists  is  monitored  by  regional 
anticoagulation clinics. Therefore, all VT events in treated outpatients are recorded 
by anticoagulation clinics. Moreover, as a secondary check for outpatient VT cases 
and  identification  of  within  hospital  (fatal)  cases,  all  study  participants  were 
searched for VT events in the national registry of death certificates and the national 
registry of hospital discharge diagnoses datasets. With the use of three independent 
sources, it is unlikely to miss VT events. The investigators who collected these data 
were  blinded  for  CKD  stages  of  the  participants.  In  addition,  all  VT  events 
according  to  the  three  sources  were  validated  by  reviewing  medical  records  of 
these patients. Only objectively verified symptomatic VT events were considered. 
Deep  vein  thrombosis  (DVT)  was  confirmed  by  compression  ultrasound  and 
pulmonary embolism (PE) by ventilation-perfusion lung scanning, spiral computed 
tomography, or at autopsy. The observation time of each participant was calculated 
as a time elapsed between the testing of albuminuria (1997-1998) and the first 
episode of VT or a censoring event (withdrawal from the study, moving out of the 
city, death, or June 2007), whichever occurred first. Incidence rates for VT were 
calculated by dividing the number of patients with a VT by the total observation 
time  at  risk.  VT  was  considered  unprovoked  in  the  absence  of  major  surgery,   Chapter 4
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trauma,  immobilization  for  >7  days,  oral  contraceptives,  hormone  therapy, 
pregnancy, malignant disease, long-distance travel for >4 hours, active infectious 
disease,  paresis/paralysis  of  the  leg,  or  heart  failure  at  or  within  three  months 
before  the  development  of  VT.  Medical  records  were  viewed  with  a  check-list 
including these well-defined and well-documented variables to categorize VT into 
provoked or unprovoked.   
 
Statistical analyses  
Baseline  characteristics  of  the  participants  were  compared  between  subjects 
without CKD and subjects with CKD stage 1-3. Continuous data were reported as 
medians with interquartile ranges. Kaplan-Meier life-tables were used to estimate 
cumulative  survival  for  CKD  stage  1-3  and  no  CKD.  To  investigate  whether 
patients  with  CKD  stage  1-3  had  an  increased  risk  of  VT,  proportional hazard 
regression was used to calculate hazard ratios (HRs) with 95% confidence intervals 
(CIs) as compared to participants without CKD (reference group). All analyses 
were performed for CKD stage 1, 2, and 3 combined and separately. In contrast to 
CKD stages 1 and 2, CKD stage 3 is only defined by decreased eGFR (between 30 
and 60 ml/min) and not by the presence of albuminuria according to the K/DOQI 
guidelines. We also calculated HRs for CKD stage 3 stratified for the presence of 
albuminuria.  We  adjusted  the  HRs  for  age,  sex,  and  BMI  and  additional  for 
hypertension, diabetes, malignancy, and hsCRP. HRs were not adjusted for other 
cardiovascular risk factors such as hyperlipidemia and smoking, since these were 
not  associated  with  VT  in  the  PREVEND  cohort.[9]  We  repeated  the  same 
analyses for provoked and unprovoked VT separately. 
   
To investigate whether eGFR is a risk factor for VT apart from albuminuria, we 
calculated  HRs  with  95%  CIs  for  eGFR  adjusted  for  albuminuria  and  for 
albuminuria adjusted for eGFR to evaluate the associations of level of eGFR and 
albuminuria with risk of VT. Furthermore, we divided subjects in six categories 
based on albuminuria and eGFR (>90 ml/min, between 60 and 90 ml/min, and 
between  30  and  60  ml/min).  HRs  with  95%  CIs  were  calculated  for  eGFR  in 
absence  or  presence  of  albuminuria  as  compared  to  subjects  with  eGFR  >90 
ml/min without albuminuria (reference group). 
   
Finally, we calculated HRs with 95% CIs for CKD stages 1-3 as compared to 
participants without CKD using the CKD-EPI formula for staging CKD. STATA Chronic kidney disease and venous thromboembolism 
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software  version  10.1  (StataCorp  LP,  College  Station,  Tx)  was  used  for  the 
statistical analyses.        Chapter 4
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RESULTS 
 
The baseline characteristics of the 8 495 subjects are shown in Table 1. Of the 6 
905 subjects without CKD, 26.4% had a GFR >90 ml/min and 73.6% had a GFR 
between 60 and 90 ml/min. Of the 1 590 with CKD, 243 were in stage 1, 856 in 
stage  2,  and  491  in  stage  3.  Of  the  491  subjects  with  stage  3  CKD,  164  had 
albuminuria (≥30 mg per day). Subjects with CKD stage 1-3 were older, were more 
often  male,  had  more  often  diabetes,  hypertension  and  malignancy,  and  had  a 
higher body mass index and higher CRP levels than subjects without CKD. The 
age of CKD patients increased with the CKD stage. 
 
Table 1. Baseline characteristics 
Characteristic  No CKD 
 
(n=6905) 
CKD 
stage 1-3 
(n=1590) 
CKD 
stage 1 
(n=243) 
CKD 
stage 2 
(n=856) 
CKD 
stage 3 
(n=491) 
Age* (years)  46 (37-56)  59 (48-67)  47 (39-56)  58 (48-66)  65 (58-70) 
Male, %  49  56  66  64  38 
Caucasians, %  95  96  93  97  97 
Diabetes, %  2.4  9.8  12.8  11.2  5.9 
Hypertension, %  27  65  50  65  72 
Hypercholesterolemia,% 28  46  36  44  54 
BMI* (kg/m
2)  25 (23-28)  27 (24-30)  27 (24-30)  27 (25-30)  27 (25-30) 
hsCRP* (mg/L)  1.1 (0.5-0.7)  2.2 (1.0-4.6)  2.1 (0.9-4.9)  2.3 (1.0-4.4) 2.2 (1.1-4.8) 
Malignancy, %  1.4  2.3  1.6  2.2  2.8 
eGFR* (ml/min)  81 (73-91)  72 (59-83)  97 (93-104)  76 (69-82)  55 (51-58) 
UAE* (mg per day)  8 (6-12)  47 (33-93)  57 (39-101)  59 (39-107)  14 (7-47) 
CKD indicates chronic kidney disease; BMI, body mass index; hsCRP, high-sensitivity c-
reactive protein; eGFR, estimated glomerular filtration rate; UAE, urinary albumin excretion. 
* median (interquartile range) 
 
Overall, 128 subjects developed VT during a median observation period of 9.2 
years (ranging from 0 to 10 years). Of the 128 patients with VT, 72 (56%) had 
DVT only, 44 had PE only (34%), and 12 (9%) had a combination of both. Of the 
1590 subjects with CKD stage 1-3, 49 developed VT as compared with 79 of the 
6905 subjects without CKD. Seven of the 243 patients with CKD stage 1, 26 of the 
856 patients with CKD stage 2, and sixteen of 491 patients with CKD stage 3 
developed VT. Four patients died because of a PE (three in CKD stage 3 and one 
without CKD). Furthermore, there was no significant difference in the distribution 
of PE and DVT in CKD stage 3 (63% of VT patients had a PE) as compared to Chronic kidney disease and venous thromboembolism 
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Adjusted* HR 1.8 (95% CI, 1.2-2.9) 
CKD stage 1-2 (36% had a PE) (P=0.09) or as compared to no CKD (43% had a 
PE) (P=0.16). The cumulative incidence for VT at eight years of follow-up were 
3.2% for CKD stage 1, 3.0% for stage 2, 3.3% for stage 3, 3.1% for stage 1-3, and 
1.1% for no CKD. The number needed to treat to prevent one VT event in patients 
with CKD stage 1-3 was approximately 400 patients per year. Figure 2 shows the 
Kaplan-Meier risk curves for VT events for patients with CKD stage 1-3 versus 
subjects without CKD.  
  
 
Figure 2. Kaplan-Meier estimates of the risk of venous thrombosis according to 
stages of chronic kidney disease.  
CKD, chronic kidney disease; prs-yrs, person-years; yrs, years. 
*Adjusted for age, sex, body mass index, hypertension, diabetes, malignancy, and hsCRP. 
 
The incidence rate for VT in subjects without CKD was 1.3 (95% CI 1.1-1.7) per 
1000 person-years and 3.7 (95% CI 2.8-4.0) for subjects with CKD stage 1-3 with 
a corresponding HR for VT of 2.8 (95% CI 2.0-7.3) for CKD stage 1-3 compared   Chapter 4
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to no CKD. The HR decreased to 1.8 (95% CI 1.2 -2.9) after adjustment for age, 
sex, BMI, hypertension, diabetes, malignancy, and hsCRP. 
 
The crude HRs were 2.6 (95% CI 1.2-5.6), 2.8 (95% CI 1.8-4.3), and 3.0 (95% CI 
1.8-5.2) for respectively CKD stage 1, 2, and 3. Figure 3 shows adjusted HRs with 
95% CIs for CKD stages 1, 2, and 3, the latter with or without the presence of 
albuminuria compared to no CKD. The HRs were 2.2 (95% CI 0.9 -5.1), 1.9 (95% 
CI  1.1  -3.1),  and  1.6  (95%  CI  0.9  -2.8).  For  CKD  stage  3  with  and  without 
albuminuria, the HRs were respectively 5.5 (95% CI 2.8-11.0) and 1.9 (95% CI 
0.9-4.2) without adjustment, and 3.0 (95% CI 1.4-6.5) and 1.0 (95% CI 0.4-2.4) 
after full adjustment. 
 
 
Figure 3. Adjusted hazard ratios for venous thrombosis by CKD stage.  
CKD, chronic kidney disease; HR, hazard ratio; eGFR, estimated glomerular filtration 
rate; CKD 3 Alb +, CKD stage 3 and urinary albumin excretion ≥30 mg per day; CKD 3 
Alb -, CKD stage 3 and urinary albumin excretion <30 mg per day.  
*Adjusted for age, sex, body mass index, hypertension, diabetes, malignancy, and hsCRP. 
 
Of  the  128  VT  events,  66  were  unprovoked  (51.6%)  and  62  (48.4%)  were 
provoked (Table 2). For unprovoked VT, the HRs after adjustment for age, sex, 
BMI, hypertension, diabetes, malignancy, and hsCRP.were 2.1 (95% CI 1.2-3.6) Chronic kidney disease and venous thromboembolism 
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for CKD stages 1-3, 2.5 (95% CI 0.8-7.4) for stage 1, 2.4 (95% CI 1.3-4.4) for 
stage 2, and 1.4 (95% CI 0.6-3.3) for stage 3. For provoked VT, the HRs after 
adjustment were 1.2 (95% CI 0.6-2.3) for CKD stages 1-3, 1.4 (95% CI 0.3-5.9) for 
stage 1, 0.8 (95% CI 0.3-2.2) for stage 2, and 1.7 (95% CI 0.8-3.9) for stage 3. 
 
Albuminuria was associated with a 2.1-fold increased risk of VT after adjustment 
for age, sex, BMI, hypertension, diabetes, malignancy, hsCRP, and eGFR (Table 
3). As compared to subjects with an eGFR >90 ml/min, subjects with an eGFR 
between 30 and 60 ml/min had 50% increased risk of VT after adjustment for after 
adjustment  for  age,  sex,  BMI,  hypertension,  diabetes,  malignancy,  hsCRP,  and 
albuminuria. 
Table 2. Incidence rates and hazard ratios for provoked and unprovoked venous 
thrombosis 
  No CKD 
 
(n=6905) 
CKD 
 stage 1-3 
(n=1590) 
CKD  
stage 1 
(n=243) 
CKD  
stage 2 
(n=856) 
CKD 
stage 3 
(n=491) 
Unprovoked VT           
No. of VT  35  31  5  19  7 
Incidence rate per  
1000 person-years 
0.6 (0.4-0.8)  2.4 (1.7-3.4)  2.5 (1.0-5.9)  2.7 (1.7-4.2)  1.7 (0.8-3.7) 
Crude hazard ratios 
(95% CI) 
1.0  4.0 (2.5-6.5)  4.2 (1.6-10.6) 4.5 (2.6-7.9)  3.0 (1.3-6.7) 
*Adjusted hazard  
ratios  (95% CI) 
1.0  2.1 (1.2-3.6)  2.5 (0.8-.7.4)  2.4 (1.3-4.4)  1.4 (0.6-3.3) 
Provoked VT 
         
No. of VT  44  18  2  7  9 
Incidence rate per 
1000 person-years 
0.7 (0.5-1.0)  1.4 (0.9-2.2)  1.0 (0.2-3.9)  1.0 (0.5-2.1)  2.3 (1.2-4.4) 
Crude hazard ratios  
(95% CI) 
1.0  1.9 (1.1-3.2)  1.3 (0.3-5.5)  1.3 (0.6-3.0)  3.1 (1.5-6.3) 
*Adjusted hazard  
ratios  (95% CI) 
1.0  1.2 (0.6-2.3)  1.4 (0.3-5.9)  0.8 (0.3-2.2)  1.7 (0.8-3.9) 
CKD indicates chronic kidney disease and VT indicates venous thrombosis 
*Adjusted for age, sex, and body mass index,  hypertension, diabetes, malignancy, and 
hsCRP   Chapter 4
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Table 4 shows HRs for VT for decreased eGFR (between 60 and 90 ml/min and 
between 30 and 60 ml/min) in absence and presence of albuminuria as compared to 
subjects  with  eGFR  >90ml/min  without  albuminuria.  The  adjusted  HRs  for 
subjects without albuminuria and an eGFR between 60 and 90 ml/min or an eGFR 
between 30 and 60 ml/min were respectively 1.5 (95% CI 0.7-3.1) and 1.4 (95% CI 
0.5-4.1). HRs for VT were increased in the presence of albuminuria in all eGFR 
categories. The adjusted HRs were 3.1 (95% CI 1.1-8.9), 2.7 (95% CI 1.2-6.1), and 
4.1 (95% CI 1.5-11.0) for subjects with albuminuria and respectively eGFR >90 
ml/min, eGFR between 60 and 90 ml/min, and eGFR between 30 and 60 ml/min. 
and an eGFR between 60 and 90 ml/min or an eGFR between 30 and 60 ml/min 
were respectively 1.4 (95% CI 0.7-2.7) and 1.4 (95% CI 0.5-3.8). HRs for VT were 
increased in the presence of albuminuria in all eGFR categories. The age-, sex-, 
and BMI-adjusted HRs were 2.7 (95% CI 1.0-7.1), 2.2 (95% CI 1.1-4.7), and 3.2 
(95% CI 1.3-8.3) for subjects with albuminuria and respectively eGFR >90 ml/min, 
eGFR between 60 and 90 ml/min, and eGFR between 30 and 60 ml/min.  
Table 3. Association between eGFR, albuminuria, and risk for venous 
thrombosis  
  *Adjusted hazard ratios 
estimated glomerular filtration rate (eGFR)   
  > 90 ml/min  1.0 (reference) 
  60-90 ml/min  1.3 (0.7-2.3) 
  30-60 ml/min  1.5 (0.7-3.3) 
     
   
†Adjusted hazard ratios 
Albuminuria
‡   
  No  1.0 (reference) 
  Yes  2.1 (1.4-3.2) 
* Adjusted for age, sex, body mass index, hypertension, diabetes, malignancy, 
and hsCRP, and albuminuria (continuous) 
†  Adjusted for age, sex, body mass index, hypertension, diabetes, malignancy, 
and hsCRP, and eGFR (continuous) 
‡ Albuminuria defined as urinary albumin excretion ≥30 mg per day Chronic kidney disease and venous thromboembolism 
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The HRs for VT in CKD stage 1, 2, and 3 were respectively 1.6 (95% CI, 0.7-3.8), 
1.9 (95% CI, 1.2-3.0), and 1.5 (95% CI, 0.9-2.7) using the CKD-EPI formula after 
adjustment  for  age,  sex,  and  BMI.  HRs  for  subjects  with  CKD  stage  3  and 
albuminuria and subjects with CKD stage 3 without albuminuria were respectively 
1.9 (95% CI 0.9-4.1) and 1.3 (95% CI 0.6-2.8) after adjustment. 
Table 4. Hazard ratios for venous thrombosis by decreased glomerular filtration rates and 
albuminuria  
  Crude hazard ratios  *Adjusted hazard ratios 
  No albuminuria 
†Albuminuria  No albuminuria 
†Albuminuria 
eGFR   >90  
ml/min/1.73 m
2 
1.0 
(reference) 
4.8 (1.9-12.4)  1.0 (reference)  3.1 (1.1-8.9) 
eGFR    60-90 
ml/min/1.73 m
2 
2.2 (1.2-4.1)  5.2 (2.6-10.5)  1.5 (0.7-3.1)  2.7 (1.2-6.1) 
eGFR    30-60 
ml/min/1.73 m
2 
3.6 (1.4-9.3)  10.3 (4.2-24.7)  1.4 (0.5-4.1)  4.1 (1.5-11.0) 
CKD indicates chronic kidney disease; eGFR, estimated glomerular filtration rate; UAE, 
urinary albumin excretion per day. 
*Adjusted for age, sex, and body mass index,  hypertension, diabetes, malignancy, and 
hsCRP 
†Albuminuria defined as urinary albumin excretion ≥30 mg per day   Chapter 4
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DISCUSSION 
 
In this study including 8495 subjects followed for over 8 years, we found a 2.2-fold 
(95% CI 0.9 -5.1) increased risk of VT in patients with CKD stage 1 and a 1.9-fold 
(95% CI 1.1 -3.1) increased risk of VT in patients with CKD stage 2 as compared 
to  subjects  without  CKD  according  to  the  K/DOQI  guidelines.  CKD  stage  3 
patients  with  albuminuria  had  3.0-fold  (95%  CI  1.4-6.5)  increased  risk  of  VT, 
while CKD stage 3 patients without albuminuria had a HR of 1.0 (95% CI 0.4-2.4). 
The risk of VT associated with CKD seemed related to albuminuria rather than to 
impaired  eGFR.  Furthermore,  our  findings  showed  that  CKD  stages  1-3  were 
mainly associated with unprovoked VT. Using the CKD-EPI formula instead of the 
MDRD formula for staging CKD did not result in large differences for any of the 
analyses. 
 
Previous studies have investigated the association between MDRD based eGFR 
and VT [10;16]. In the study of the LITE cohort, HRs for VT were 1.3 (95% CI 
1.0-1.6) for subjects with GFR between 60 and 90 ml/min and 2.1 (95% CI 1.5-3.0) 
for subjects with GFR between 15 and 60 ml/min (CKD stage 3-4) as compared to 
subjects with GFR >90 ml/min [10]. However, information on albuminuria was not 
available in this study and formal classification into CKD stages was therefore not 
possible.  In  our  study,  we  found  a  HR  of  1.5  for  VT  for  CKD  stage  3  after 
adjustment  for  age,  sex,  and  BMI;  we  showed  that  the  risk  of  VT  was  only 
increased in the presence of albuminuria. Recent findings from the LITE study 
group contrast their earlier findings: eGFR based on cystatin was associated with 
an approximately 1.6-fold increased risk of VTE, while eGFR based on creatinine 
was not associated with an increased risk of VT [16]. The authors, however, could 
not  explain  the  discrepancy  between  the  earlier  and  the  current  finding. 
Furthermore, albuminuria was not a risk factor for VT in their study in contrast to 
our study. An explanation for this discrepancy could be that the relatively low 
prevalence of albuminuria may have limited their power to detect an association 
between VT and albuminuria, while our cohort was enriched for the presence of 
albuminuria. Moreover, whereas in our study albuminuria was assessed in 24hr 
urine samples (gold standard) that were not frozen before assessment, albuminuria 
was assessed by albumin-creatinine ratio in frozen samples in their study. Frozen 
storage  is  known  to  induce  a  systematic  decrease  and  more  variability  in 
albuminuria  concentration  [17].  Furthermore,  subjects  with  albuminuria  are Chronic kidney disease and venous thromboembolism 
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probably mainly diabetics in their study, while in PREVEND these are mainly non-
diabetics, as per protocol insulin-using diabetics were excluded. This may have 
influenced the risk estimates, as diabetic subjects are usually on statin therapy and 
more  frequently  treated  with  anti-platelet  medication  for  their  cardiovascular 
morbidity. New findings indicate that statin use may reduce the risk of VT [18]. 
 
Although the seemingly higher risk of VT in CKD stage 1 and 2 as compared to 
stage 3 might be surprising, the same pattern in the association between CKD and 
cardiovascular disease was previously found in the PREVEND study [4]. CKD 
patients  with  stage  1  and  2  were  at  higher  risk  of  cardiovascular  disease  as 
compared to CKD patients with stage 3. A plausible explanation for this might be 
the difference in staging of CKD stage 3 and CKD stage 1 and 2. Albuminuria is 
necessary to define CKD stage 1 and 2, whereas only GFR is needed to define 
CKD stage 3 to 5. Therefore, CKD stage 3 is a heterogeneous group with subjects 
with and without evident kidney damage (albuminuria).  We found that CKD stage 
3 patients with albuminuria were at higher risk of VT as compared to CKD patients 
with stage 3 without albuminuria. These findings are in line with several other 
studies  suggesting  a  higher  risk  for  CKD  stage  3  subjects  with  albuminuria  as 
compared  to  CKD  stage  3  subjects  without  albuminuria  for  different  adverse 
outcomes, such as cardiovascular disease and the development of end-stage renal 
disease  [4;19-21].  These  data  taken  together  suggest  that  information  on 
albuminuria could be added to CKD stage 3 in order to improve the value of CKD 
staging for risk prognosis. 
 
Several mechanisms behind the increased risk of VT in CKD are possible. First, 
endothelial damage could explain the increased risk of VT. It is remarkable that the 
association  between  CKD  stage  1-3  and  VT  was  comparable  to  the  previously 
reported association between CKD stages 1-3 and cardiovascular disease in the 
PREVEND study [4]. Therefore, it is tempting to hypothesize that a common risk 
factor  for  CKD  leads  to  both  VT  and  arterial  cardiovascular  disease.    In  our 
analysis, hypertension, BMI, and diabetes did not explain the increased risk of VT. 
Second, the increased risk of VT could be due to procoagulant changes in CKD 
patients which may be predominantly present in subgroups of CKD patients such 
as patients with nephrotic syndrome [22]. CKD and nephrotic syndrome have been 
associated  with  elevated  levels  of  D-dimer,  CRP,  fibrinogen,  factor  VII,  factor 
VIII,  and  von  Willebrand  factor  [23;24],  which  are  important  proteins  in  the   Chapter 4
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development of VT. Third, inflammation may explain the increased risk of VT in 
CKD.  It  has  been  suggested  that  inflammation  leads  to  VT  [25].  However, 
additional adjustment of the HRs for hsCRP, which is currently the most widely 
used biomarker of inflammation [26], did not alter the HRs in our study. 
 
This study has several limitations. First, the K/DOQI guidelines require impaired 
GFR  or  albuminuria  for  at  least  three  months.  Like  most  studies,  repeated 
measurements for a period of at least three months were not available in our study 
and  therefore  some  subjects  may  have  been  falsely  classified  as  having  CKD. 
Second, VT events were identified through anticoagulation clinic databases and 
registries for hospital discharge diagnoses and death certificates which could lead 
to  an  underestimation  of  the  incidence  rates  of  VT.  However  as  compared  to 
previous studies, incidence rates for VT in the PREVEND cohort (i.e. 1.4 per 1000 
person-years) correspond well to those found in studies that had a complete case-
finding procedure of objectively confirmed VT events [27]. Third, we may have 
underestimated renal function in subjects with a GFR >60 ml/min, because we used 
the MDRD study equation [28;29]. However, the use of the CKD-EPI formula did 
not result in large differences in the HRs. Fourth, there are studies suggesting that 
risk of adverse events increases when GFR drops below 45 ml/min [7;20]. Our 
study  did  not  include  enough  subjects  with  a  GFR  <45  ml/min  (n=52)  to 
investigate this. Despite these limitations, PREVEND is a unique cohort in its large 
population-based prospective setting in which albuminuria was assessed in two 24-
hour urine samples.  
 
We showed that especially CKD stage 1, 2, and 3 in the presence of albuminuria 
are risk factors for VT. The relative risk of VT for CKD stage 1-3 was 1.8-fold 
increased relative to those without CKD. Although these relative risk estimates 
may  be  considered  weak  compared  to  for  example  relative  risk  estimates  for 
venous thrombosis that have been reported for genetic thrombophilia [30], on a 
population level it may be an important contributor to VT because of the high 
prevalence of CKD, i.e. 12.7% for CKD stage 1-3 in the general population [3]. 
This  is  more  than  most  well-known  genetic  risk  factors  for  VT,  such  as 
prothrombin gene mutation [31]. Clinicians should be aware of the increased risk 
of  VT  in  these  patients.  Further  studies  are  needed  to  show  whether  VT 
prophylaxis  in  subgroups  of  these  patients  will  be  safe  and  cost-effective, Chronic kidney disease and venous thromboembolism 
  84 
especially  as  the  high  risk  of  anticoagulant  treatment-related  major  bleeding 
episodes applies to CKD stage 4 and 5, and not CKD stage 1-3 [32].  
  
In conclusion, CKD stage 1, 2, and CKD stage 3 in presence of albuminuria were 
risk factors for VT. The risk of VT is more related to albuminuria than to impaired 
GFR. 
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ABSTRACT 
 
Background: Overt proteinuria is a strong risk factor for thromboembolism due to 
changes in levels of various coagulation proteins and urinary antithrombin loss. 
The  described  coagulation  disturbances  in  these  patients  are  based  on  outdated 
studies  conducted  primarily  in  the  1970’s  and  80’s.  Whether  these  coagulation 
disturbances resolve with antiproteinuric therapy has yet to be studied. 
 
Methods:  A  total  of  32  adult  patients  with  overt  proteinuria  (median  3.7  g/d; 
interquartile  range  1.5-5.6)  were  matched  for  sex  and  age  with  32  healthy 
volunteers. Patients were participants of an intervention trial designed to assess 
optimal antiproteinuric therapy with losartan and diuretics. Levels of various pro- 
and anticoagulant proteins, and two thrombin generation assays (i.e., Calibrated 
Automated Thrombogram [CAT] and prothrombin fragment 1+2) were performed 
at baseline and after anti-proteinuric treatment. 
 
Results: Whereas levels of fibrinogen, factors V, VIII and Von Willebrand were 
higher in patients (P<0.004), levels of antithrombin were comparable in patients 
versus controls (P=0.70). Based on both thrombin generation assays, patients were 
substantially more prothrombotic than controls (P<0.001). Twenty-four weeks after 
start  of  antiproteinuric  therapy,  median  proteinuria  was  reduced  to  0.9  g/d 
(interquartile range 0.6-1.4). Similarly, levels of various liver-synthesized pro- and 
anticoagulant  proteins  as  well  as  prothrombin  fragment  1+2  levels  were 
significantly reduced. However, of CAT parameters only moderate amelioration in 
activated protein C resistance was observed, and Von Willebrand and factor VIII 
levels remained elevated. 
 
Conclusions: Proteinuric patients are in a more prothrombotic state with increased 
thrombin  generation,  as  compared  to  non-proteinuric  controls.  Antiproteinuric 
therapy reverses the protrombotic state.   Chapter 5   
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INTRODUCTION 
 
Nephrotic syndrome is a  known strong risk factor for both arterial and venous 
thromboembolism.
1-4 The nephrotic syndrome is characterized by urinary protein 
losses in excess of 3.5 g per 1.73 m
2 body surface area per day in association with 
hypoalbuminemia,  hypercholesterolemia,  and  peripheral  edema.  The  exact 
pathophysiological  mechanisms  of  thromboembolism  in  patients  with  nephrotic 
syndrome have yet to be unraveled. Low levels of antithrombin due to urinary loss 
and alterations in plasma levels of various proteins involved in coagulation are 
considered to be the main predisposing factors.
4-6 Enhanced platelet aggregation, 
decreased  fibrinolysis,  hyperviscosity  and  hyperlipidemia  are  other  less  often 
postulated mechanisms that may be responsible for the prothrombotic state in these 
patients.
4,7-9 Finally, in the general population, generalized endothelial dysfunction 
and low-grade inflammation, as reflected by microalbuminuria and elevated levels 
of  high  sensitivity  C-reactive  protein,  respectively,  may  be  additional  factors 
supporting a prothrombotic state.
10-12 
 
Although the association between the extent of proteinuria and changes in plasma 
levels of various coagulation proteins including low plasma antithrombin levels has 
been  considered  common  textbook  knowledge,  solid  evidence  is  lacking.  The 
previously  reported  high  risk  of  thromboembolism  at  presentation  of  nephrotic 
syndrome  and  the  positive  correlation  between  the  extent  of  proteinuria  and 
coagulation disturbances or venous thromboembolism suggest that antiproteinuric 
therapy may reduce the risk of thromboembolism in these patients.
1,5,13,14 Of note, 
the supposed beneficial effect of antiproteinuric therapy on the prothrombotic state 
rests  on  observational  studies  with  immunosuppressive  regimens,  with  major 
methodological shortcomings.
5,13,14 Studies evaluating the impact of intervention in 
the renin-angiotensin system, which is nowadays the cornerstone of antiproteinuric 
treatment, on coagulation disturbances in patients with overt proteinuria have yet to 
be conducted. Therefore, we set up this study in patients with overt proteinuria to 
assess  the  exact  coagulation  disturbances  and  the  impact  of  renin-angiotensin 
system inhibiting antiproteinuric therapy on the prothrombotic state. 
 Prothrombotic state in proteinuric patients 
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MATERIAL AND METHODS 
 
Patients and study protocol 
This study was conducted on patients who participated in a randomized, double-
blind,  placebo-controlled,  crossover  trial  designed  to  investigate  the  effects  of 
sodium  restriction,  hydrochlorothiazide,  and  their  combination  on  proteinuria 
during losartan use in patients with overt proteinuria.
15 Details of the study protocol 
have been published elsewhere.
15 In brief, patients with overt proteinuria and stable 
renal  function  (i.e.,  creatinine  clearance  >30  ml/min),  aged  18-70  years  were 
considered eligible. Patients with uncontrolled hypertension (mean arterial pressure 
>100  mm  Hg),  serum  potassium  >5.5  mmol/L,  cardiovascular  disease, 
contraindication  for  losartan  or  hydrochlorothiazide  use,  and/or  diabetes  were 
excluded, as well as frequent users of nonsteroidal anti-inflammatory drugs (>2 
doses/week). All enrolled patients were treated for 6-week periods with placebo, 
losartan, and losartan plus hydrochlorothiazide, in combination with either high or 
low sodium diet, in a random order.
15 In one out of 33 patients citrate plasma was 
not available; this patient was therefore excluded from the current analysis. The 
study was approved by the local medical ethics committee and was conducted in 
accordance with the guidelines of the Declaration of Helsinki. Written informed 
consent was obtained from all participants. 
 
All participants were matched with control subjects for sex and age within 5 years. 
Controls  were  healthy  volunteers  who  had  no  (family)  history  of 
thromboembolism,  renal  disease,  were  not  pregnant,  and  had  not  used  oral 
contraceptives for at least 3 months before testing. 
 
Study Measures 
Blood samples were obtained in the morning hours between 8:00 and 9:30 before 
study initiation (baseline) and at the end of the 36 weeks study period. Venous 
blood  samples  were  anticoagulated  with  1:10  volume  of  0.109  mol/l  trisodium 
citrate. Platelet-poor plasma was prepared by centrifugation at 2500 x g for 15 
minutes,  aliquoted  and  immediately  frozen  at  -80
oC  and  analysed  later  after 
thawing at 37
 oC for 15 minutes. 
 
On the day before study visit, patients collected 24-h urine samples to determine 
proteinuria  and  creatinine  excretion.  Urinary  protein  was  determined  using  the   Chapter 5   
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pyrogallol red-molybdate method. Serum creatinine, cholesterol, triglycerides, total 
protein, and albumin levels were determined using an automated multi-analyzer 
(SMA-C;  Technicon,  Tarrytown,  NY).  Quantitative  determination  of  fibrinogen 
was assessed with Siemens Thrombin Reagent (Siemens, Marburg, Germany) on a 
Sysmex CA-7000 automated coagulation analyzer (Siemens Diagnostics, Leusden, 
the Netherlands). Factor V:C and factor VIII:C levels were assessed by one-stage 
clotting  assay  (Siemens,  Marburg,  Germany).  Total  protein  S  antigen  and  Von 
Willebrand  factor  levels  were  measured  with  different  enzyme-linked 
immunosorbent  assays  (ELISA)  with  reagents  obtained  from  DAKO,  Glostrup, 
Denmark. Free protein S antigen levels were assessed by ELISA after precipitation 
of protein S bound to C4-binding protein (C4BP) with 3.75% PEG 6000. Activity 
of  protein  C  (Berichrom  Protein  C,  Dade  Behring,  Liederbach,  Germany),  and 
antithrombin  (Coatest,  Chromogenix,  Mölndal,  Sweden)  were  assessed  by 
chromogenic  substrate  assays.  The  thrombin  generation  was  measured  with  the 
Calibrated  Automated  Thrombogram  (CAT)  method  by  Hemker  et  al
16  and 
commercialized by Thrombinoscope BV (Maastricht, The Netherlands). The CAT 
assay was performed in triplo, using a polypropylene round-bottomed microtiter 
plate (Greiner Bio-one Ltd, Stonehouse, UK) containing 20 µL trigger with 1 pM 
tissue  factor  and  4  µM  phospholipids  (Thrombinoscope  BV,  Maastricht,  The 
Netherlands) in the absence and presence of 1.5 nM soluble thrombomodulin (TM; 
American Diagnostica, Stamford, CT, USA) that was added to 80 µL platelet poor 
plasma as previously described. After addition of 20 µL substrate-calcium reagent, 
the reaction was monitored in a Fluoroskan Ascent reader (Thermo Labsystems 
OY, Helsinki, Finland) equipped with a 390/460-nm filter set (excitation/emission) 
and a dispenser. Using a software program (Thrombinoscope BV, Maastricht, The 
Netherlands), the fluorescent signal was converted to a thrombin concentration by 
continuous  comparison  with  the  signal  generated  by  a  thrombin  calibrator 
(obtained  from  Thrombinoscope  BV,  Maastricht,  the  Netherlands)  added  to  a 
parallel  sample  of  the  test  plasma.
16  Next,  the  thrombin  concentration  was 
calculated and displayed in time.
16 The thrombin generation curve is characterized 
by  a  lag  phase,  followed  by  a  burst  of  thrombin  which  is  finally  completely 
terminated by plasma coagulation inhibitors. Five parameters were derived from 
the  thrombin  generation  curves.  The  endogenous  thrombin  potential  (ETP, 
mM.min)  was  calculated  from  the  area  under  the  thrombin  generation  curve 
corrected for alpha-macroglobulin–thrombin activity. The lag time (min) was the 
time to the start of thrombin formation and defined as the time to reach one-sixth of Prothrombotic state in proteinuric patients 
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the peak thrombin height, peak thrombin (nM) was the maximum concentration of 
thrombin formed, time to peak (min) was the time to reach the peak thrombin 
height  and  the  velocity  index  (nmol/s)  was  the  rate  of  thrombin  formation  per 
second (i.e. velocity index = peak thrombin / [peak time – lag time]). The ETP and 
peak  thrombin  are  given  as  percentage  to  human  normal  pooled  platelet  poor 
plasma assayed in the same run, as described previously.
17 In the presence of TM 
the effects of the anticoagulant pathway by activated protein C and its cofactor 
protein S were additionally analyzed. Relative ETP reduction after TM addition 
was calculated as 100 – (ETP in presence of TM / ETP in absence of TM)*100%. 
Relative peak thrombin reduction after TM addition was calculated as 100 – (peak 
thrombin in presence of TM / peak thrombin in absence of TM)*100%.To assess 
the  magnitude  of  in  vivo  thrombin  generation  we  also  measured  prothrombin 
fragment 1+2, which are released from prothrombin during activation by factor Xa, 
using  a  commercially  available  ELISA  assay  system  (Enzygnost  F1+F2;  Dade 
Behring, Marburg, Germany). 
 
Laboratory technicians who measured the levels of (anti-)coagulant proteins and 
performed the CAT and prothrombin fragment 1+2 assays were not aware of the 
extent of proteinuria and the demographics of either study participants or controls. 
 
Statistical analysis 
The  association  between  proteinuria  and  various  coagulation  proteins,  CAT 
parameters  and  prothrombin  fragment  1+2  were  assessed  by  performing  linear 
regression analysis. Both crude and age- and sex-adjusted standardized beta and the 
corresponding P values are presented. 
 
Continuous variables are presented as medians with the interquartile range (IQR). 
Categorical  data  are  presented  as  counts  and  frequencies.  For  continuous  data, 
differences were evaluated by Wilcoxon rank-sum test or Wilcoxon matched-pairs 
signed-ranks  test,  depending  on  whether  unpaired  or  paired  analyses  were 
performed.  Statistical  significance  was  considered  as  a  2-tailed  P  <0.05.  All 
statistical analyses were  performed using STATA  software version 10.1 (Stata-
Corp LP, College Station, Texas).   Chapter 5   
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RESULTS 
 
Table 1 represents baseline characteristics of the 32 study participants and 32 sex 
and age-matched controls. Of the patients, ten participants had renal biopsy proven 
primary glomerulopathy, 19 had secondary glomerulopathies and in the remaining 
three  cases  renal  biopsies  were  inconclusive.  The  median  proteinuria  was  3.7 
mg/24 h (interquartile rage, 1.5 – 5.6) and median serum albumin levels were 39 
g/l (interquartile range, 38 – 42). The levels of procoagulant fibrinogen, factor V, 
factor  VIII  and  Von  Willebrand  factor  were  significantly  higher  in  patients  as 
compared to controls (P≤0.004). In contrast, levels of anticoagulant antithrombin, 
protein C and total protein S were comparable in patients versus controls (P≥0.31). 
However,  levels  of  free  proteins  S  were  significantly  higher  in  patients  as 
compared  to  controls  (P<0.001).  Except  the  lag  time  with  and  without 
thrombomodulin and time to peak in presence of thrombomodulin, all other CAT 
parameters  including  ETP,  peak  thrombin,  and  velocity  index  either  with  or 
without  thrombomodulin  were  significantly  higher  in  patients  as  compared  to 
controls. In the presence of thrombomodulin, the differences between patients and 
controls in especially ETP levels were substantially accentuated from 1.7 fold to 
3.3 fold. In patients, median prothrombin fragment 1+2 levels were 330 picomol/L 
(interquartile range, 209-419) versus 158 picomol/L (interquartile range, 125-197) 
in the controls (P<0.001). 
 
Table  2  describes  crude  and  age-  and  sex-adjusted  associations  between 
proteinuria  and  various  coagulation  factors  as  well  as  CAT  parameters  and 
prothrombin fragment 1+2 levels. The extent of proteinuria was positively related 
to  both  pro-  and  anticoagulant  proteins,  except  for  antithrombin  that  was  not 
associated with proteinuria at all. Parameters of CAT were also not related to the 
extent of proteinuria, whereas a positive trend was observed for the link between 
proteinuria and fragment 1+2 levels. 
 
It is assumed that in response to reduction in levels of serum albumin, production 
of  all  liver-synthesized  proteins  is  upregulated,  including  procoagulant  and 
anticoagulant factors and lipoproteins.
8,13,18 If we substituted proteinuria by serum 
albumin, in Table 2 presented associations were almost the same, though in general 
somewhat  weaker.  When  we  introduced  serum  cholesterol  in  the  regression Prothrombotic state in proteinuric patients 
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analysis  instead  of  proteinuria,  only  factor  V  and  protein  C  showed  a  positive 
association with serum cholesterol. 
 
 
Table 1. Baseline characteristics. 
Variable  Patients  Controls  P-value 
Subjects, n  32  32  - 
  Male, n (%)  24 (75)  24 (75)  - 
Age, yrs*  51 (43–59)  46 (32–52)  - 
Laboratory measurements*       
  Fibrinogen, g/l  3.9 (3.6–4.3)  2.7 (2.4–2.9)  <0.001 
  Factor V, %  137 (111–164)  104 (83–121)  0.004 
  Factor VIII, %  180 (140–213)  117 (94–136)  <0.001 
  Von Willebrand factor, %  191 (151–232)  100 (85–114)  <0.001 
  Antithrombin, %  98 (93–109)  99 (93–108)  0.70 
  Protein C, %  113 (103–131)  109 (100–126)  0.51 
  Total protein S, %  129 (111–140)  121 (104–135)  0.31 
  Free protein S, %  127 (101–147)  81 (66–101)  <0.001 
  CAT parameters†       
    ETP, %  163 (146–191)  96 (76–110)  <0.001 
    With TM  147 (126–171)  44 (33–55)  <0.001 
    Lag time, min   3.6 (3.2–4.3)  3.3 (3.0–3.8)  0.24 
    With TM    3.6 (3.1–4.3)  3.1 (3.0–3.7)  0.18 
    Peak thrombin, %   280 (242–328)  90 (66–123)  <0.001 
    With TM  242 (203–294)  64 (49–84)  <0.001 
    Time to peak, min  6.8 (5.9–7.3)  8.3 (7.4–9.0)  <0.001 
    With TM  6.6 (5.9–7.0)  6.7 (6.3–7.3)  0.16 
    Velocity index, nmol/s  80 (66–113)  19 (14–36)  <0.001 
    With TM  85 (61–121)  22 (14–35)  <0.001 
  Prothrombin fragment 1+2, pmol/l  330 (209-419)  158 (123-197)  <0.001 
Patients-specific variables       
  Primary glomerulopathies, n (%)  10 (31)  -  - 
  Secondary glomerulopathies, n (%)  19 (59)  -  - 
  Urinary protein excretion, mg/24h*  3.7 (1.5–5.6)  -  - 
  Serum albumin, g/l*  39 (38–42)  -  - 
  Serum cholesterol, mmol/l*  6.1 (5.1–6.8)  -  - 
CAT denotes Calibrated Automated Thrombogram; ETP, endogenous thrombin potential 
and TM, thrombomodulin. 
* Values are medians and interquartile ranges. 
†ETP was calculated from the area under the thrombin generation curve corrected for 
alpha-macroglobulin–thrombin activity. The lag time is the time to the first burst in 
thrombin formation, peak is the maximum concentration of thrombin formed and the 
velocity index is the rate of thrombin formation per second, that is, velocity index = peak 
thrombin / (peak time – lag time).   Chapter 5   
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Table 2. Association between the extent of proteinuria and coagulation 
disturbances. 
Variable  Crude std 
beta 
P-value  Adjusted 
std beta* 
P-value 
Procoagulant proteins         
  Fibrinogen  0.542  0.001  0.545  0.002 
  Factor V  0.467  0.007  0.404  0.03 
  Factor VIII  0.447  0.01  0.430  0.02 
  Von Willebrand factor  0.371  0.04  0.391  0.05 
Anticoagulant proteins         
  Antithrombin  0.199  0.27  0.085  0.66 
  Protein C  0.400  0.02  0.370  0.06 
  Protein S total  0.243  0.20  0.408  0.04 
  Protein S free  0.309  0.09  0.392  <0.05 
Tests for prothrombotic state         
  CAT parameters         
    ETP  0.072  0.69  0.118  0.56 
    With TM  -0.045  0.81  -0.000  1.0 
    Lag time  -0.175  0.34  -0.340  0.08 
    With TM    -0.140  0.45  -0.289  0.15 
    Peak  -0.050  0.79  -0.030  0.88 
    With TM  -0.100  0.59  -0.095  0.64 
    Time to peak  -0.157  0.39  -0.289  0.14 
    With TM  -0.172  0.35  -0.315  0.11 
    Velocity index  -0.042  0.82  -0.063  0.76 
    With TM  -0.103  0.58  -0.130  0.53 
  Prothrombin fragment 1+2  0.380  0.04  0.330  0.10 
Std beta denotes standardized beta; CAT, Calibrated Automated Thrombogram; ETP, 
endogenous thrombin potential and TM, thrombomodulin. 
* adjusted for age and sex. 
 
Figure 1 depicts the extent of proteinuria and levels of serum albumin, cholesterol, 
high sensitivity C-reactive protein, various pro- and anticoagulant proteins, CAT 
parameters and prothrombin fragment 1+2 at baseline versus after treatment. As we 
previously reported, sodium restriction, hydrochlorothiazide, and their combination 
during losartan use reduced the extent of proteinuria and serum cholesterol levels, 
and increased serum albumin levels (Figure 1A).
15 Of procoagulant proteins only 
factor V levels were reduced, and a negative trend was observed for fibrinogen at 
the  end  of  treatment  as  compared  to  baseline  (Figure  1B).  Of  anticoagulant 
proteins, protein C and free protein S levels were lower, total protein S were higher 
and  antithrombin  levels  were  unaltered  (Figure  1C).  Interestingly,  CAT 
parameters in proteinuric patients were the same after treatment as compared to Prothrombotic state in proteinuric patients 
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baseline, whereas levels of prothrombin fragment 1+2 were significantly reduced 
after treatment (Figure 1D).  
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C. Anticoagulant proteins levels at baseline vs end of study 
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D. Parameters of CAT and prothrombin fragment 1+2 levels at baseline vs end of study 
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Figure 1. Components of nephrotic syndrome, high sensitivity C reactive protein, various 
pro- and anti-coagulation proteins and functional coagulation assays at baseline versus 
after antiproteinuric treatment.   Chapter 5   
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Panel A: Error-bars depict the median values and interquartile ranges. Panel B and C: Error-
bars depict the median values and interquartile ranges. The horizontal gray lines depict the 
median vales and the gray area’s the interquartile ranges in the control group. The P values refer 
to the differences between baseline versus end of study, in patients. Panel D: The black error-
bars represent the medians and interquartile ranges of the prothrombin fragment 1+2 levels and 
parameters of Calibrated Automated Thrombogram (CAT) without thrombomodulin addition. 
Medians and interquartile rages of CAT parameters with thrombomodulin addition are depicted 
by the gray error-bars. The horizontal gray lines represent the median vales and the gray area’s 
the interquartile ranges in the control group. ETP denotes endogenous thrombin potential. 
 
Next, we focussed on the relative reduction of ETP and relative peak thrombin 
reduction  after  thrombomodulin  addition  as  these  parameters  appeared  better 
predictors of activated protein C resistance.
17 The mean relative reduction in ETP 
after trombomodulin addition in our patients was 12.6% at baseline versus 15.9% 
after treatment (P=0.17) and the relative reduction in peak thrombin was 14.4% at 
baseline versus 19.1% after treatment (P=0.007), respectively. Finally, the higher 
levels  of  coagulation  factors  and  inhibitors  in  these  patients,  at  baseline  as 
compared to after treatment could not be ascribed to hemo-concentration: the mean 
hematocrit at baseline was 44.1% versus 43.7% after treatment (P=0.81). 
 
 
DISCUSSION 
 
This  study  explored  the  relationship  between  overt  proteinuria  and  coagulation 
disturbances,  as  well  as  the  effect  of  renin-angiotensin  system  inhibiting-based 
antiproteinuric  therapy  on  the  coagulation  disturbances  in  patients  with  non-
diabetic nephropathies. As compared to age- and sex-matched controls, the patients 
were more prothrombotic, as indicated by markedly elevated thrombin generation 
levels, both by the CAT method and prothrombin fragment 1+2 measurements. 
This  prothrombotic  state  was  likely  caused  by  the  elevated  levels  of  various 
procoagulant  proteins,  including  fibrinogen,  while  the  major  inhibiting  proteins 
antithrombin, protein C and total protein S were surprisingly similar in patients as 
compared to controls. Except antithrombin levels that had no association with the 
extent of proteinuria, levels of all other measured pro- and anti-coagulant factors 
were positively correlated with the extent of proteinuria. Antiproteinuric therapy 
reversed the prothrombotic state as reflected by reduction in prothrombin fragment 
1+2 and amelioration in relative peak thrombin generation. 
 Prothrombotic state in proteinuric patients 
  100 
This  is  the  first  study  addressing  the  effect  of  non-steroidal  and  non-
immunosuppressive,  symptomatic  anti-proteinuric  therapy  on  coagulation 
disturbances  in  patients  with  overt  proteinuria.  Despite  effective  reversal  of 
proteinuria, factor V, protein C, free protein S and to a lesser extent fibrinogen 
levels were decreased after treatment, as compared to baseline. Other coagulation 
factors remained unchanged and total protein S levels were even increased after 
treatment.  We speculate that lack of decrease in factor VIII, Von Willebrand factor 
and increase in total protein S levels could be explained by persistent endothelial 
damage. In previous studies mainly in children with nephrotic syndrome, remission 
of nephrotic syndrome with corticosteroid or immunosuppressive therapy reversed 
the high levels of especially fibrinogen and antithrombin.
5,13,14  
 
Our  baseline  results  on  levels  of  coagulation  proteins  in  patients  with  overt 
proteinuria are comparable to previous studies, in patients with untreated nephrotic 
syndrome, that mainly date back to the seventies and eighties.
2,6,8,13,14 Based on 
these  studies  it  is  generally  accepted  that  the  prothrombotic  state  in  nephrotic 
patients  is  due  to  elevated  levels  of  various  procoagulant  proteins  and  low 
antithrombin levels. Low antithrombin levels are presumed to be due to urinary 
loss, though results are inconsistent.
4,5 Indeed, we also observed normal circulating 
levels of antithrombin in all patients. Because antithrombin was the only protein 
that had no positive association with the extent of proteinuria, we postulated that 
upregulation in antithrombin synthesis might be counterbalanced by urinary loss as 
antithrombin  has    relatively  low  molecular  weight,  which  is  comparable  to  the 
molecular weight of albumin. Indeed, in a small pilot study, we could confirm the 
presence  of  considerable  amounts  of  antithrombin  (6-21%)  in  urine  of  three 
patients with proteinuria ranging from 0.5 g/d to 1.5 g/d (data not shown). 
 
The application of the CAT assay
16 for the assessment of the prothrombotic state in 
patients with overt proteinuria is new. Based on previous studies in non-proteinuric 
patients, this assay has been propagated as a  suitable  method for assessing the 
prothrombotic  state.
19  Interestingly,  though  CAT  parameters  including  peak 
thrombin,  ETP  and  velocity  index  were  substantially  higher  in  patients  as 
compared to controls, these were not correlated with the extent of proteinuria and 
remained  elevated  after  proteinuria  reduction  with  anti-proteinuric  therapy.  Lag 
time, which could be interpreted as a proxy of prothrombin time (PT) and in part as 
the activated partial thromboplastin time (APTT), was comparable between our   Chapter 5   
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patients and controls. This is in line with a previous study that found no difference 
in  PT  or  APTT  in  nephrotic  patients  as  compared  to  controls.
20  In  contrast, 
prothrombin fragment 1+2 levels that reflect in vivo thrombin generation showed a 
positive trend for the association with proteinuria and were significantly reduced 
after anti-proteinuric treatment. This suggests that in vivo thrombin generation is 
ameliorated  by  antiproteinuric  therapy.  Thus,  despite  the  reduction  in  levels  of 
liver-synthesized proteins, persistent high levels of endothelial derived proteins in 
particular  factor  VIII  might  be  responsible  for  the  lack  of  reduction  in  CAT 
parameters after antiproteinuric therapy. The effect of thrombomodulin addition in 
the  CAT  assay  that  boosts  the  protein  C  and  S  pathway  was  almost  absent  in 
patients, as compared to controls. This activated protein C resistance in our patients 
might  be  also  caused  by  high  factor  VIII  levels,  as  previously  reported.
17,21 
However,  some  degree  of  amelioration  in  activated  protein  C  resistance  was 
observed as reflected by the relative ETP and especially relative peak thrombin 
reductions after treatment as compared to baseline. The relative reduction in ETP 
and  peak  thrombin  are  considered  more  sensitive  for  assessment  of  activated 
protein C resistance than the absolute values of ETP and peak thrombin in the 
presence of thrombomodulin. 
 
This study has several limitations that warrant attention. Firstly, we measured only 
a selection of coagulation proteins. However, this selection was performed with a 
predefined aim by assessing the role of antithrombin, the protein C and S pathway, 
endothelial damage (as measured by factor VIII and Von Willebrand factor), liver 
synthesis  function  (as  measured  by  among  others  factor  V  and  protein  C)  and 
thrombin generation (as measured by the CAT assay and prothrombin fragment 
1+2).  Secondly,  the  association  between  coagulation  disturbances  due  to 
proteinuria  might  be  better  demonstrated  in  more  extreme  cases  of  proteinuria, 
whereas  in  our  study  almost  half  of  the  participants  had  non-nephrotic  range 
proteinuria  (i.e.,  <3.5g/day).  Obviously,  more  extreme  phenotypes  of  overt 
proteinuria are nowadays rare since the availability of effective anti-proteinuric 
medication. Despite these limitations, this is the first study that addressed the effect 
of  renin-angiotensin  system  inhibiting  anti-proteinuric  medication  on  the 
coagulation disturbances and adds new insights into the role of endothelium in the 
pathogenesis of prothrombotic state in these patients with overt proteinuria.  
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In conclusion, patients with overt proteinuria are in a more prothrombotic state 
with  increased  thrombin  generation,  as  compared  to  non-proteinuric  controls. 
Antiproteinuric therapy reverses the protrombotic state as reflected by reduction in 
prothrombin fragment 1+2 and activated protein C resistance, though increased 
levels of endothelial derived factor VIII and von Willebrand factor persist. 
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ABSTRACT 
 
Background: Absolute risks of venous thromboembolism (VTE) in protein S-, 
protein C-, or antithrombin-deficient subjects are mainly based on retrospective 
data.  Screening  asymptomatic  relatives  of  these  patients  are  disputed,  though 
studies addressing this issue have yet to be conducted. 
 
Methods: We prospectively followed 382 relatives of 84 probands. Participants 
were assessed for other thrombophilic defects and occurrence of exogenous risk 
factors  (i.e.,  surgery,  trauma,  immobilization,  malignancies,  use  of  systemic 
estrogens, and pregnancy or puerperium). After screening, deficient subjects were 
advised  to  use  thromboprophylaxis  during  exogenous  risk  factors;  use  of  oral 
contraceptives was discouraged. 
 
Results:  Overall  annual  incidence  of  VTE  was  1.53%  (95%CI,  1.00-2.34)  in 
deficient versus 0.29% (0.13-0.64) in non-deficient relatives; adjusted hazard ratio, 
7.0  (95%CI,  2.7-18.0).  Annual  incidence  of  unprovoked  VTE  was  0.95%  in 
deficient versus 0.05% in non-deficient subjects; age-adjusted hazard ratio, 22.3 
(P=0.003).  In  contrast,  annual  incidence  of  provoked  VTE  was  0.58%  versus 
0.24%; age-adjusted hazard ratio, 2.8 (P=0.08). Fifty-five (37%) deficient and 80 
(34%)  non-deficient  subjects  experienced  91  and  143  exogenous  risk  factors, 
respectively,  during  which  6  versus  5  VTE  (6.6%  vs  3.5%  per  risk-period) 
occurred, despite the higher compliance with recommended thromboprophylaxis 
use in deficient (51%) versus non-deficient (22%) subjects. In deficient subjects all 
provoked VTE occurred when thromboprophylaxis was not used. 
 
Conclusions:  Protein  S,  protein  C  or  antithrombin  deficiencies  confer  high 
absolute  risk  of  VTE.  Screening  and  subsequent  augmentation  of 
thromboprophylaxis use may result in reduction of provoked VTE, whereas risk of 
unprovoked VTE could not be affected by screening. Chapter 6 
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INTRODUCTION 
 
Several  coagulation  disorders  are  associated  with  an  increased  risk  of  venous 
thromboembolism  (VTE).  These  thrombophilic  disorders  include  hereditary 
deficiencies  of  protein  S,  protein  C  and  antithrombin;  factor  V  Leiden;  the 
prothrombin  G20210A  mutation;  high  levels  of  clotting  factor  VIII;  and 
antiphospholipid antibodies.
[1] Hereditary deficiencies of protein S, protein C or 
antithrombin  are  rare  (0.1%  to  0.4%  each  in  the  general  population),  but  the 
strongest hereditary risk factors for VTE.
[2] In retrospective studies the incidence 
rate of VTE ranged from 0.5% to 3.1% per year.
[3-6] Only three prospective studies 
addressed this issue, which reported incidence rates ranging from 0.7% to 4.0% per 
year.
[7-9] The differences between studies may be explained by differences in study 
populations  as  these  deficiencies  interact  with  other  genetic  and  acquired  risk 
factors for VTE.
[2,10] 
 
Since in the general population long-term oral anticoagulant treatment is associated 
with a major bleeding risk of about 2.8% per year,
[11] there is reluctance to advocate 
long-term primary prophylaxis in asymptomatic subjects with protein S, protein C 
or  antithrombin  deficiencies.
[12]  As  about  50%  of  VTE  cases  are  provoked  by 
exogenous risk factors,
[10] transient thromboprophylaxis at 
exposure to exogenous risk factors is nowadays highly recommended even in non-
deficient subjects.
[13] Therefore, screening asymptomatic relatives of subjects with 
protein S, protein C or antithrombin deficiencies is a matter of debate,
[14,15] even 
though studies addressing this issue have yet to be conducted. 
 
We conducted a prospective follow-up study to assess the absolute risk of VTE in a 
large series of deficient versus non-deficient asymptomatic relatives of protein S-, 
protein  C-  or  antithrombin-deficient  patients.  We  also  assessed  the  impact  of 
screening, followed by preventative recommendations, on the VTE risk in deficient 
relatives of these patients.  Hereditary thrombophilia and VTE 
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METHODS 
 
Study population and design 
 Details of the study protocol have been published elsewhere.
[10,16] In brief, 1600 
consecutive patients with VTE were screened over 12 years to identify 91 index 
subjects (probands) with either protein S, protein C or antithrombin deficiency. 
First-degree relatives, of these probands, older than 15 years of age were identified 
by pedigree analysis. As the number of antithrombin-deficient probands was small, 
second degree relatives from  a deficient parent were also identified. For living 
relatives, response rates between 90% and 97% per cohort allowed us to identify 
725 relatives. Subjects were enrolled after informed consent was obtained. Detailed 
information  on  previous  episodes  of  VTE  and  anticoagulant  treatment  were 
collected, using a standardized questionnaire and reviewing medical records. Blood 
samples were taken after clinical data had been collected. Relatives were tested for 
other  thrombophilic  defects  in  addition  to  their  index  deficiencies,  including 
deficiencies  of  protein  S,  protein  C,  and  antithrombin;  factor  V  Leiden;  the 
prothrombin  G20210A  mutation;  high  levels  of  factor  VIII;  and  lupus 
anticoagulant.  
 
Asymptomatic  relatives  (i.e.,  without  a  history  of  VTE),  irrespective  of  their 
deficiency status, were eligible for inclusion in the current prospective analysis 
(Figure  1).  Subjects  were  excluded  if  they  were  on  long-term  (≥  12  months) 
treatment with vitamin K antagonists. All subjects were instructed to seek medical 
attention when they encountered signs or symptoms of VTE. Both study subjects 
and their general physicians received written information concerning presence or 
absence of protein S, protein C or antithrombin deficiencies. In deficient subjects, 
additional information was provided concerning the implications of the observed 
deficiency and the advice to strongly consider anticoagulant thromboprophylaxis at 
exposition to exogenous risk factors (i.e., major surgery or trauma, immobilization 
for  >7  days,  pregnancy  and  puerperium).  Nonetheless,  the  decision  to  use 
thromboprophylaxis  was  left  to  the  discretion  of  the  treating  physician. 
Furthermore, use of oral contraceptives and hormonal replacement therapy were 
discouraged  in  deficient  subjects.  In  nondeficient  subjects  no  preventative 
recommendations were given and their treating physicians were expected to apply 
thromboprophylaxis in agreement with national guidelines that are based on the 
contemporary American College of Chest Physicians guidelines.
[17] Chapter 6 
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Patients tested
(n = 1600)
Established deficiencies 
(n = 95)
Deceased or unknown
relatives (n = 4)
Protein C-deficient
probands (n = 40)
Protein S-deficient
probands (n = 39)
Antithrombin-deficient
probands (n = 12)
Total deficient probands
(n = 91)
Relatives
(n = 263)
Relatives
(n = 725)
Relatives
(n = 277)
Relatives
(n = 185)
Tested relatives
(n = 172)
Tested relatives
(n = 487)
Tested relatives
(n = 192)
Tested relatives
(n = 123)
Inheritance not
established (n = 19)
Inheritance not
established (n = 15)
Inheritance not
established (n = 4)
Inheritance not
established (n = 0)
Analyzed relatives
(n = 125), belonging 
to 34 probands
Analyzed relatives
(n = 382), belonging 
to 84 probands
Analyzed relatives
(n = 157), belonging 
to 38 probands
Analyzed relatives
(n = 100), belonging 
to 12 probands
Age < 15 y
(n = 61)
Age < 15 y
(n = 22)
Age < 15 y
(n = 24)
Age < 15 y
(n = 15)
Deceased
(n = 136)
Deceased
(n = 50)
Deceased
(n = 43)
Deceased
(n = 43)
No consent
(n = 30)
No consent
(n = 15)
No consent
(n = 12)
No consent
(n = 3)
Geographic
reasons (n = 6)
Geographic
reasons (n = 4)
Geographic
reasons (n = 1)
Geographic
reasons (n = 11)
History of VTE
(n = 76)
History of VTE
(n = 27)
History of VTE
(n = 27)
History of VTE
(n = 22)
Long-term VKA use
(n = 10)
Long-term VKA use
(n = 5)
Long-term VKA use
(n = 4)
Long-term VKA use
(n = 1)
 
Figure 1. Recruitment of the family cohorts with hereditary deficiencies of protein S, 
protein C, or antithrombin.  
VKA denotes vitamin K antagonists; VTE, venous thromboembolism. 
 
Data from the participants were collected in family groups, and were seen at our 
outpatient clinic at start of the study and during follow-up that took place about  Hereditary thrombophilia and VTE 
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once every 3 years by phone or by visits to our outpatient clinic. In each case a 
standardized questionnaire was used to update information on the occurrence of 
VTE,  exposition  to  exogenous  risk  factors  and  the  use  of  thromboprophylaxis. 
Participants  were  last  contacted  in  the  period  between  September  2005  and 
December 2007. The study protocol was approved by the institutional review board 
of our hospital. 
 
Diagnosis of venous thromboembolism 
Only objectively verified symptomatic thromboembolic events were considered. 
Events  were  independently  adjudicated  and  were  classified  using  the  following 
criteria: deep vein thrombosis had to be confirmed by compression ultrasound; and 
pulmonary embolism by ventilation/perfusion lung scanning or spiral computed 
tomography.  Isolated  calf  vein  thrombosis  and  superficial  phlebitis  were  not 
classified as VTE. VTE was considered provoked if it had occurred at or within 3 
months  after  exposure  to  exogenous  risk  factors,  including  major  surgery  or 
trauma,  immobilization  for  >7  days,  oral  contraceptives,  hormone  replacement 
therapy, pregnancy, or malignant disease. In the absence of these risk factors, VTE 
was considered unprovoked. 
 
Laboratory studies 
Protein S and protein C antigen levels were measured by Enzyme Linked Immuno 
Sorbent  Assay  (ELISA)  (reagents  obtained  from  DAKO,  Glostrup,  Denmark), 
activity of protein C (Berichrom Protein C, Dade Behring, Liederbach, Germany), 
and  antithrombin  (Coatest,  Chromogenix,  Mölndal,  Sweden)  by  chromogenic 
substrate assays. Normal ranges (mean±SD) were determined in 393 healthy blood 
donors, who had no (family) history of thromboembolism, were not pregnant, and 
had not used oral contraceptives for at least three months. Protein S deficiency type 
I was defined by lowered total (<68 IU/dl) and free (<65 IU/dL) protein S levels. 
Protein C deficiency type I and type II were defined by reduced levels of either 
protein C antigen (<63 IU/dl) and/or activity (<64 IU/dl). Antithrombin deficiency 
was defined by decreased levels of antithrombin activity (<74 IU/dl), using heparin 
co-factor  assay  which  identifies  both  type  I  and  type  II  antithrombin 
deficiencies.
[18] Deficiencies were considered inherited if they were confirmed by 
measuring a second sample that was collected 3 months later and were found in at 
least 2 family members, while acquired conditions were excluded. If there was a 
discrepancy  between  the  results  of  the  2  tests,  a  third  sample  was  tested.  A 
deficiency  was  considered  acquired,  through  use  of  oral  contraceptives  or Chapter 6 
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pregnancy,  unless  it  was  confirmed  at  least  3  months  after  withdrawal  of  oral 
contraceptives  or  delivery,  respectively.  Factor  V  Leiden  and  the  prothrombin 
G20210A mutation were demonstrated by polymerase chain reactions.
[19,20] Factor 
VIII:C was measured by one-stage clotting assay and was considered increased at 
levels above 150 IU/dl.
[21] Lupus anticoagulant was defined by abnormal values of 
dilute Russell viper venom time, activated partial thromboplastin time and/or tissue 
thromboplastin  inhibition,  which  normalized  by  adding  phospholipids  to  the 
subject’s plasma.
[22] 
 
Statistical analysis 
We  calculated  absolute  risks  of  VTE  in  subjects  with  protein  S,  protein  C  or 
antithrombin deficiency, separately, and in the pooled cohorts of deficient and non-
deficient subjects. Annual incidences were calculated by dividing the number of 
symptomatic subjects by the total number of follow-up years. Follow-up time was 
defined as the period from testing for the index deficiency until first VTE, death or 
end of study, whichever occurred first. The 95 percent confidence intervals (95% 
CI)  around  the  annual  incidences  were  assessed  with  the  Poisson  distribution 
assumption. Annual incidences in current prospective analysis were compared to 
our  previously  published  retrospective  analysis
[10]  by  calculating  incidence  rate 
ratios with the corresponding 95% CI and P-values by using the immediate method 
in STATA software, version 10.1 (StataCorp LP, College Station, Texas, USA).
[23] 
Annual  incidences  in  previous  retrospective  analysis  were  calculated  as  the 
numbers of subjects with VTE that have occurred prior to screening divided by the 
total  observation  years.  Observation  period  in  the  retrospective  analysis  was 
defined as the period from the age of 15 years until VTE, death or screening for the 
index deficiencies, whichever came first.
[10] 
 
In a multivariate Cox-model, hazard ratios conferred by these deficiencies were 
adjusted for age, sex, concomitant thrombophilic defects (i.e., factor V Leiden, the 
prothrombin G20210A mutation or factor VIII:C >150 IU/dl) and for clustering of 
VTE within families that used the robust sandwich method in STATA software. 
Results were expressed as hazard ratios, with 95% CIs and Pvalues.  
 
Continuous variables were expressed as median values with the interquartile range 
(IQR) and categorical data as counts with frequencies. Differences between groups 
were evaluated by the Student’s t test or Mann-Whitney U test, depending on the 
normality of data for continuous data, and by Fisher exact test for categorical data.  Hereditary thrombophilia and VTE 
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Statistical significance was considered as a 2-tailed probability <0.05. All statistical 
analyses  were  performed  using  STATA  software,  version  10.1  (StataCorp  LP, 
College Station, Texas, USA). 
 
RESULTS 
 
Subjects 
Ninety-one subjects with objectively verified VTE and either protein S, protein C 
or antithrombin deficiency served as index patients in this study (Figure 1). In 7 
families, inheritance of the index deficiency was not established in at least two 
relatives, therefore, these families were excluded from analysis (19 relatives). After 
exclusion due to various reasons depicted in Figure 1, the current analysis was 
performed on 382 relatives. These subjects belonged to 84 different kindreds with 
protein S (n=34), protein C (n=38) or antithrombin (n=12) deficiency.  
 
Table 1 shows the clinical characteristics of the pooled and separate study cohorts. 
Overall,  39%  of  subjects  were  deficient  for  either  protein  S,  protein  C  or 
antithrombin.  Deficiencies  were  equally  distributed  between  men  and  women. 
Deficient subjects were on average 10 years younger than non-deficient subjects at 
testing for index deficiencies (P<0.001). If subjects with prior VTE and/or subjects 
using long-term vitamin K antagonists were not excluded from the analysis, the 
mean age at testing for these deficiencies in deficient subjects was 39 years versus 
41 years in non-deficient relatives. Concomitance of other thrombophilic defects 
(i.e.,  factor  VIII:C  >150  IU/dl,  prothrombin  G20210A  and  factor  V  Leiden 
mutations) were comparable between deficient and non-deficient subjects. 
 
Table 1. Baseline characteristics of the study population
Variable
Subjects, n
Women, n (%)
FVIII:C >150 IU/dl
PT G20210A
Factor V Leiden
Median age at testing for
index deficiency (IQR), yr
Concomitance of, n (%)*
                  Antithrombin cohort Total cohort Protein S cohort Protein C cohort
Deficient Non-
deficient
Deficient Non-
deficient
Deficient Non-
deficient
Deficient Non-
deficient
149
73 (49)
233
121 (52)
31 (18-43) 41 (27-52)
36 (30) 62 (32)
4 (3) 15 (7)
11 (8) 32 (15)
50
26 (52)
75
39 (52)
33 (18-42) 43 (25-55)
11 (28) 18 (26)
1 (2) 4 (6)
4 (10) 7 (10)
53
25 (47)
104
52 (50)
26 (18-44) 40 (30-52)
16 (35) 30 (38)
3 (6) 6 (7)
6 (12) 23 (24)
46
22 (48)
54
30 (56)
27 (17-47) 42(20-52)
9 (25) 14 (30)
0 (0) 5 (11)
1 (3) 2 (4)
P
0.60
<0.001
0.71
0.15
0.09
1.00
0.01
1.00
0.65
1.00
P
0.87
0.003
0.85
1.00
0.09
P P
0.55
0.05
0.63
0.06
1.00
IQR denotes interquartile range; FVIII:C, factor VIII:C; PT G20210A, the prothrombin G20210A mutation. 
* Of total study cohort 17%, 13% and 10% of subjects were not tested for FVIII:C, the prothrombin G20210A mutation and factor V Leiden, respectively.
   None of these subjects were positive for lupus anticoagulant.Chapter 6 
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The total follow-up time was 1,375 years in deficient subjects (mean±SD, 9.2±5.9) 
and  2,097  years  in  non-deficient  subjects  (mean±SD,  9.0±5.9).  Participating 
families were contacted on average once every 3 years. During follow-up, five 
(3.4%) deficient subjects and seven (3.0%) non-deficient subjects died; according 
to death certificates, none of the death causes were related to VTE. 
 
Risk of venous thromboembolism 
Twenty-one  (14.1%)  deficient  and  six  (2.6%)  non-deficient  subjects  developed 
VTE during follow-up, corresponding to an annual incidence of 1.53% (95%CI, 
1.00 – 2.34) in deficient and 0.29% (95%CI, 0.13 – 0.64) in non-deficient subjects, 
respectively (Table 2). Nineteen (70%) of the 27 VTE were classified as deep-vein 
thrombosis  in  the  leg  and  8  (30%)  as  pulmonary  embolism  either  alone  or  in 
combination with deep-vein thrombosis. There was no difference in types of VTE 
(i.e., deep-vein thrombosis and pulmonary embolism) between deficient and non-
deficient  subjects  (P=0.82).  Compared  to  the  pooled  cohort  of  non-deficient 
subjects,  subjects  with  antithrombin  deficiency  had  the  highest  risk  for  VTE, 
followed by protein S and protein C deficiencies. In a multivariate Cox-model that 
was adjusted for age, sex, concomitant thrombophilic defects (i.e., factor V Leiden, 
the prothrombin G20210A mutation or factor VIII:C >150 IU/dl) and clustering, 
any (i.e., protein S, protein C or antithrombin) deficiency conferred a hazard ratio 
of  7.0  (95%  CI,  2.7  –  18.0;  P<0.001),  as  compared  to  non-deficient  relatives. 
Adjusted hazard ratios for separate deficiencies were 9.6 (95% CI, 3.0 – 30.1), 4.1 
(95% CI, 1.2 – 13.9) and 10.2 (95% CI, 3.3 – 31.6) in subjects with protein S, 
protein C and antithrombin deficiencies, respectively. 
 
A total of 13 deficient and only one non-deficient subject developed unprovoked 
VTE,  corresponding  to  an  annual  incidence  of  0.95%  (95%CI,  0.55  –  1.63)  in 
deficient versus 0.05% (95%CI, 0.01 – 0.34) in non-deficient subjects; age adjusted 
hazard ratio 22.3 (95% CI, 2.9 – 172.7) (Table 2). The risk of provoked VTE in 
deficient subjects was not significantly higher (P=0.08). Fifty-five (37%) deficient 
and 80 (34%) non-deficient subjects experienced a total of 91 and 143 high-risk 
periods, respectively (Table 3). At time of high-risk periods, thromboprophylaxis 
was  used  more  often  in  deficient  (51%)  subjects  as  compared  to  non-deficient 
subjects (22%). The incidence of risk-period related VTE (provoked VTE) per risk-
period was almost two-fold higher in deficient subjects (6.6% vs. 3.5%), despite 
more  often  used  thromboprophylaxis.  Furthermore,  whereas  no  VTE  were  Hereditary thrombophilia and VTE 
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encountered during 166 pill-years in non-deficient subjects, 2 VTE occurred during 
only 54 pill-years in deficient subjects. 
 
 
 
 
 
 
 
 
Table 2. Annual incidence of Venous Thromboembolism 
Variable  Total 
Follow-
up, yrs 
First 
VTE, 
n 
Annual incidence, 
% (95% CI) 
Hazard ratio 
(95% CI)* 
P 
Any VTE  3,472  27  0.78 (0.53 – 1.13)     
  No deficiency  2,097  6  0.29 (0.13 – 0.64)  1.0, reference   
  Any deficiency  1,375  21  1.53 (1.00 – 2.34)  7.0 (2.7 – 18.0)  <0.001 
    PSD  453  7  1.55 (0.74 – 3.24)  9.6 (3.0 – 30.8)  <0.001 
    PCD  528  5  0.95 (0.39 – 2.27)  4.1 (1.2 – 13.9)  0.02 
    ATD  394  9  2.29 (1.19 – 4.39)  10.2 (3.3 – 31.6)  <0.001 
Unprovoked VTE  3,472  14  0.40 (0.24 – 0.68)     
  No deficiency  2,097  1  0.05 (0.01 – 0.34)  1.0, reference   
  Any deficiency  1,375  13  0.95 (0.55 – 1.63)  22.3 (2.9 – 172.7)  0.003 
    PSD  453  5  1.10 (0.46 – 2.65)  25.5 (2.9 – 221.3)  0.003 
    PCD  528  1  0.19 (0.03 – 1.34)  4.4 (0.3 – 71.7)  0.29 
    ATD  394  7  1.78 (0.85 – 3.73)  42.7 (5.2 – 350.7)  <0.001 
Provoked VTE  3,472  13  0.37 (0.22 – 0.64)     
  No deficiency   2,097  5  0.24 (0.10 – 0.57)  1.0, reference   
  Any deficiency  1,375  8  0.58 (0.29 – 1.16)  2.8 (0.9 – 8.6)  0.08 
    PSD  453  2  0.44 (0.11 – 1.77)  2.0 (0.4 – 10.7)  0.40 
    PCD  528  4  0.76 (0.28 – 2.02)  3.6 (0.9 – 13.8)  0.06 
    ATD  394  2  0.51 (0.13 – 2.03)  2.5 (0.5 – 12.9)  0.28 
VTE denotes venous thromboembolism; PSD, protein S deficiency; PCD, protein C 
deficiency and ATD, antithrombin deficiency. 
* Hazard ratios for any VTE are adjusted for age, sex, concomitant thrombophilic defects 
(i.e., Factor V Leiden, prothrombin G20210A mutation or factor VIII levels >150 IU/dl) 
and clustering. Hazard ratios for unprovoked and provoked VTE were only adjusted for 
age due to the low numbers of events. Chapter 6 
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Table 3.  Number of risk periods and correlated venous thromboembolic events. 
  Total cohort 
Deficient (n=149)  Variable    Non-def 
(n=233)  Any  def 
(n=149) 
  PS  def 
(n=50) 
  PC def 
(n=53) 
  AT def 
(n=46) 
Surgery, trauma or 
immobilization , n 
116  60  22  27  11 
  With Prophylaxis, n (%)  24 (21)  27 (45)  11 (50)  6 (22)  10 (91) 
  VTE, n  5  5  1  4  0 
    Associated incidence  
    of VTE/risk period, % 
4.3  8.3  4.5  14.8  0.0 
Pregnancy or  
puerperium, n 
27  31  8  11  12 
  With Prophylaxis, n (%)  7 (26)  19 (61)  4 (50)  10 (91)  5 (42) 
    VTE, n  0  1  0  0  1 
  Associated incidence  
  of VTE/risk period, % 
0.0  3.2  0.0  0.0  8.3 
Any risk moment , n*  143  91  30  38  23 
  With Prophylaxis, n (%)  31 (22)  46 (51)  15 (50)  16 (42)  15 (65) 
  VTE, n  5  6  1  4  1 
  Associated incidence  
  of VTE/risk period, % 
3.5  6.6  3.3  10.5  4.3 
Oral contraceptive use, pill-yrs  166  54†  24  20  10 
  VTE, n  0  2  1  0  1 
  Associated incidence  
  of VTE/pill-yrs, % 
0.0  3.7  4.2  0.0  10.0 
* Two subjects in non-deficient group and 3 subjects in deficient group were known with 
malignant disease. One subject with protein C deficiency and malignant disease developed 
VTE. Any risk moment included surgery, trauma, immobilization, pregnancy, puerperium 
and malignant disease. 
† Fifty-four pill years were obtained in 6 deficient women. 
 
We compared the incidence rates of VTE in the current prospective analysis to our 
previously published retrospective analysis in these same thrombophilic families 
(Figure 2).
[10] In deficient subjects, the overall annual incidence of VTE during the 
prospective time period was comparable to annual incidence of VTE during the 
retrospective  period  (1.53%  vs  1.65%;  P=0.77).  Compared  to  our  retrospective  Hereditary thrombophilia and VTE 
  116 
analysis,[10] the slight elevation in annual incidence of unprovoked VTE (0.77% 
vs 0.95%; P=0.58) and a decrease in the annual incidence of provoked VTE (0.84% 
vs 0.58%; P=0.32) were statistically not significant. In contrast, in the 46 of the 91 
risk  moments  in  which  thromboprophylaxis  was  used,  no  VTE  have  occurred; 
underlining the effectiveness of primary thromboprophylaxis in VTE prevention in 
deficient subjects. 
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Figure 2. Incidence rates of VTE prior to screening versus after screening in the 
same thrombophilic families. 
Histogram  represents  annual  incidence  of  VTE  in  previously  published  retrospective 
(white)[10] versus current prospective analysis (gray), with the corresponding 95% CIs 
represented by the error-bars. IRR denotes incidence rate ratio. 
*  All  provoked  VTE  during  prospective  follow-up  have  occurred  when  thrombo-
prophylaxis was not used. 
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DISCUSSION 
 
This  prospective  analysis  confirmed  the  high  risk  of  VTE  in  subjects  with 
hereditary deficiencies of protein S, protein C or antithrombin. As compared to the 
pooled  cohort  of  nondeficient  subjects,  antithrombin  deficient  subjects  had  the 
highest  risk  for  VTE  followed  by  protein  S  and  protein  C  deficient  subjects. 
Whereas the risk of unprovoked VTE was about 22-fold higher in subjects with 
any deficiency (i.e., protein S, protein C or antithrombin), the risk of provoked 
VTE was only 2 to 3-fold elevated, as compared to non-deficient subjects. The 
incidence  of  exogenous  risk-periods  was  similar  between  deficient  and  non-
deficient subjects, but primary thromboprophylaxis was used more frequently in 
deficient subjects, especially in subjects with antithrombin deficiency. Although 
the  overall  annual  incidence  of  VTE  in  the  current  prospective  analysis  was 
comparable to our retrospective analysis,
[10] the probability to capture a VTE is 
higher in a prospective than in a retrospective analysis. Therefore the two studies 
are not comparable. 
 
Our results on the absolute risks are in line with previous prospective studies.
[7-9] In 
a comparable family cohort study by Sanson et al,
[7] the overall annual incidence of 
VTE was 0.7% (protein S), 1.0% (protein C) and 4.0% (antithrombin), in contrast 
to 1.6% (protein S), 1.0% (protein C) and 2.3% (antithrombin) in our study. The 
higher risk of VTE in protein S deficient subjects in our study could be attributed 
to the selection of severely affected subjects in our study (only type I protein S 
deficiency), whereas in the study of Sanson et al both type I and type III protein S 
deficient subjects were enrolled.
[7] Though the risk of overall VTE in antithrombin 
deficient subjects was lower in our study, the risk of unprovoked VTE in our study 
was comparable to the study by Sanson et al (1.8% vs 1.6%),
[7] Of note, the risk 
estimates in the study by Sanson et al were based on only 9 cases of VTE in 209 
deficient subjects, reflecting a substantially shorter follow-up, as compared to our 
study.
[7] In another study by Vossen et al,
[8] annual incidences of 0.7% for each 
protein S and protein C deficiency, and 1.7% for antithrombin deficiency were 
reported. The observed differences might be attributed to difference in subjects’ 
selection as we enrolled subjects from families with familial 
thrombophilia  with  proven  inheritance,  which  was  established  if  at  least  two 
relatives were tested positive for the index deficiency, whereas in the study of 
Vossen  et  al  only  one  relative  with  the  index  deficiency  was  required.
[8] 
Furthermore, both type I and type III protein S deficient subjects were included in  Hereditary thrombophilia and VTE 
  118 
that study.
[8] Finally, in a prospective study by Pabinger et al annual incidences of 
VTE were much higher than in our study, in both protein S (3.5% vs. 1.6%) and 
protein C deficient subjects (2.5% vs. 1.0%).
[9] However, annual incidences in that 
study were based on only 3 VTE in each protein S (n=24) and protein C (n=20) 
deficient  subjects  with  total  follow-up  of  only  93  and  119  person-years, 
respectively.
[9] Given that the risk estimates in previous prospective studies were 
based on very low number of VTE and/or small cohort with short follow-up, we 
presume that our estimates reflect the most accurate assessment of the absolute 
VTE risk conferred by these deficiencies. 
 
In previous prospective studies as well as in our study, annual incidences in the 
three types of deficiencies varied widely, with antithrombin deficiency conferring 
the  highest  absolute  risk  for  VTE.
[8]  It  could  be  speculated  that  antithrombin 
deficiency  is  a  stronger  risk  factor  for  VTE  than  are  protein  S  or  protein  C 
deficiencies. Therefore, it could be questioned whether it is correct to pool these 
deficiencies.  Nevertheless,  annual  incidences  in  protein  S,  protein  C  or 
antithrombin  deficiencies  fell  within  each  other’s  95%  confidence  intervals. 
Furthermore, in retrospective studies, differences in annual incidences among the 
three  types  of  deficiencies  were  less  evident  and  similar  relative  risks  were 
reported.
[3-6] 
 
Though VTE risk estimates in current prospective analysis were nearly the same as 
the risk estimates prior to screening in these families (i.e., 1.53% vs 1.61%; Figure 
2), these results may not give further credence against screening. This is especially 
important as the lack of overall VTE risk reduction, after screening and subsequent 
preventative recommendations, could be attributed to low compliance (51% of high 
risk-periods  in  deficient  subjects).  Moreover,  all  provoked  VTE  occurred  when 
thromboprophylaxis  was  not  used,  underlining  the  effectiveness  of  thrombo-
prophylaxis in these deficient subjects. Finally, two out of six deficient women 
using oral contraceptives developed VTE. Therefore, the relevance of discouraging 
oral contraceptive use in deficient women could be considered beneficial, but was 
hampered  by  small  numbers.  Taken  together,  since  screening  could  be  only 
considered beneficial for avoiding provoked VTE, it will be especially valuable in 
subjects  with  frequent  external  risk  factors.  Especially  young  women  are  more 
often exposed to external risk factors due to oral contraceptive use and pregnancy 
and may therefore benefit the most from screening. 
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For the first time we evaluated the impact of screening followed by preventative 
recommendations on VTE risk in asymptomatic deficient relatives of patients with 
protein S, protein C or antithrombin deficiency. Further strengths of the current 
study are its prospective nature, its relatively large size and long follow-up, and 
carefully  established  inheritance  of  protein  S,  protein  C  or  antithrombin 
deficiencies. Moreover, in our study the control group consisted of non-deficient 
relatives, whereas in previous prospective studies controls were not available or 
consisted  of  unrelated  subjects.
[7,8]  Selecting  unrelated  subjects  as  controls  for 
subjects with these hereditary deficiencies may result in overestimated relative risk 
of VTE, as other thrombophilic defects also aggregate in these families.
[10] 
 
This study has some potential limitations. Subjects were contacted on average once 
every 3 years. This may have resulted in underreporting of exposure to exogenous 
risk factors and/or thromboprophylaxis use as this information was self-reported 
rather than additionally validated from medical records. However, it is likely that 
potential underreporting would have been similar in deficient versus non-deficient 
subjects,  because  data  from  the  participants  were  collected  in  family  groups, 
thereby  avoiding  bias  in  follow-up  time  between  deficient  versus  non-deficient 
relatives. Moreover, the reasons for the low compliance in current study were not 
registered, nevertheless, the low compliance was in line with previous reports.
[24,25] 
Selection  bias  seems  less  likely  as  consecutive  subjects  with  VTE  and  either 
protein  S,  protein  C  or  antithrombin  deficiency  served  as  probands.  To  limit 
ascertainment  bias,  we  considered  only  symptomatic  VTE.  An  appropriate 
comparison between the prospective and our previous retrospective analysis could 
be hampered by differences in study design, as it is possible that awareness of the 
deficiency status could have resulted in higher capturing of VTE incidence in the 
prospective analysis. Even though this is the largest prospective study on this issue, 
the results should be handled with caution as numbers were small, while use of 
thromboprophylaxis was not specifically evaluated in this study. 
 
In  conclusion,  we  confirmed  the  high  absolute  risk  of  VTE  in  subjects  with 
hereditary protein S, protein C or antithrombin deficiencies in a large well-defined 
prospective  cohort  with  long  follow-up.  As  far  as  screening  of  asymptomatic 
carriers of these deficiencies is concerned, it is important to differentiate between 
provoked and unprovoked VTE cases. For the prevention of unprovoked VTE, the 
value of testing is obviously limited. However, most cases of provoked VTE will  Hereditary thrombophilia and VTE 
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be avoidable if appropriate thromboprophylaxis is applied, underlining the value of 
screening. 
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ABSTRACT 
 
Background: Whether hereditary protein S, protein C, or antithrombin deficiency 
is associated with arterial thromboembolism (ATE) and whether history of venous 
thromboembolism in these subjects predisposes them to subsequent ATE have yet 
to be determined. 
 
Methods and Results: On the basis of pedigree analysis, we enrolled a total of 552 
subjects (52% women; mean age, 46±17 years), belonging to 84 different kindreds, 
in this retrospective family cohort study. Detailed information on previous episodes 
of  venous  thromboembolism,  ATE,  anticoagulant  use,  and  atherosclerosis  risk 
factors was collected. Primary study outcome was objectively verified symptomatic 
ATE. Of 552 subjects, 308 had protein S (35%), protein C (39%), or antithrombin 
(26%) deficiency. Overall, annual incidences of ATE were 0.34% (95% confidence 
interval [CI], 0.23 to 0.49) in deficient versus 0.17% (95% CI, 0.09 to 0.28) in 
nondeficient subjects; the hazard ratio was 2.3 (95% CI, 1.2 to 4.5). Because the 
risk hazards varied over lifetime, we performed a time-dependent analysis. After 
adjusting for atherosclerosis risk factors and clustering within families, we found 
that deficient subjects had a 4.7-fold (95% CI, 1.5 to 14.2; P=0.007) higher risk for 
ATE before 55 years of age versus 1.1 (95% CI, 0.5 to 2.6) thereafter compared 
with nondeficient family members. For separate deficiencies, the risks were 4.6- 
(95% CI, 1.1 to 18.3), 6.9- (95% CI, 2.1 to 22.2), and 1.1- (95% CI, 0.1 to 10.9) 
fold  higher  in  protein  S–,  protein  C–,  and  antithrombin-deficient  subjects, 
respectively, before 55 years of age. History of venous thromboembolism was not 
related to subsequent ATE (hazard ratio, 1.1; 95% CI, 0.5 to 2.2). 
 
Conclusions: Compared with nondeficient family members, subjects with protein 
S or protein C deficiency but not antithrombin deficiency have a higher risk for 
ATE before 55 years of age that is independent of prior venous thromboembolism. Chapter 7 
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INTRODUCTION 
 
Several  coagulation  disorders  are  associated  with  an  increased  risk  of  venous 
thromboembolism  (VTE).  These  thrombophilic  conditions  include  hereditary 
deficiencies  of  protein  S,  protein  C,  and  antithrombin;  factor  V  Leiden;  the 
prothrombin G20210A mutation; high levels of clotting factors VIII, IX, and XI; 
and antiphospholipid antibodies.
1 Hereditary deficiencies of protein S, protein C, 
and  antithrombin  have  been  recognized  as  the  most  potent  thrombophilic 
conditions for VTE.
2–6 Recently, we demonstrated that the concomitance of other 
thrombophilic  defects  further  enhances  the  risk  of  VTE  associated  with  these 
deficiencies.
2 Whether hereditary protein S, protein C, or antithrombin deficiency 
also is involved in the development of arterial thromboembolism (ATE) has still to 
be elucidated. Evidence of such an association has been derived mainly from case 
reports.
7,8 
 
In 2003, a link between VTE and atherosclerosis was reported.
9 In the ensuing 
years,  several  other  studies  addressed  this  issue,  most  of  these  confirming  this 
association.
10  This  possible  link  has  thus  far  been  attributed  to  the  sharing  of 
common  risk  factors  by  the  2  conditions.
9,11  The  contribution  of  thrombophilic 
defects to the link between VTE and ATE has yet to be defined.  
 
We performed a retrospective follow-up study to assess the risk of ATE in a large 
series of protein S–, protein C–, or antithrombin-deficient subjects compared with 
nondeficient  family  members.  Moreover,  assuming  that  VTE  and  ATE  share 
similar  risk  factors,  we  hypothesized  that  a  relationship  between  VTE  and 
subsequent ATE would be likely, especially in these subjects. 
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METHODS 
 
Subjects 
The study contained 3 cohorts of families with hereditary deficiency of protein S, 
protein C, or antithrombin. Probands were consecutive patients with VTE who had 
one of these deficiencies. First-degree relatives >15 years of age were identified by 
pedigree  analysis.  Because  the  number  of  antithrombin-deficient  probands  was 
small, second-degree relatives from a deficient parent also were identified. Subjects 
were  enrolled  after  informed  consent  was  obtained.  Detailed  data  on  previous 
episodes  of  VTE  and  ATE,  risk  factors  for  atherosclerosis,  and  anticoagulant 
treatment  were  collected  by  using  a  standardized  questionnaire  and  reviewing 
medical records. Blood samples were taken after clinical data had been collected. 
Probands and relatives were tested for other thrombophilic defects in addition to 
their  index  deficiencies,  including  deficiencies  of  protein  S,  protein  C,  and 
antithrombin; factor V Leiden; the prothrombin G20210A mutation; high levels of 
factor VIII; and lupus anticoagulant.  
Risk factors for atherosclerosis included hypertension, defined as a systolic blood 
pressure of ≥140 mm Hg or ≥160 mm Hg in patients ≥60 years of age, a diastolic 
blood pressure of ≥90 mm Hg measured on at least 2 occasions, or the use of 
antihypertensive drugs; diabetes mellitus
12; cigarette smoking; and hyperlipidemia, 
defined  as  total  cholesterol  level  >6.5  mmol/L  (250  mg/dL),  triglycerides  >2.5 
mmol/L (220 mg/dL), or use of lipid-lowering drugs. The study was approved by 
the institutional review board of our hospital. 
 
Diagnosis of Thromboembolism 
ATE was considered established if myocardial infarction, ischemic stroke, transient 
ischemic  attack,  or  peripheral  artery  disease  was  symptomatic  and  objectively 
verified. Q-wave and non–Q-wave myocardial infarction was confirmed by typical 
ECG  features,  elevated  levels  of  cardiac  enzymes,  radionuclide  imaging 
techniques,  or  coronary  angiography.  Ischemic  stroke  was  documented  by 
computed  tomography  scanning  or  magnetic  resonance  imaging.  Transient 
ischemic  attack  required  neurological  symptoms  and  signs  lasting  <24  hours. 
Peripheral  artery  disease  was  considered  thromboembolic  at  acute  signs  and 
symptoms of ischemia and was documented by arteriography. VTE was considered 
established  if  deep  vein  thrombosis  was  confirmed  by  compression 
ultrasonography  or  venography,  and  pulmonary  embolism  was  confirmed  by 
ventilation-perfusion  lung  scanning,  spiral  computed  tomography  scanning,  or Chapter 7 
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pulmonary  angiography.  Before  these  techniques  were  available,  VTE  was 
considered  established  when  the  patient  had  received  full-dose  unfractionated 
heparin and a vitamin K antagonist for at least 3 months.
2 
 
Laboratory Studies 
Protein S and protein C antigen levels were measured by ELISA (reagents obtained 
from  DAKO,  Glostrup,  Denmark);  activity  of  protein  C  (Berichrom  Protein  C, 
Dade  Behring,  Liederbach,  Germany)  and  antithrombin  (Coatest,  Chromogenix, 
Mölndal, Sweden) was measured by chromogenic substrate assays. Normal ranges 
(mean±SD) were determined in 393 healthy blood donors who had no (family) 
history  of  thromboembolism,  were  not  pregnant,  and  had  not  used  oral 
contraceptives for at least 3 months. Protein S deficiency type I was defined by 
lowered total protein S antigen levels (<68 IU/dL). Protein C deficiency types I and 
II were defined by reduced levels of protein C antigen (<63 IU/dL) and/or activity 
(<64  IU/dL);  antithrombin  deficiency  was  defined  by  decreased  levels  of 
antithrombin activity (<74 IU/dL). Deficiencies were considered inherited if they 
were confirmed by measurement of a second sample that was collected 3 months 
later and were found in at least 2 family members, whereas acquired conditions 
were excluded. If a discrepancy was found between the results of the 2 tests, a third 
sample  was  tested.  A  deficiency  was  considered  acquired  through  use  of  oral 
contraceptives  or  pregnancy  unless  it  was  confirmed  at  least  3  months  after 
withdrawal of oral contraceptives or delivery, respectively. Factor V Leiden and 
the  prothrombin  G20210A  mutation  were  demonstrated  by  polymerase  chain 
reactions.
13,14  Factor  VIII:C  was  measured  by  1-stage  clotting  assay  and  was 
considered increased at levels >150 IU/dL. Lupus anticoagulant was defined by 
abnormal  values  of  dilute  Russell  viper  venom  time,  activated  partial 
thromboplastin time, and tissue thromboplastin inhibition, which was normalized 
by  the  addition  of  phospholipids  to  the  subject’s  plasma.
15  In  probands  and 
symptomatic  relatives,  blood  samples  were  collected  at  least  3  months  after  a 
thrombotic  event.  If  they  were  on  long-term  treatment  with  acenocoumarol,  a 
short-acting vitamin K antagonist, samples were taken after treatment had been 
interrupted for at least 2 weeks; meanwhile, nadroparin was given subcutaneously. 
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Statistical Analysis 
We  calculated  overall  and  age-specific  absolute  risks  of  ATE  in  subjects  with 
protein  S,  protein  C,  or  antithrombin  deficiency  separately  and  in  the  pooled 
cohorts of deficient and nondeficient subjects. Because all probands were selected 
on the basis of VTE and the presence of protein S, protein C, or antithrombin 
deficiency, they were included in the current analysis for ATE. Annual incidences 
were  calculated  by  dividing  the  number  of  symptomatic  subjects  by  the  total 
number of observation years. Observation time was defined as the period from 15 
years of age until the first episode of ATE or the end of the study, considering that 
thrombosis is rare at younger ages. The 95% confidence intervals (CIs) around the 
annual incidences were assessed with the Poisson distribution assumption. 
 
Kaplan-Meier  methods  were  used  for  survival  plots.  On  the  basis  of  the 
observation  that  Kaplan-Meier  curves  in  the  pooled  cohorts  of  deficient  and 
nondeficient  subjects  diverged  until  approximately  55  years  of  age  and  then 
showed  less  divergence,  the  assumption  for  proportional  hazards  for  the  final 
model was not met over the entire observation period. Therefore, we chose a time-
dependent Cox proportionalhazards model for the analyses of index deficiencies 
with a cutoff point set at 55 years of age.16 A multivariable model with additional 
adjustment for clustering of ATE within families that used the robust sandwich 
method  in  SAS  version  9.1  (SAS  Institute  Inc,  Cary,  NC)  was  applied  to  all 
variables that yielded a value of P<0.15 from the univariable model.16 Results 
were expressed as hazard ratios with 95% CIs and P values.   
 
Continuous  variables  were  expressed  as  median  values  and  ranges;  categorical 
data, as numbers and frequencies. Differences between groups were evaluated by 
the Student t test or Mann-Whitney U test, depending on the normality of data for 
continuous  data,  and  by  the  Fisher  exact  test  for  categorical  data.  Statistical 
significance  was  considered  at  a  2-tailed  P<0.05.  Statistical  analyses  were 
performed with SAS software, version 9.1. 
 
The authors had full access to and take full responsibility for the integrity of the 
data. All authors have read and agree to the manuscript as written. 
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RESULTS 
 
Subjects 
Sixteen hundred consecutive patients with VTE were screened over 12 years to 
identify 91 probands with protein S, protein C, or antithrombin deficiency. For 
living relatives, response rates between 90% and 97% per cohort allowed us to 
identify  725  relatives  who  were  the  subjects  in  our  study.  Figure  1  details  the 
reasons for exclusion of 257 relatives. Sixty-one relatives (8%) were <15 years of 
age;  136  (19%)  died  before  enrollment;  30  (4%)  refused  or  could  not  provide 
consent because of mental illness; and 11 (1.5%) were not enrolled for geographic 
reasons. Nineteen additional relatives and their 7 probands were excluded because 
inheritance of the index deficiency could not be established. The remaining 468 
relatives and 84 probands were analyzed: 191 subjects in the protein S cohort, 226 
in the protein C cohort, and 135 in the antithrombin cohort (Figure 1). 
 
Characteristics of the study subjects are summarized in the Table. Deficiencies 
were demonstrated in 48% of relatives and were equally distributed among men 
and women. Age of enrollment in deficient and nondeficient subjects was similar. 
Overall, 50% of deficient subjects had a history of VTE in contrast to only 3% of 
nondeficient subjects. When probands were excluded from this analysis, 31% of 
deficient  versus  3%  of  nondeficient  relatives  had  a  history  of  VTE  (P<0.001). 
Moreover, 21% of overall deficient subjects received long-term (ie, ≥12 months) 
treatment with vitamin K antagonists compared with 2% of nondeficient subjects 
(median, 10 years; range, 1 to 42 years). Long-term use of antiplatelet agents was 
similar in deficient (2%) and nondeficient (1%) subjects. Although concomitance 
of the prothrombin G20210A mutation and factor V Leiden was equally distributed 
among  deficient  and  nondeficient  subjects,  factor  VIII  levels  >150  IU/dL  were 
more prevalent in deficient subjects. Of risk factors for atherosclerosis, smoking 
history tended to be more frequent in deficient than nondeficient subjects (P=0.06), 
especially in protein C–deficient subjects, whereas diabetes mellitus tended to be 
more common in nondeficient subjects (P=0.06). 
 
Risk of arterial thromboembolic events 
ATE  occurred  in  11%  (protein  S),  11%  (protein  C),  and  8%  (antithrombin)  of 
deficient  subjects  compared  with  5%,  5%,  and  7%  of  nondeficient  subjects, 
respectively (the Table). Median age at onset of the first episode of ATE was 11 
years lower in pooled cohorts of deficient subjects versus nondeficient subjects Hereditary thrombophilia and ATE 
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(P=0.006).  Compared  with  the  pooled  cohort  of  nondeficient  subjects,  this 
difference was most prominent in subjects with protein C deficiency (22 years; 
P<0.001),  followed  by  protein  S–deficient  subjects  (10  years;  P=0.14)  and 
antithrombin-deficient subjects (5 years; P=0.29). 
 
Patients tested
(n = 1600)
Established deficiencies 
(n = 95)
Deceased or unknown
relatives (n = 4)
Protein C-deficient
probands (n = 40)
Protein S-deficient
probands (n = 39)
Antithrombin-deficient
probands (n = 12)
Total deficient probands
(n = 91)
Relatives
(n = 263)
Relatives
(n = 725)
Relatives
(n = 277)
Relatives
(n = 185)
Tested relatives
(n = 172)
Tested relatives
(n = 487)
Tested relatives
(n = 192)
Tested relatives
(n = 123)
Inheritance not
established (n = 26)
Inheritance not
established (n = 20)
Inheritance not
established (n = 6)
Inheritance not
established (n = 0)
Analysed relatives
(n = 157)
Analysed relatives
(n = 468)
Analysed relatives
(n = 188)
Analysed relatives
(n = 123)
Age < 15 y
(n = 61)
Age < 15 y
(n = 22)
Age < 15 y
(n = 24)
Age < 15 y
(n = 15)
Died
(n = 136)
Died
(n = 50)
Died
(n = 43)
Died
(n = 43)
No consent
(n = 30)
No consent
(n = 15)
No consent
(n = 12)
No consent
(n = 3)
Geographic
reasons (n = 6)
Protein S cohort
(n = 191)
Protein C cohort
(n = 226)
Antithrombin cohort
(n = 135)
Total analysed study
cohort (n = 552)
Geographic
reasons (n = 4)
Geographic
reasons (n = 1)
Geographic
reasons (n = 11)
 
Figure 1. Recruitment of 3 family cohorts with hereditary protein S, protein C, or 
antithrombin deficiency.  
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The probability of ATE-free survival was 87% and 98% at 55 years of age and 
71% and 74% at 73 years of age in deficient and nondeficient subjects, respectively 
(Figure  2).  Overall,  the  annual  incidences  of  ATE  in  the  pooled  cohorts  were 
0.34% (95% CI, 0.23 to 0.49) in deficient subjects versus 0.17% (95% CI, 0.09 to 
0.28)  in  nondeficient  subjects  (hazard  ratio,  2.3;  95%  CI,  1.2  to  4.5;  P=0.01). 
However,  on  the  basis  of  the  observation  that  the  Kaplan-Meier  curves  in  the 
pooled cohorts diverged until approximately 55 years of age and then showed less 
divergence  (Figure  2),  we  opted  for  time-dependent  analysis  of  the  index 
deficiencies (age <55 versus ≥55 years). 
 
No. at Risk
Age (Years)
A
T
E
 
-
 
f
r
e
e
 
s
u
r
v
i
v
a
l
 
(
%
)
0
50
60
70
80
90
100
No-def
Any-def 210
182
131
136 212
271
244
308
Overall Log-rank P = 0.008
HR for age < 55 y = 5.6 (1.7 - 19.1); P = 0.006
HR for age > 55 y = 1.3 (0.6 - 3.0); P = 0.51
15 35 55 75 45 25 65
14 40 79
16 39 76
 
Figure 2. Event-free survival comparing subjects with and without any deficiency.  
HR indicates hazard ratio; No-def, no deficiency; and Any-def, any deficiency (ie, protein 
S, protein C, or antithrombin deficiency). 
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Figure  3  depicts  the  annual  incidences  of  ATE  in  deficient  and  nondeficient 
subjects <55 and ≥55 years of age compared with age- and sex-weighted annual 
incidences in the general population.
17,18 Annual incidences in deficient subjects 
after 55 years of age were several-fold higher than before 55 years of age, but the 
former were similar to the age and sex-weighted annual incidence in the general 
population.
17,18  In  contrast,  annual  incidences  before  55  years  of  age  were 
significantly  higher  in  subjects  with  protein  S,  protein  C,  or  any  deficiency 
compared with the general population.
17,18  
 
Annual incidence, %
(95% CI)
0.21
(0.08 - 0.45)
0.34
(0.17 - 0.61)
0.05
(0.001 - 0.27)
0.22
(0.13 - 0.35)
0.04
(0.01 - 0.13)
1.94
(0.71 - 4.21)
0.57
(0.07 - 2.06)
1.92
(0.62 - 4.47)
1.41
(0.75 - 2.42)
1.06
(0.51 - 1.95)
PS def PC def AT def Any def No def
A
n
n
u
a
l
 
i
n
c
i
d
e
n
c
e
,
 
%
< 55 years of age
> 55 years of age
0.0
5.0
4.0
2.0
1.0
 
Figure 3. Annual incidences of ATE in subjects with hereditary protein S, protein 
C, or antithrombin deficiency <55 and ≥55 years of age.  
Solid diamonds (black) and squares (dark grey) indicate annual incidences of ATE <55 
and  ≥55  years  of  age,  respectively.  The  corresponding  95%  CIs  are  represented  by 
vertical error bars. The vertical gray bars represent the age- and sex-weighted ATE in the 
general population (ARIC study for myocardial infarction
17 and Framingham study for 
cerebrovascular and peripheral artery disease
18). PS def indicates protein S deficiency; 
PC def, protein C deficiency; AT def, antithrombin deficiency; Any def, any (ie, protein 
S, protein C, or antithrombin) deficiency; No def, no deficiency. Hereditary thrombophilia and ATE 
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Figure 4 shows the univariable association of various variables with the risk for 
ATE. Compared with nondeficient subjects, the risk for ATE was 5.6-fold (95% 
CI, 1.7 to 19.1; P=0.006) higher in individuals with any deficiency (ie, protein S,  
Variable P value
Sex, male
Arterial thromboembolism
HR (95% CI)
0.06 1.8 (1.0 - 3.3)
PS deficiency (age < 55 y)
No deficiency (age < 55 y)
PS, PC or AT deficiency
Factor VIII:C >150 IU/dl
Other thrombophilic defects
Factor V Leiden
Classic risk factors for ATE 
Prothrombin G20210A
Hypertension
Prior venous thromboembolism
Diabetes
Smoking history 
Hyperlipidemia
0.001
1.7 (0.8 - 3.6)
5.7 (1.4 - 22.8)
1.8 (0.6 - 4.8)
0.01
1.0, reference
0.16
8.4 (2.3 - 30.0)
0.28
2.2 (1.2 - 4.0)
2.4 (0.7 - 8.1)
1.3 (0.5 - 3.8)
0.5 (0.1 - 1.5)
1.8 (1.0 - 3.4)
0.002
0.14
1.0 (0.5 - 1.9)
2.6 (1.4 - 4.8)
0.21
0.96
0.57
0.06
0.009
Any deficiency (age < 55 y)
0.6 (0.1 - 2.6)
0.006
1.0, reference No deficiency (age > 55 y)
PS deficiency (age > 55 y)
PC deficiency (age < 55 y)
PC deficiency (age > 55 y)
Any deficiency (age > 55 y)
5.6 (1.7 - 19.1)
1.3 (0.6 - 3.0)
1.2 (0.1 - 11.3)
1.8 (0.6 - 5.2)
AT deficiency (age < 55 y)
AT deficiency (age > 55 y)
0.51
0.89
0.30
0.46
HR (95% CI)
0.1 1 10 50
 
Figure 4. Univariable proportionalhazards analysis of association with the time to 
the first arterial thromboembolic event.  
Solid  squares  indicate  the  hazard  ratio  of  ATE  with  the  corresponding  95%  CIs 
represented  by  the  horizontal  error  bars.  Index  deficiencies  were  analyzed  as  time-
dependent variables, ie, age  <55 and ≥55 years. HR indicates hazard ratio; PS, protein S; 
PC, protein C; and AT, antithrombin. Chapter 7 
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protein C, or antithrombin) before 55 years of age. It was 1.3-fold (95% CI, 0.6 to 
3.0; P=0.51) higher thereafter. The high risk for ATE conferred by any deficiency 
before 55 years of age was confined to protein S– or protein C–deficient subjects. 
Although factor VIII:C levels >150 IU/dL (P=0.16) and the prothrombin G20210A 
mutation (P=0.14) tended to be positively related to ATE, factor V Leiden did not 
show a similar trend. However, subjects with factor V Leiden had significantly 
lower  prevalence  of  hypertension  and  smoking  compared  with  noncarriers 
(P≤0.02).  Of  416  tested  subjects,  only  2  were  positive  for  lupus  anticoagulant. 
History of VTE was not related to subsequent ATE (hazard ratio, 1.0; 95% CI, 0.5 
to 1.9; P=0.96). After the duration of anticoagulant treatment was subtracted from 
the observation period and 4 ATEs that occurred while these subjects were on 
anticoagulant  therapy  were  excluded,  the  risk  estimates  remained  unchanged 
(hazard  ratio,  1.1;  95%  CI,  0.5  to  2.2;  P=0.86).  Of  the  classic  risk  factors  for 
atherosclerosis, hyperlipidemia and history of smoking were associated with ATE 
(P<0.01). Furthermore, hypertension and male sex tended to be associated with 
ATE (P=0.06). 
 
Multivariable  analysis  with  additional  adjustment  for  clustering  within  families 
was applied to any deficiency, the prothrombin G20210A mutation, hypertension, 
hyperlipidemia, smoking history, and sex. Of these variables, any deficiency before 
55 years of age, hypertension, hyperlipidemia, and smoking were independently 
associated  with  ATE  (P≤0.03)  (Figure  5).  The  adjusted  hazard  ratio  for  ATE 
conveyed by any deficiency before 55 years of age was 4.7 (95% CI, 1.5 to 14.2; 
P=0.007) versus 1.1 (95% CI, 0.5 to 2.6; P=0.84) thereafter. Adjusted hazard ratios 
conferred by hypertension, hyperlipidemia, and smoking were each about 2-fold 
elevated. Adjusted hazard ratios conferred by separate deficiencies were 4.6 (95% 
CI, 1.1 to 18.3; P=0.03), 6.9 (95% CI, 2.1 to 22.2; P=0.001), and 1.1 (95% CI, 0.1 
to  10.9;  P=0.94)  in  subjects  with  protein  S,  protein  C,  and  antithrombin 
deficiencies, respectively, before 55 years of age (data not shown). No significant 
interaction  was  found  between  smoking  and  any  deficiency  or  between  other 
atherosclerosis risk factors or any of the concomitant thrombophilic defects (ie, 
elevated factor VIII:C, the prothrombin G20210A mutation, and factor V Leiden) 
and any deficiency (P≥0.37). 
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Variable P value
Arterial thromboembolism
HR (95% CI)
0.007 4.7 (1.5 - 14.2) PS, PC or AT deficiency
(age < 55 y)
0.03
1.8 (1.1 - 3.0)
2.0 (1.1 - 3.7)
0.03
1.1 (0.5 - 2.6)
2.1 (1.1 - 3.6)
0.02
PS, PC or AT deficiency
(age > 55 y)
Hypertension
Smoking history
Hyperlipidemia
0.84
HR (95% CI)
0.1 1 10
 
Figure 5. Multivariable proportionalhazards analysis.  
Solid  squares  indicate  the  hazard  ratio  of  ATE  with  the  corresponding  95%  CIs 
represented  by  the  horizontal  error  bars.  Any  deficiency  was  analyzed  as  a  time-
dependent variable (ie, age <55 and ≥55 years). The hazard ratios (HR) are adjusted for 
clustering  of  ATE  within  families.  PS  indicates  protein  S;  PC,  protein  C;  and  AT, 
antithrombin. 
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DISCUSSION 
 
Overall, the lifetime risk of ATE was about 2-fold higher in subjects with any 
deficiency (ie, protein S, protein C, or antithrombin) compared with nondeficient 
subjects. However, the high risk of ATE conferred by any deficiency was evident 
only until approximately 55 years of age, a 5-fold risk increase. Moreover, subjects 
with  any  deficiency  were  on  average  11  years  younger  at  the  onset  of  ATE 
compared with nondeficient subjects. Interestingly, only protein S and protein C 
deficiencies were related to ATE before 55 years of age. Antithrombin deficiency 
was not related to a significantly increased risk either before 55 years of age or 
thereafter. Subjects with both a history of VTE and any deficiency had a risk of 
subsequent ATE similar to that of subjects with any deficiency alone. 
 
Only a few previous studies and several case reports have reported on this issue.
7,8 
A comparison with our study is hampered by differences in design. In a family 
cohort study, arterial events were observed in 8% of 144 protein S– or protein C–
deficient  subjects  and  in  1%  of  94  antithrombin-deficient  subjects.
4  Annual 
incidences in that study were stratified into types of ATE, sex, and age according to 
the Framingham study.
18 However, because of the limited number of events, annual 
incidences  were  only  estimated  in  a  few  strata,  which  hindered  an  appropriate 
comparison  with  our  study.  Furthermore,  data  on  nondeficient  relatives  and 
conventional risk factors for atherosclerosis were not provided. In a large study in 
carriers  of  familial  thrombophilia  (the  European  Prospective  Cohort  on 
Thrombophilia  [EPCOT]  study),
19  overall  annual  incidences  of  myocardial 
infarction and/or ischemic stroke after 20 years of age were 0.15%, 0.18%, and 
0.15% in subjects with protein S (n=111), protein C, (n=150), and antithrombin 
deficiency (n=92), respectively. When we confined our analysis to >20 years of 
age, annual incidences of myocardial infarction and/or ischemic stroke were 0.32% 
(protein S), 0.32% (protein C), and 0.21% (antithrombin) in deficient subjects and 
0.19% in nondeficient subjects. It is likely that the risks of ATE in the EPCOT 
study
19 were underestimated because annual incidences in their control group also 
were  remarkably  low,  only  0.03%  in  men  (mean  age,  58  years)  and  0.01%  in 
women (mean age, 58 years). Moreover, information on cardiovascular risk factors 
and on whether the recorded events were objectively verified was not available. In 
a case-control study, ATE was recorded more frequently in 88 cases with protein S, 
protein C, or antithrombin deficiency (19% ATE) compared with control subjects Hereditary thrombophilia and ATE 
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with VTE without these deficiencies (1% ATE).
20 Although the control group in 
this study might not be appropriate because not all deficient subjects had history of 
VTE, no difference in ATE prevalence was found among protein S–, protein C–, or 
antithrombin-deficient subjects. Another case-control study reported significantly 
lower  plasma  levels  of  activated  protein  C  in  young  patients  with  myocardial 
infarction (n=231) compared with healthy controls (n=231).
21 In a Japanese study, 
subjects  with  established  inherited  protein  C  deficiency  and  either  myocardial 
infarction  (n=10)  or  ischemic  stroke  (n=11)  were  on  average  11  and  7  years 
younger at onset of myocardial infarction and ischemic stroke, respectively, than 
control subjects with myocardial infarction (n=42) or ischemic stroke (n=48) with 
normal protein C levels.
22 Finally, the prospective epidemiological Atherosclerosis 
Risk  in  Communities  (ARIC)  study  reported  that  plasma  protein  C  appeared 
protective against ischemic stroke but not myocardial infarction.
23 
 
On the other hand, in other case-control studies, prevalences of these deficiencies 
were similar between cases with ischemic stroke
7,24 or myocardial infarction
7,25,26 
and matched controls, even young patients.
25,26 Furthermore, in the ARIC study, 
low levels of plasma protein C and antithrombin were not related to coronary heart 
disease.
27  However,  the  lack  of  association  between  protein  S,  protein  C,  or 
antithrombin deficiency and risk for ATE in these studies could be explained by 
the low prevalence of these hereditary deficiencies in the general population. This 
notion is given further credence by the finding that more common, but weaker, 
thrombophilic defects (ie, factor V Leiden, the prothrombin G20210A mutation) 
were more frequently related to myocardial infarction
25,26,28 and/or overall coronary 
disease (ie, myocardial infarction or coronary stenosis).
28 In addition, it could be 
speculated that protein S, protein C, or antithrombin deficiency in these studies 
might be acquired rather than hereditary, considering that acquired deficiencies are 
more prevalent. The latter is consistent with the exceptionally high prevalence of 
these deficiencies (up to 4%) in control subjects.
24 
 
Surprisingly, the increased risk for ATE was confined to subjects with protein S 
and protein C deficiencies. Subjects with antithrombin deficiency had a risk for 
ATE  comparable  to  that  for  nondeficient  subjects.  That  this  difference  is 
attributable by chance, for instance, as a result of the smaller cohort of subjects 
with antithrombin deficiency, could be argued because high risk for ATE conferred 
by  protein  S  or  protein  C  but  not  antithrombin  deficiency  also  was  reported 
earlier.
4,8  It  could  be  speculated  that  the  higher  risk  for  ATE  in  subjects  with Chapter 7 
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protein C deficiency could be ascribed to the potent cytoprotective effects of the 
protein  C  pathway.
29  Why  protein  S  deficiency,  rather  than  deficiency  of 
antithrombin,  was  associated  with  ATE  may  be  the  synthesis  of  protein  S  by 
endothelial  cells,
30  whereas  antithrombin  is  synthesized  by  hepatocytes. 
Endothelial injury as a trigger of thrombosis may be enhanced by a preexisting 
defect in protein S synthesis at the site of injury. Furthermore, some cytoprotective 
effects also have been attributed to protein S.
30,31 
 
Since its first description,
9 the amount of data indicating a link between VTE and 
subsequent ATE has been increasing.
10 In our study, subjects with prior VTE had a 
risk for ATE similar to that of subjects without prior VTE. This lack of association 
could not be ascribed to use of vitamin K antagonists. On the basis of our estimated 
hazard risk, even in a larger sample, a link between VTE and subsequent ATE 
seems unlikely in these subjects. The potential link between VTE and subsequent 
ATE  is  believed  to  be  due  to  the  sharing  of  common  pathophysiological 
mechanisms.
9 Because protein S and protein C deficiencies but not antithrombin 
deficiency were significantly related to ATE in our study, it could be speculated 
that endothelial dysfunction rather than coagulation disorders is the main actor in 
the link between VTE and subsequent ATE. Moreover, atherosclerosis risk factors 
are somewhat stronger risk factors for VTE than are the prothrombin G20210A 
mutation  and  factor  V  Leiden  for  ATE.
11,28  However,  it  remains  unclear  why 
subjects with both prior VTE and protein S or protein C deficiency had a risk for 
ATE similar to that of subjects with these deficiencies alone. 
 
Concomitant  thrombophilic  events  apparently  aggregated  in  our  families.  The 
prevalence of factor V Leiden was 3 to 5 times higher in families with protein S or 
C deficiency than that reported in the general population (14% to 25% versus 5%).
5 
The prothrombin G20210A mutation was more prevalent in families with any of 
the 3 deficiencies than in the general population (5% to 13% versus 2%),
5 as were 
increased factor VIII:C levels (29% to 49% versus 11%).
5 Aggregation of these 
concomitant  thrombophilic  defects  was  independent  of  the  index  deficiencies, 
except that factor  VIII:C levels >150 IU/dL were more frequently observed in 
subjects with protein S or C deficiency. The latter might be secondary to these 
deficiencies per se because, in theory, low levels of activated protein C or protein S 
may result in less FVIII inactivation. In contrast to VTE,
2 the concomitance of 
factor VIII:C levels >150 IU/dL, the prothrombin G20210A mutation, or factor V Hereditary thrombophilia and ATE 
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Leiden was not related to higher risk for ATE compared with subjects with the 
index deficiencies alone. 
 
One may consider screening for protein S or protein C deficiency in young subjects 
with ATE if a family history is suspected or positive for thrombophilia because 
diagnosis of these deficiencies has clinical implications for the prevention of VTE. 
Further  studies  are  needed  to  demonstrate  clinical  utility  of  thrombophilia 
screening for primary or secondary prevention of ATE. 
 
The main limitation of this study is its retrospective design. Consequently, because 
patients  were  not  routinely  screened  for  atherosclerosis  risk  factors  and  the 
information  on  these  factors  was  self-reported  and/or  derived  from  medical 
records,  it  is  possible  that  the  true  incidence  of  these  risk  factors  has  been 
underestimated in asymptomatic subjects. This would have resulted in a slightly 
lower  adjusted  hazard  ratio  for  ATE  conferred  by  protein  S,  protein  C,  or 
antithrombin deficiency. Referral bias may have been introduced by the university 
hospital setting but was probably reduced by testing all consecutive patients with 
VTE for deficiencies. Because probands were consecutive patients with VTE and 
the response rate of eligible relatives was high, selection bias was probably limited. 
Although we cannot exclude the possibility that more deficient than nondeficient 
subjects died of VTE or ATE, this potential source of bias would have resulted in 
an  underestimated  risk  for  ATE  in  deficient  subjects.  Moreover,  hereditary 
deficiencies  were  not  associated  with  a  reduced  life  expectancy  in  previous 
studies.
32,33  Despite  these  limitations,  we  believe  that  this  is  the  first  study  to 
document the age-dependent elevated risk for ATE conveyed by hereditary protein 
S or protein C deficiency but not antithrombin deficiency in these thrombophilic 
families. 
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CONCLUSIONS 
This study delineates an increased risk for ATE conferred by protein S or protein C 
deficiency before age 55 years compared with nondeficient family members. In 
contrast, antithrombin deficiency was not associated with a significantly elevated 
risk for ATE either before age 55 years or thereafter. Prior VTE was not related to 
subsequent ATE in these subjects. 
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ABSTRACT 
 
Context: Evidence on the relation between venous and arterial thromboembolism 
is inconsistent. Furthermore, age and other cardiovascular risk factors were not 
always taken into account. 
Objective:  To  determine  the  risk  of  arterial  thromboembolism  after  venous 
thromboembolism, independent of cardiovascular risk factors. 
Design,  Setting,  and  Participants:  In  1997-1998,  inhabitants  of  the  city  of 
Groningen,  the  Netherlands,  aged  28-75  years  (n=85,421),  were  sent  a 
questionnaire on cardiovascular risk factors, and a vial to collect a urine sample. 
After entry, all responding subjects (n=40,856) were followed and monitored for 
venous  and  arterial  thromboembolism.  Median  follow-up  time  was  7.8  years. 
Thromboembolism  was  verified  with  national  registries  of  hospital  discharge 
diagnoses and death certificates, the regional anticoagulation clinic and medical 
records. 
Main Outcome measure: Arterial thromboembolism (ie, myocardial infarction, 
coronary artery disease, peripheral arterial occlusive disease, or ischemic stroke) 
between study initiation and December, 31, 2005. 
Results: Of 40,856 responding subjects (46% male; median age at enrollment, 48 
years),  410  developed  venous  thromboembolism  (42%  unprovoked),  and  2314 
developed  arterial  thromboembolism  during  a  median  follow-up  period  of  7.8 
(interquartile range, 7.5-8.1) years. Annual incidence of arterial thromboembolism 
after venous thromboembolism was 2.36% (95% confidence interval [CI], 1.59-
3.37),  compared  to  0.80%  [95%  CI,  0.77-0.83]  in  subjects  without  venous 
thromboembolism. Adjusted hazard ratio of arterial thromboembolism after venous 
thromboembolism was 1.81 [95% CI, 1.26-2.60]. This risk was highest within the 
first year after venous thromboembolism (annual incidence, 3.51% [95% CI, 1.81-
6.13]; adjusted hazard ratio, 2.58 [95% CI, 1.46-4.55]) and after an unprovoked 
event (annual incidence, 2.78% [95% CI, 1.62-4.45]; adjusted hazard ratio, 1.94 
[95% CI, 1.20-3.12]).  
Conclusions: Subjects with venous thromboembolism are at a high risk to develop 
arterial  thromboembolism,  independent  of  age  and  other  cardiovascular  risk 
factors.  This  risk  is  particularly  high  in  the  first  year  after  venous 
thromboembolism and after an unprovoked event.     Chapter 8 
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INTRODUCTION 
 
The  concept  that  venous  and  arterial  thromboembolism  are  separate 
pathophysiological entities has been challenged.
1 In 2003, Prandoni et al. were the 
first to report a twofold increased risk for unprovoked deep vein thrombosis in 
patients with atherosclerotic plaques.
2 More recently, a large case-control study 
showed a 2-3 fold increased relative risk of arterial thromboembolism after first 
venous thromboembolism, most predominantly in the first year following initial 
venous thromboembolism.
3 However, evidence on the relation between venous and 
arterial  thromboembolism  is  inconsistent.  Two  observational  studies  could  not 
identify an increased risk of overall or unprovoked venous thromboembolism in 
patients with atherosclerosis.
4,5 Furthermore, age effects were not fully taken into 
account in all studies that considered venous and arterial thromboembolism as two 
related  diseases.
6-9  Age  is  a  strong  confounder  to  the  risk  of  both  venous  and 
arterial thromboembolism, hence it is doubtful whether the high absolute risk of 
arterial thromboembolism after venous thromboembolism (reported to be as high as 
5.5% per year),
8 is truly related to previous venous thrombotic disease or merely a 
result  of  ageing.  In  addition,  previous  studies  did  not  always  correct  for  the 
presence of cardiovascular risk factors.
3 This is remarkable as these factors (i.e. 
elevated albuminuria, hypertension, dyslipidemia, diabetes mellitus, and smoking) 
are also reported to be associated with venous thromboembolism.
6,10  
 
This study was conducted to advance our understanding of both venous and arterial 
thrombotic disease and to provide further insight into the clinical course of patients 
with venous thromboembolism. Our aims were to determine the absolute risk of 
arterial thromboembolism after venous thromboembolism, and to establish whether 
venous thromboembolism is a risk factor for subsequent arterial thromboembolism, 
independent of age, sex and other cardiovascular risk factors, in a population-based 
cohort of more than 40,000 subjects. ATE incidence in patienst with VTE 
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METHODS 
 
Study population 
This study was conducted on participants in the Prevention of REnal and Vascular 
ENd  stage  Disease  (PREVEND)  study.  The  PREVEND  study  was  designed  to 
prospectively investigate the natural course of albuminuria and its relation with 
renal  and  cardiovascular  disease  in  a  large  cohort  drawn  from  the  general 
population. Details of this study have been published previously
11 and can be found 
at http://www.prevend.org. In 1997-1998, all inhabitants of the city of Groningen, 
the Netherlands, aged 28 to 75 years (n=85421) were sent a postal questionnaire 
and a vial to collect an early morning urine sample. A total of 40,856 subjects 
(47.8%) responded. The questionnaire provided information about the presence of 
established risk factors for cardiovascular disease. Subjects were classified as being 
diabetic when they positively answered the question whether they were diagnosed 
with  diabetes  by  a  physician,  regardless  of  the  type  of  antidiabetic  treatment. 
Subjects  were  considered  hypertensive  or  dyslipedemic  when  they  positively 
answered  the  question  whether  high  blood  pressure  or  high  cholesterol, 
respectively,  had  ever  been  measured.  Those  who  reported  smoking  or  having 
smoked cigarettes during the previous 5 years were regarded as smokers. A history 
of  myocardial  infarction  or  stroke  was  considered  present  if  associated  with  a 
hospitalization for at least 3 days. 
 
All  participants  gave  written  informed  consent.  The  PREVEND  study  was 
approved by the local medical ethics committee and was conducted in accordance 
with the guidelines of the Declaration of Helsinki. 
 
Measurements 
Morning urinary albumin concentration (UAC) was established by a commercial 
immunoturbidimetry assay with sensitivity of 2.3 mg/L and inter- and intra-assay 
coefficients  of  variation  of  2.2  and  2.6%,  respectively  (BN  II,  Dade  Behring 
Diagnostica).
11,12 First morning urine was used for analysis. Urine samples could 
be  analyzed  for  40,854  subjects.  Albuminuria  was  considered  elevated  at  a 
concentration of 20 mg/L or more. 
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Definition of thrombotic events 
To identify subjects with thromboembolism between January 1997 and December 
2005,  the  databases  of  the  national  registry  of  hospital  discharge  diagnoses 
(Prismant,  Utrecht,  the  Netherlands)  and  death  certificates  (Central  Bureau  of 
Statistics, The Hague/Heerlen, the Netherlands) were used. Previous reports have 
shown that the Prismant-database is of good quality, with 84-87% of the Prismant 
diagnoses matching the diagnoses found in the patient chart.
13,14 Venous events 
were  verified  with  the  database  of  the  regional  anticoagulation  clinic,  which 
monitors the anticoagulant therapy of all inhabitants of the city of Groningen and 
environs. For further corroboration, patients’ medical records were examined for 
all subjects with venous thromboembolism according to any of the abovementioned 
databases.  Arterial  thromboembolism  was  defined  as  myocardial  infarction, 
coronary artery disease, peripheral arterial occlusive disease, and ischemic stroke. 
Deep  vein  thrombosis  had  to  be  confirmed  by  compression  ultrasound,  and 
pulmonary  embolism  by  ventilation/perfusion  lung  scanning,  spiral  computed 
tomography,  or  at  autopsy.  Venous  thromboembolism  was  classified  as  being 
provoked  when  it  had  occurred  at  or  within  3  months  after  exposure  to  an 
exogenous risk factor including surgery, trauma, immobilization for more than 7 
days,  pregnancy,  puerperium,  the  use  of  oral  contraceptives  or  hormonal 
replacement therapy, or malignancy. Venous thromboembolism was classified as 
unprovoked when no such exogenous risk factor occurred. 
 
Statistical analysis 
We estimated the absolute risk of arterial thromboembolism in subjects with and 
without venous thromboembolism to assess whether venous thromboembolism is a 
risk factor for arterial thromboembolism. The absolute risk was expressed as an 
annual incidence and was calculated by dividing the number of arterial events by 
the number of years of follow-up. For subjects without venous thromboembolism, 
observation  time  started  at  time  of  enrollment  and  ended  at  time  of  arterial 
thromboembolism, a censoring event (intracranial arterial bleeding, death, moving 
out of the city) or end of study (December 2005). For subjects who had venous 
thromboembolism, observation time started at time of diagnosis and also ended at 
time of arterial thromboembolism, a censoring event or end of study. The 95% 
confidence intervals (CIs) around the annual incidences were assessed with the 
Poisson distribution assumption. A time-varying exposure Cox proportional hazard 
model was used to estimate whether venous thromboembolism was a risk factor for 
arterial  thromboembolism.  Adjustments  were  made  for  age,  sex,  hypertension, ATE incidence in patienst with VTE 
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dyslipidemia, diabetes mellitus, smoking status, elevated albuminuria and history 
of  arterial  thromboembolism.  Additional  preplanned  sensitivity  analyses  were 
performed for the first year of follow-up after venous thromboembolism and for the 
rest of follow-up, to investigate the persistence of venous thromboembolism as a 
risk factor through time. To exclude the possibility of hospitalization bias, causing 
patients  with  venous  thromboembolism  to  have  a  spurious  increased  risk  of 
subsequent  arterial  thromboembolism  due  to  close  monitoring  in  the  period 
following the event, we also restricted these sensitivity analyses to hard arterial 
thrombotic endpoints (i.e. myocardial infarction, ischemic stroke or cardiovascular 
death). 
 
Categorical data are presented as counts and percentages, continuous variables as 
medians with interquartile ranges (IQR). Statistical analyses were performed using 
SPSS version 16.0 (SPSS, Chicago, Illinois, United States) and SAS version 9.1 
(SAS Institute, Inc, Cary, NC, USA).      Chapter 8 
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RESULTS 
 
Study Population 
Clinical characteristics of the 40,856 participants are shown in the Table. Slightly 
more women responded than man. Median age at enrolment was 60 (IQR, 49-68) 
and 48 (IQR, 39-60) years for subjects with and without venous thromboembolism, 
respectively. Venous thromboembolism had occurred in 410 subjects at a median 
age of 64 years (IQR, 51-72). In 192 subjects the venous event was secondary to an 
external risk factor, 174 events were unprovoked. In 44 events the presence of an 
external risk factor was unknown. Thirty subjects with venous thromboembolism 
developed arterial thromboembolism at a median age of 71 years (IQR, 65-77). In 
the  group  without  venous  thromboembolism,  2284  subjects  developed  arterial 
thromboembolism  at  a  median  age  of  68  years  (IQR,  60-74).  A  total  of  7181 
subjects  (107  subjects  with  venous  thromboembolism,  7074  without)  were 
censored at time of intracranial arterial bleeding (n=151, 0.37%), death (n=1770, 
4.3%) or moving out of the city (n=5260, 12.9%). Median follow-up time was 7.8 
(IQR, 7.5-8.1) years. 
 
Table. Clinical Characteristics 
  Venous thrombosis  No venous 
thrombosis 
TOTAL  410 (100)  40,446 (100) 
Baseline characteristics     
   Male  200 (49)  18,425 (46) 
   Age at enrolment, y  60 (49-68)  48 (39-60) 
   Cardiovascular risk factors         
     Hypertension  148 (36)  11,691 (29) 
     Dyslipidemia  65 (16)  5584 (14) 
     Diabetes Mellitus  12 (3)  1039 (3) 
     Current Smokers  151 (37)  16,997 (42) 
     Microalbuminuria (≥20 mg/L)  49 (12)  3151 (8) 
     History of arterial 
thromboembolism 
26 (6)  1754 (4) 
Characteristics during follow-up       
   Thrombotic cardiovascular event  30 (7)  2284  (6) 
   Age at onset, y  71 (65-77)  68 (60-74) 
     Classification         
     Myocardial infarction  14 (3)  813 (2) 
     Coronary artery disease  6 (1)  873 (2) 
     Peripheral arterial occlusive disease  4 (1)  170 (0) 
     Ischemic stroke  6 (2)  428 (1) 
Continuous variables are presented as median (IQR), categorical variables as number (%) ATE incidence in patienst with VTE 
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Risk of arterial thromboembolism after venous thromboembolism 
The  Figure  shows  the  risk  of  arterial  thromboembolism  after  venous 
thromboembolism. The annual incidence of arterial thromboembolism after prior 
venous  thromboembolism  was  2.36%  (95%  CI,  1.59-3.37), compared  to  0.80% 
(95% CI, 0.77-0.83) in subjects without venous thromboembolism. Crude hazard 
ratio  of  subsequent  arterial  thromboembolism  was  2.90  (95%  CI,  2.02-4.16)  in 
subjects  with  venous  thromboembolism,  compared  to  subjects  without.  After 
adjustment  for  age,  sex,  cardiovascular  risk  factors  and  previous  arterial 
thromboembolism, this risk was 1.81 (95% CI, 1.26-2.60). Within this model, age 
was a strong confounder as adjustment for age only, resulted is a hazard ratio of 
1.91 (95% CI, 1.33-2.74). 
 
When subgroups of venous thromboembolism were analyzed separately (i.e., deep 
vein  thrombosis  versus  pulmonary  embolism  and  unprovoked  versus  provoked 
venous  thromboembolism),  subjects  with  deep  vein  thrombosis  or  unprovoked 
venous thromboembolism had the highest risk of arterial thromboembolism, with 
adjusted hazard ratios of 2.30 (95% CI, 1.49-3.53) and 1.94 (95% CI, 1.20-3.12), 
respectively. 
 
Risk of arterial thromboembolism was highest within the first year after venous 
thromboembolism with an annual incidence of 3.51% (95% CI, 1.81-6.13) and an 
adjusted hazard ratio of 2.58 (95% CI, 1.46-4.55). After 1 year of follow-up, the 
adjusted hazard ratio of arterial thromboembolism after venous thromboembolism 
decreased  to  1.51  (95%  CI,  0.95-2.41).  When  limited  to  myocardial  infarction, 
ischemic stroke and cardiovascular death, overall adjusted hazard ratio after venous 
thromboembolism was 2.04 (95% CI, 1.31-3.19), and within the first year this was 
2.88 (95% CI, 1.43-5.77).  
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DISCUSSION 
 
This large population-based cohort study shows that subjects with previous venous 
thromboembolism  are  at  increased  risk  to  develop  arterial  thromboembolism. 
Although age was a strong confounder to this risk, the relative risk was still 1.8-
fold increased after adjustment for age, sex, cardiovascular risk factors and history 
of arterial thromboembolism. The overall absolute risk was as high as 2.4% per 
year and 3.5% within the first year after venous thromboembolism was diagnosed. 
These values approach the absolute risks of recurrent venous thromboembolism.
15-
17 This implicates that clinicians should be aware of both arterial thromboembolism 
and  recurrent  venous  thromboembolism,  since  both  diseases  are  almost  equally 
common in patients with previous venous thromboembolism. The risk of arterial 
thromboembolism was highest within the first year after venous thromboembolism. 
This early occurrence is in accordance with other studies.
3,9 Although the adjusted 
hazard ratio for subsequent arterial thromboembolism decreased from a statistically 
significant 2.6-fold (95% CI, 1.46-4.55; P-value, 0.001) increased risk in the first 
year of follow-up to a non-statistically significant 1.5-fold (95% CI, 0.95-2.41; P-
value, 0.08) increased risk in the following years, a similar tendency was found in 
the study of Sørensen et al.
3  
 
The high risk of arterial thromboembolism in subjects with an unprovoked venous 
event compared to those with a provoked event suggests that a joint mechanism 
causes events in both venous and arterial systems. Our finding that the relation 
between arterial and venous thromboembolism remains persistent after adjustment 
for cardiovascular risk factors supports this idea. Obesity is related to a higher risk 
of  arterial
18,19  and  venous  thromboembolism.
20-24  This  might  partly  explain  the 
relation between arterial and venous thromboembolism through endothelial damage 
and/or the related changes in the levels of procoagulant proteins.
25-32 Unfortunately, 
data on weight and height were not available for all the 40,856 participants in our 
cohort. 
 
Our study has both strengths and limitations. Strengths are the large population-
based cohort, the long follow-up time, the prospectively collected data on arterial 
events,  the  estimation  of  absolute  risks,  the  possibility  to  analyze  confounding 
cardiovascular risk factors, and the adjustments we made for age and sex in all 
analyses. A possible limitation of our study is that the data on cardiovascular risk 
factors  were  collected  using  self-reported  histories.  A  certain  degree  of Chapter 8 
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misclassification might have occurred, which may have caused bias. Exact start- 
and stopping dates of anticoagulation were not available and hence not used in our 
analyses.  However,  since  use  of  anticoagulation  reduces  the  risk  of  arterial 
thromboembolism,
33  it  is  reasonable  to  have  caused  an  underestimation  of  the 
strength of the association between arterial and venous thromboembolism in our 
study. 
 
Interestingly,  among  the  subjects  with  venous  thromboembolism,  subjects  with 
pulmonary  embolism  seemed  not  to  be  at  increased  risk  of  arterial 
thromboembolism. A possible explanation for this finding could be that subjects 
with pulmonary embolism had a reduced life expectancy, and therefore did not 
have  the  opportunity  to  be  at  risk  for  arterial  thromboembolism.  However, 
compared to subjects with deep vein thrombosis, the life expectancy of patients 
with pulmonary embolism was not shorter in our cohort. Another explanation could 
be that pulmonary events were mainly provoked events, since provoked events did 
not increase the risk of arterial thromboembolism. Yet, the distribution of provoked 
versus  unprovoked  events  were  comparable  in  the  subjects  with  deep  vein 
thrombosis  and those with pulmonary embolism.  Klok et al. could not show  a 
relation between pulmonary embolism and arterial thromboembolism either, but 
they did show an increased risk after unprovoked pulmonary embolism.
9 In our 
study, numbers were too small for this analysis.  
 
The  possibility  that  a  higher  risk  of  arterial  thromboembolism  after  venous 
thromboembolism  was  spurious  due  to  a  hospitalization  bias  was  ruled  out  as 
hazard ratios were not materially affected when we restricted the analysis to hard 
endpoints. 
 
We  conclude  from  this  large  cohort  study  that  subjects  with  venous 
thromboembolism are at a high risk to develop arterial thromboembolism. This risk 
is  especially  high  in  the  first  year  after  venous  thromboembolism  and  after  an 
unprovoked  event.  The  risk  remains  persistent  after  adjustment  for  age,  sex, 
cardiovascular risk factors and previous arterial thromboembolism. Our findings 
implicate  that,  from  now  on,  the  clinical  course  of  patients  with  venous 
thromboembolism  should  not only  focus  on  the prevention  of recurrent  venous 
thromboembolism but also on the prevention of arterial thromboembolism. ATE in patients with VTE 
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In  the  last  decade  the  dichotomy  between  venous  (VTE)  and  arterial  thrombo-
embolism (ATE) has been challenged. Chapter 1 summarizes recent research on 
this issue and depicts the rationale and outline of this thesis. 
 
In chapter 2 the association between nephrotic syndrome and thromboembolism, 
including  both  VTE  and  ATE,  was  assessed.  Though  the  association  between 
nephrotic syndrome and especially VTE has been known for decades, for the first 
time we assessed the annual incidences of symptomatic and objectively verified 
thromboembolic endpoints in a large cohort of patients with nephrotic syndrome. 
Absolute risks of VTE (1.02% per year) and ATE (1.48% per
 year) were each 
about 8 times higher in these patients than the estimated
 age- and sex-weighted 
annual incidences in the general population. Risks of both VTE and ATE were 
particularly  high  within  the  first  6  months  after  the  diagnosis  of  nephrotic 
syndrome  (annual  incidences  9.85%  and  5.52%,  respectively).  Moreover,  we 
reported for the first time that the ratio of proteinuria to serum albumin predicts 
VTE, and that various classic risk factors for atherosclerosis are associated with 
ATE, also in patients with nephrotic syndrome, including sex, age, hypertension, 
diabetes, smoking, prior ATE, and eGFR. 
 
Chapter  3  describes  the  associations  between  various  established 
atherosclerosis/ATE  risk  factors  and  incident  VTE.  These  associations  were 
studied  in  a  population-based  cohort  study  (the  PREVEND  study).  Besides 
albuminuria,  various classic atherosclerosis risk factors were related to VTE in 
univariate analyses. However, after adjustment for sex and age, only albuminuria, 
body  mass  index,  premenopausal  use  of  oral  contraceptives,  and  plasminogen 
activator inhibitor type-1 levels were related to VTE incidence. In a multivariate 
model, albuminuria remained an independent predictor of VTE. A dose-response 
relationship  between  albuminuria  and  VTE  was  observed  even  in  the  range  of 
albuminuria that is currently regarded as “normal” (i.e., <30 mg/day). Higher levels 
of urinary albumin excretion were particularly associated with unprovoked VTE, 
which formed about half of the VTE cases. In chapter 4 the association of eGFR 
and  albuminuria  with  the  risk  of  VTE  was  studied  using  the  Kidney  Disease 
Outcome  Quality  Initiative  (K/DOQI)  classification  for  chronic  kidney  disease. 
Though a trend was observed for decreased eGFR predicting VTE, only in the 
presence of elevated levels of albuminuria the association between low eGFR and 
VTE was statistically significant.  
   Chapter 9   
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In chapter 2 through 4 urinary protein loss of various degrees of severity, ranging 
from microalbuminuria to nephrotic-range proteinuria, turned out to be associated 
with  increased  risk  of  thromboembolism.  To  assess  the  pathophysiological 
mechanisms  that  may  explain  this  association,  and  to  assess  the  impact  of 
antiproteinuric therapy on the prothrombotic state in these patients, we evaluated in 
chapter 5 thirty-two patients with overt proteinuria for coagulation disturbance at 
baseline and after treatment with losartan (an angiotensin II receptor blocker). The 
32  patients  with  proteinuria  (median  3.7  g/d;  interquartile  range  1.5-5.6)  were 
compared to 32 healthy controls. Patients were treated with losartan alone or in 
combination  with  diuretics  for  a  period  of  24  week  with  another  6  weeks  of 
placebo before and at the end of losartan treatment. As compared to age- and sex-
matched  controls,  patients  with  overt  proteinuria  were  more  prothrombotic,  as 
indicated by markedly elevated thrombin generation. This prothrombotic state was 
likely caused by high levels of various procoagulant proteins, including fibrinogen, 
while the major inhibiting proteins antithrombin, protein C and total protein S were 
surprisingly  similar  in  proteinuric  patients  as  compared  to  controls.  However, 
except  for  antithrombin  levels  that  had  no  association  with  the  extent  of 
proteinuria, levels other anticoagulant as well as all measured procoagulant factors 
were positively correlated with the extent of proteinuria. Antiproteinuric therapy 
(partially) reversed the prothrombotic state, though increased levels of endothelial 
derived factor VIII and von Willebrand factor persisted. 
 
Hereditary  thrombophilia  is  another  well  known  entity  that  leads  to  a 
prothrombotic state. Deficiencies of the natural anticoagulant proteins (i.e., protein 
S, protein C and antithrombin) are considered the strongest hereditary risk factors 
for VTE. This raises two questions. Firstly, the absolute risks in these subjects have 
mainly  been  based  on  retrospective  studies  due  to  the  low  prevalence  of  these 
deficiencies in the general population. Firstly, since retrospective studies are prone 
for  bias,  might  it  be  that  the  true  VTE  risk  conferred  by  these  deficiencies  is 
different than reported in the past? Secondly, how important is it to diagnose any of 
these  deficiencies  in  asymptomatic  subjects  by  screening?  Chapter  6  reports 
results of a prospective family cohort study on the absolute risks of VTE and the 
yield of screening asymptomatic relatives of patients with hereditary deficiencies 
of protein S, protein C or antithrombin. After screening, deficient subjects were 
advised to use thromboprophylaxis during exogenous risk factors and the use of 
oral contraceptives was discouraged. Whereas the risk of unprovoked VTE was 
about 22-fold higher in subjects with any deficiency (i.e., protein S, protein C or Summary 
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antithrombin),  the  risk  of  provoked  VTE  was  only  2-  to  3-fold  elevated,  as 
compared with non-deficient subjects. Screening and subsequent augmentation of 
thromboprophylaxis may result in reduction of provoked VTE, whereas risk of 
unprovoked VTE could not be affected by screening. 
 
Though hereditary deficiencies of protein S, protein C, and antithrombin are the 
strongest  hereditary  risk  factors  for  VTE,  their  association  with  ATE  has  been 
controversial and well-designed large studies were not available. In chapter 7 we 
describe  the  risk  of  ATE  in  a  large  cohort  of  families  with  these  deficiencies. 
Overall, the lifetime risk of ATE was about 2-fold higher in subjects with any 
deficiency (i.e., protein S, protein C, or antithrombin) compared with non-deficient 
subjects. However, the high risk of ATE conferred by any deficiency was evident 
only until about 55 years of age, consisting of a 5-fold risk increase. Interestingly, 
only protein S and protein C deficiencies were related to ATE before 55 years of 
age.  Antithrombin  deficiency  was  not  related  to  a  significantly  increased  risk 
neither before 55 years of age, nor thereafter. 
 
Finally, whereas the increased risk of VTE after ATE is well recognized, especially 
in stroke patients, a possibly higher risk of ATE after a VTE is new. In chapter 8 
this association was assessed in the baseline cohort of the PREVEND study. In this 
large population-based cohort study subjects with previous VTE were at increased 
risk to develop ATE. After adjustment for age, sex, cardiovascular risk factors and 
history of arterial thromboembolism the relative risk was still 1.8-fold increased. 
The overall absolute risk was as high as 2.4% per year, and was highest (3.5%) in 
the first year after VTE was diagnosed. 
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Thromboembolic diseases of venous and arterial systems have historically been 
viewed  as  two  different  diseases  with  distinct  risk  factors.
1  This  notion  was 
challenged in the last decade since an increased incidence of atherosclerosis and 
arterial  thromboembolism  (ATE)  had  been  observed  in  subjects  with  venous 
thromboembolism  (VTE).
2-12  Moreover,  an  increasing  amount  of  data  indicated 
that classic atherosclerosis risk factors (ie, hypertension, hyperlipidemia, diabetes, 
obesity, and smoking) may also predispose individuals to VTE, though results were 
sometimes  inconsistent.
13-26    Moreover,  not  all  data  in  literature  support  the 
hypothesis  that  VTE  and  ATE  may  be  two  different  phenotypes  of  the  same 
disease.  For  instance,  hereditary  thrombophilic  deficiencies  of  the  natural 
anticoagulant proteins (i.e., antithrombin, protein C and protein S) are considered 
strong  risk  factors  for  VTE; 
27-29  while  their  association  with  ATE  has  been 
controversial.
30,31  Similarly, overt proteinuria in patients with nephrotic syndrome 
is considered an established risk factor for VTE, while its association with ATE in 
non-diabetics has been less well recognized.
32-34 Microalbuminuria on the other 
hand  has  been  considered  an  established  risk  factor  for  ATE,
35-39  whereas  its 
association with VTE was for the first time studied in the current thesis. Finally, 
decreased  estimated  glomerular  filtration  rate  (eGFR)    is  also  a  long  and  well 
recognized risk factor for ATE,
35,40 whereas its possible link to increased risk of 
VTE  has  been  studied  only  recently.
41  Thus  whether  VTE  and  ATE  are  two 
different entities or two different phenotypes of the same disease is a matter of 
intensive research in the field of cardiovascular research and has been the main 
topic of current thesis. 
 
Classic atherosclerosis risk factors and risk of venous thromboembolism  
The  association  of  classic  atherosclerosis  risk  factors  (i.e.,  hypertension, 
dyslipidemia, smoking, obesity and diabetes) and incident VTE has been reported 
in  various  epidemiological  studies.
13-26  Although  the  exact  pathophysiological 
mechanisms  accounting  for  this  potential  association  have  yet  to  be  unraveled, 
endothelial  dysfunction,  which  is  strongly  associated  with  atherosclerosis  risk 
factors,  is  considered  the  main  culprit.  This  also  fits  the  Virchow  triad,  as 
endothelial dysfunction or damage is one of the three components of the Virchow 
triad that historically classified the pathophysiological mechanisms of factors that 
may  lead  to  VTE.  In  chapter  3  we  assessed  the  association  of  various 
atherosclerosis  risk  factors  and  VTE.  Whereas  in  univariate  analysis  various 
atherosclerosis risk factors were related to VTE, after age and sex adjustment only 
body mass index and albuminuria remained significant predictors of VTE. This   Chapter 10   
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demonstrates that crude association of atherosclerosis risk factors and VTE that is 
observed  may  be  due  to  aging  alone,  and  that  in  epidemiological  studies 
appropriate  adjustment  or  matching  should  take  place.  The  results  of  studies 
investigating the association of atherosclerosis risk factors and incident VTE are 
consistently  positive  for  overweight  or  obesity,  whereas  for  hypertension, 
dyslipidemia,  and  diabetes  these  are  equivocal.
13-15,17-21,23-26  The  differences 
between studies with respect to the predictive yield of these latter risk factors could 
be  ascribed  to  differences  in  study  populations  with  respect  to  presence  of 
concomitant established and/or unknown VTE risk factors. For instance, subjects 
with diabetes may have a higher risk of VTE, but concomitant use of statins and/or 
antiplatelet agents in subjects with diabetes may neutralize this increased risk for 
VTE. Many of the studies that have been conducted thus far did not adjust for such 
potential confounders. In conclusion, at the moment there is insufficient data to 
consider hypertension, dyslipidemia, diabetes and smoking as established VTE risk 
factors. To assess whether there is an association of these variables with VTE, and 
whether these associations are causal, ideally clinical intervention studies should be 
conducted randomizing subjects to treatment or to no/less intensive treatment of 
these risk factors, with incident VTE serving as end-point. Of note, this may be less 
appropriate for dyslipidemia, because of the pleiotropic effects of statins.
42 For 
dyslipidemia and smoking, prospective observational cohort studies that adjust for 
potential confounders might be a better choice to study their relevance as VTE risk 
factors.  
 
Thrombophilia and risk of venous and arterial thromboembolism 
Thrombophilia is the clinical term for a hypercoagulable state that was originally 
used to define young patients with VTE mainly due to hereditary defects. The five 
best established hereditary thrombophilic defects include the two prevalent gain-of-
function  mutations  (i.e.,  the  factor  V  Leiden  and  the  prothrombin  G20210A 
mutation) and the relatively rare hereditary deficiencies of the natural anticoagulant 
proteins (i.e., protein S, protein C and antithrombin). Since these thrombophilic 
defects alone, or in combination with acquired risk factors, are responsible for only 
about 50-75% of VTE cases,
43 it is likely that other unknown acquired and genetic 
risk  factors  eventually  will  be  identified.  Considering  the  fact  that  literature 
indicates that the later the identification of a thrombophilic defect, the weaker the 
associated risk of VTE, potential new hereditary risk factors are expected to be 
even weaker risk factors for VTE than the presently known factors. An exception 
to this assumption would be if thrombophilic families that have tested negative for Discussion and future perspectives 
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the  known  hereditary  defects  are  analyzed.  However,  any  discovered  new 
thrombophilic defects in such families will probably be family specific, be very 
rare and responsible for only a very low number of VTE on a population level. In 
contrast, if a risk factor is only weakly associated with VTE incidence, but highly 
prevalent in the general population, this may account for a considerable proportion 
of the overall VTE incidence at population level. At the same time the value of 
such a weak but prevalent risk factor for risk assessment at an individual patient 
level will be limited. Therefore, experts presently question the clinical relevance of 
screening for VTE prevention even for strong thrombophilic defects, such as the 
antithrombin, protein C and protein S deficiencies.
44 Their uncertainty is primarily 
based on two reasons: first, in the setting of continuous thromboprophylaxis, the 
risk  of  major  bleeding  outweighs  the  risk  of  VTE  in  the  general  population;
45 
second,  in  the  setting  of  temporary  external  risk  factors  for  VTE, 
thromboprophylaxis is momentarily recommended even in non-deficient subjects.
46  
Hence, screening asymptomatic relatives of patients with protein S, protein C or 
antithrombin  deficiencies  may  be  unnecessary.  Of  note,  the  risk  of  bleeding 
associated with long-term oral anticoagulants in subjects with protein S, protein C 
or  antithrombin  deficiency  might  be  lower  than  is  reported  in  the  general 
population.
47 In chapter 6 we therefore assessed the absolute risks of VTE and the 
effect of screening on the VTE risk, in asymptomatic relatives of patients with 
protein  S,  protein  C  or  antithrombin  deficiency,  in  a  prospective  analysis.  The 
overall  VTE  risks  were  comparable  to  the  risks  of  VTE  in  our  previous 
retrospective  analysis,
48  which  was  performed  in  these  same  thrombophilic 
families. Hence, screening and subsequent prophylactic recommendations may not 
affect the overall risk of VTE in relatives of protein S, protein C or antithrombin 
deficient patients. However, thromboprophylaxis was utilized in only half of all 
high-risk  situations  and  still  a  trend  for  risk  reduction  of  provoked  VTE  was 
observed. Moreover, all provoked VTE occurred when thromboprophylaxis was 
not used, underlining the effectiveness of thromboprophylaxis in these deficient 
subjects.  On  the  other  hand  current  guidelines  strongly  recommend 
thromboprophylaxis  at  time  of  high-risk  situations  such  as  surgery, 
immobilizations  and  trauma,  even  in  non-deficient  subjects.
46  Consequently, 
augmentation  of  thromboprophylaxis  in  these  settings,  in  accourdance  with  the 
prevailing  guidelines,  may  make  screening  unnecessary  as  provoked  VTE  in 
deficient  subjects  would  then  also  be  reduced.  Exceptions  to  this  rule  may  be 
asymptomatic female relatives of patients with these deficiencies, as they are also 
exposed  to  higher  VTE  risk  during  pregnancy  and  oral  contraceptive  use.  The   Chapter 10   
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possible  relevance  of  discouraging  oral  contraceptive  was  demonstrated  by  the 
observation that 2 out of 6 deficient women using oral contraceptives developed 
VTE  during  oral  contraceptives  use  (chapter  6).  Therefore,  screening  of 
asymptomatic female relatives of patients with protein S, protein C or antithrombin 
deficiencies may be considered beneficial, because, if proven positive for the index 
deficiency, use of oral contraceptives should be discouraged in these women.  
 
Though the association of the known hereditary thrombophilic defects with VTE is 
well acknowledged, the risk of arterial thromboembolism (ATE) has been shown to 
be  only  slightly  increased  in  subjects  with  Factor  V  Leiden  or  prothrombin 
G20210A  mutation.
49  Data  on  the  association  of  protein  S,  protein  C  or 
antithrombin  deficiencies  with  ATE  is  based  on  case-series  and  case-control 
studies that reported inconsistent results.
30,31 As assessed in chapter 7, only protein 
S and protein C deficiencies, but not antithrombin deficiency, were risk factors for 
ATE before 55 years of age. That protein S and C deficiencies were found to be 
risk factors at young age could be ascribed to the fact that at higher age other ATE 
risk  factors  (i.e.  classic  atherosclerosis  risk  factors)  overrule  the  risk  of  ATE 
conferred  by  these  relatively  weak  risk  factors  (i.e.,  protein  S  and  protein  C 
deficiencies). Why only protein S and protein C deficiencies, but not antithrombin 
deficiency, were found to be associated with an increased risk of ATE might be 
due  to  non-anticoagulant  effects  of  protein  C  and  protein  S.
50-52  It  could  be 
speculated that the higher risk for ATE in subjects with protein C deficiency could 
be ascribed to the potent cytoprotective effects of the protein C pathway.
51 The 
higher risk for ATE in subjects with protein S deficiency may be explained by the 
fact that protein S is synthesized by endothelial cells,
52 whereas antithrombin is 
synthesized  by  hepatocytes.  Endothelial  injury  as  a  trigger  of  thrombosis  may 
therefore be enhanced by a preexisting defect in protein S synthesis at the site of 
injury.  Furthermore,  some  cytoprotective  effects  also  have  been  attributed  to 
protein S.
50,52  
 
In conclusion, even in thrombophilic families the risk of ATE is particularly driven 
by (classic) atherosclerosis risk factors. However, in young subjects without classic 
atherosclerosis risk factors, protein S or protein C deficiency increase the risk of 
ATE.  In  future  studies,  it  will  be  interesting  to  assess  any  synergetic  effects 
between thrombophilic defects and atherosclerosis risk factors for both venous and 
arterial thromboembolic events. Such studies, however, will be difficult to perform 
given the low prevalence of protein S, protein C and antithrombin deficiencies in Discussion and future perspectives 
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the general population as (very) large numbers of participants will be necessary for 
this  question.  For  the  more  prevalent  factor  V  Leiden  and  the  prothrombin 
G20210A mutation, however, such studies could be very well feasible.  
 
Risk of arterial thromboembolism in patients with prior venous 
thromboembolism 
Several studies have consistently shown that the risk of ATE in subjects with prior 
VTE is higher than in matched controls.
2,3,5,10,11 In contrast, studies in subjects with 
VTE reported contradictory results with respect to the presence of asymptomatic 
atherosclerotic lesions.
4,6,8,9,12 If atherosclerosis is not or less associated with VTE, 
it may be postulated that the higher risk of ATE after VTE is probably due to 
medical  conditions  that  predispose  to  both  VTE  and  ATE.  Examples  of  such 
predisposing  conditions  are  cancer,  antiphospholipid  antibodies,  infectious 
diseases, use of hormonal therapy and renal disease.  On the other hand, thrombus 
formation in each the arterial and venous system is due to platelet aggregation and 
coagulation activation, which may also explain the stronger and more consistent 
association of VTE with subsequent ATE, as compared to the association of VTE 
with asymptomatic atherosclerosis. Moreover, the high risk of ATE especially after 
idiopathic VTE indicates that the association of VTE with subsequent ATE is not 
only due to aforementioned predisposing conditions. Another remarkable fact is 
that the risk of ATE after VTE is particularly high in the first year after diagnosis 
of VTE,
11 as we also observed in chapter 8. This is surprising because the standard 
treatment for VTE, which consists of 3 to 6 months of oral anticoagulant drugs, 
should have lowered the risk of ATE. A possible explanation includes inaccuracy 
in  the  exact  dates  of  the  two  diagnoses,  because  data  were  based  on  hospital 
registries that may be prone to inaccurate date entry. Other possibilities include: 1) 
Failure to restart aspirin after cessation of anticoagulant therapy in patients who 
were on aspirin before VTE diagnosis. 2) In addition to the anticoagulant effects of 
vitamin  K  antagonists  by  blocking  γ  –  carboxylation  of  various  vitamin  K 
dependent coagulation factors in the liver, these drugs may also promote arterial 
calcification  by  blocking  γ  –  carboxylation  of  peripheral  vitamin  K  dependent 
proteins.
53-55 In a recent small cross-sectional study long-term (>10 years) use of 
vitamin K antagonists was indeed associated with increased extracoronary arterial 
calcification.
53 Two potentially important peripheral vitamin K dependent proteins 
are Matrix Gla protein (MGP) and Growth Arrest Specific gene 6 protein (Gas-6).
54 
These proteins have many diverse biologic functions. Produced by vascular smooth 
muscle  cells,  MGP  functions  primarily  as  a  vascular  calcification  inhibitor and   Chapter 10   
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Gas-6 affects vascular smooth muscle cell movement and apoptosis.
54 On the other 
hand, it should be mentioned that the vitamin K antagonists appeared effective in 
various trials in ATE prevention that could be ascribed to the anticoagulant effects 
of these drugs.
56,57 3) Finally, patients with VTE might be diagnosed earlier with 
subsequent ATE in the first year due to enrollment in the medical circuit. 
 
For  clinical  implications,  an  important  issue  that  warrants  attention  is  the 
effectiveness of statins in the prevention of VTE. It is assumed that the VTE risk 
reduction by these drugs is not due to their cholesterol-lowering effects, but rather 
to  the  pleiotropic  effects  of  statins.
42  These  include  particularly  endothelial 
stabilization that is accompanied by reduction of among others the tissue factor 
levels and reduction of thrombin generation.
42 The JUPITER trial indeed reported 
primary VTE risk reduction in the intervention arm with rosuvastatin as compared 
to the placebo-controlled arm.
58 Use of statin therapy in secondary preventions of 
VTE probably may have more clinical implications. Since patients with VTE have 
a high risk of recurrent VTE (about 5% in the first year)
59 and – as we know now – 
also an increased risk of ATE, prospective randomized trials are needed to address 
the effect of statin therapy on VTE recurrence and ATE incidence after a prior 
VTE. The Du Lac randomized trial will address this issue. In this trial, subjects 
with a VTE, after cessation of standard oral anticoagulants treatment of 6 months, 
will be randomized to a maintenance intervention-arm with rosuvastatin versus a 
control-arm with placebo. All patients will be followed for 2 years with recurrent 
VTE serving as the primary endpoint, and the development of ATE as one of the 
secondary endpoints. 
 
Renal disease and risk of venous and arterial thromboembolism 
As presented in chapter 1, renal disease with overt proteinuria predisposes to both 
VTE and ATE. Though this association was assumed for decades, the absolute 
risks were unknown, due to lack of data on large patient cohorts. In chapter 2 we 
assessed the absolute risk of VTE (1.02% per year) and ATE (1.48% per year), in a 
large cohort of patients with nephrotic-range proteinuria. These risks were each 
about 8-fold higher than the age- and sex-weighted absolute risks in the general 
population. Compared with the general population, the risk of both VTE (about 140 
fold) and ATE (about 50 fold) were particularly high in the first 6 months after 
diagnosis of nephrotic-range proteinuria. Therefore, one might consider primary 
thrombo-prophylaxis  during  this  period.  However,  given  the  bleeding  risk 
associated  with  the  use  of  anticoagulants,
45  in  the  setting  of  proteinuria-related Discussion and future perspectives 
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hypercoagulability, safer therapies such as antiproteinuric medications and statins 
warrants evaluation first. Indeed, our unpublished retrospective observational data 
in this same cohort of patients indicated that statin therapy was associated with a 
50% reduction of the VTE risk (data not shown). Furthermore, in chapter 5 we 
assessed the effect of antiproteinuric therapy (i.e. losartan alone or in combination 
with  diuretics  and/or  low  sodium  diet)  on  the  procoagulant  state  in  proteinuric 
patients. Antiproteinuric therapy indeed reversed the prothrombotic state in these 
patients,  re-emphasizing  the  importance  of  proteinuria  reduction  as  a  treatment 
target. The pathophysiological mechanisms responsible for the increased risk of 
thromboembolism  in  patients  with  nephrotic-range  proteinuria  are  unclear. 
Alterations in plasma levels of proteins involved in coagulation and fibrinolysis, 
urinary  antithrombin  loss,  enhanced  platelet  aggregation,  hyperviscosity,  and 
hyperlipidemia  are  all  considered  to  be  predisposing  factors.
34,60-62  Of  these, 
changes in the levels of plasma coagulation proteins and loss of antithrombin in the 
urine have been historically considered the main predisposing factors, especially 
for VTE. In contrast with these historical assumptions, we observed in chapter 5 
that  the  levels  of  plasma  antithrombin  levels  in  patients  with  proteinuria  were 
similar as in healthy controls, whereas all procoagulant proteins were elevated in 
these patients. Interestingly, except antithrombin, all pro- and other anticoagulant 
proteins  were  positively associated  with  the  extent  of  proteinuria  and  inversely 
associated with serum albumin. The higher levels of various coagulation proteins in 
patients with proteinuria are assumed to be secondary to the decrease in levels of 
serum  albumin,  as  in  response  to  this  decrease  in  serum  albumin  the  liver 
upregulates the production of all liver-synthesized proteins, including coagulation 
proteins  and  lipoproteins.
63  We  postulate  that  upregulation  of  antithrombin 
synthesis might be counterbalanced by urinary loss. Antithrombin has a relatively 
low molecular weight, comparable to the molecular weight of albumin, and will 
therefore easily leak via the glomeruli in (pre)urine. Indeed, in a small pilot study, 
including three patients with proteinuria ranging from 0.5 g/d to 1.5 g/d, we could 
confirm urinary loss of considerable amounts of antithrombin (6-21%).  
 
At the population level,  the association of  microalbuminuria or a mildly decreased 
eGFR (i.e. stage 1-3 chronic kidney disease, CKD) with thromboembolism is more 
relevant than that of nephrotic-range proteinuria, due to the higher prevalence of 
stage 1-3 CKD when compared to the prevalence of overt proteinuria (10-12% 
versus <0.1% of the general population, respectively).
64,65 Whereas the association 
of microalbuminuria and decreased eGFR with ATE is well-recognized,
35-40 we   Chapter 10   
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described for the first time the association of microalbuminuria (i.e. mainly stage 1-
2 CKD) with VTE in the Prevention of REnal and Vascular ENd-stage Disease 
(PREVEND)  study  (chapter  3).  The  association  of  decreased  eGFR  (i.e.  CKD 
stage 3-4) with VTE was for the first time described by the investigators of the 
Longitudinal Investigation of Thromboembolism Etiology (LITE) project, which 
comprises  the  pooled data  of  the  Atherosclerosis  Risk  in  Communities  (ARIC) 
study and the Cardiovascular Health Study (CHS).
41,66 As described in chapter 4 
the  association  of  decreased  eGFR  and  VTE  in  the  PREVEND  study  was 
particularly driven by the presence of albuminuria of ≥30 mg/24h, while the ARIC 
study suggested that microalbuminuria had no significant association with VTE 
risk,
66 and that only eGFR showed an inverse association with VTE incidence. 
These discrepancies between the ARIC and the PREVEND studies could possibly 
be ascribed to differences in characteristics of the enrolled study participants. In the 
PREVEND  study  increased  hazard  ratios  of  VTE  by  eGFR  level  have  been 
described that were comparable to those found in ARIC, but these did not reach 
statistical significance, which is likely due to limited power. In the PREVEND 
study a relatively limited number of subjects with more severely decreased eGFR 
participated. The PREVEND study is better powered to investigate the predictive 
value of albuminuria due to the enrichment of this study cohort with albuminuric 
subjects.  The  ARIC  study  on  the  other  hand,  is  probably  better  powered  for 
subjects with lower eGFR given the larger sample size and higher number of VTE 
events, but under-powered for albuminuria.
66 The weaker hazard ratio conferred by 
albuminuria in ARIC as compared to PREVEND, may be due to several reasons. In 
PREVEND albuminuria is assessed in 24hr urine samples, the gold standard, that 
were not frozen before assessment. Frozen storage is known to induce a systematic 
decrease and more variability in albuminuria concentration.
67 Furthermore, subjects 
with microalbuminuria in ARIC are mainly diabetics, while in PREVEND these 
are mainly non-diabetics, as per protocol insulin-using diabetics were excluded in 
PREVEND. This may have influenced the risk estimates, as diabetic subjects are 
usually on statin therapy and these subjects are more frequently treated for their 
cardiovascular morbidity with anti-platelet medication. To assess more definitively 
whether either eGFR or microalbuminuria or both are independent risk factors for 
VTE  we  are  currently  preparing  a  pooled  individual  patient  level  analysis  of 
several databases, among others PREVEND and ARIC to increase the statistical 
power to address this issue. 
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The exact pathophysiological mechanisms linking decreased eGFR and increased 
albuminuria to VTE have yet to be identified. However, endothelial dysfunction 
might  be  the  main  culprit  of  this  link  that,  in  turn,  is  associated  with  mild 
coagulation disturbances, such as increased levels of factor VIII and plasminogen 
activator inhibitor-1.
68-70 This is in contrast to the situation with nephrotic-range 
proteinuria,  in  which  coagulation  disturbances  probably  play  a  more  prominent 
role. However, these assumptions are merely based on literature, as we did not 
assess endothelial dysfunction in either microalbuminuric subjects or in patients 
with nephrotic-range proteinuria. In the near future we are planning to assess the 
exact coagulation disturbances in patients with microalbuminuria. Depending on 
the results, it will subsequently be interesting to assess the impact of antiproteinuric 
therapy  with  for  example  losartan  and  the  effect  of  statins  on  the  coagulation 
disturbances in subjects with microalbuminuria.  
 
As compared to the risk of VTE, the risk of ATE in patients with CKD is relatively 
better established. In a recent meta-analysis by the CKD Prognosis Consortium the 
independent association of both eGFR and albuminuria with ATE was confirmed, 
using pooled data of 21 general population-based cohorts with over one million 
study participants.
40 Separate meta-analyses of the same consortium addressing the 
same issues in other populations, such as those at high risk of CKD and those with 
known CKD, are currently submitted. Notably, the classification of CKD according 
to the 2002 KDOQI classification has been increasingly criticized in the field of 
nephrology.
71 These criticisms ranged from terminology, methodology, definition, 
classification to prognosis. Based on the four meta-analyses by the CKD Prognosis 
Consortium a proposal for a new guideline to reclassify CKD is being developed. 
Of note, this consortium is led by the department of Nephrology of the University 
Medical  Center  Groningen  and  the  department  of  Epidemiology  and  Clinical 
Research of the Johns Hopkins University in Baltimore, USA.  
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Conclusions 
In conclusion, VTE and ATE share some, such as obesity and renal disease, but not 
all risk factors as summarized in the above Figure. Even for those risk factors that 
seem to be associated with both VTE and ATE the associations with each of both 
endpoints  are  in  general  not  of  similar  strength.  There  may  be  at  least  one 
exception. Urinary protein loss, ranging from microalbuminuria to nephrotic-range 
proteinuria, turned out to be associated with similar relative risks for VTE and 
ATE. Based on the current available data, it seems therefore that VTE and ATE are 
probably  not  different  phenotypes  of  the  same  disease,  but  rather  different 
multifactorial  diseases  that  share  some  risks  factors.  Nevertheless,  a  shared 
preventative intervention might be beneficial that needs to be addressed in future 
studies. Especially, the role of albuminuria lowering by intervention in the renin-
angiotensin-aldosterone system and the use of statins are interesting and could be 
highly relevant for prevention of recurrent VTE and prevention of ATE in patients 
with a prior VTE.  
Figure. Association of risk factors with arterial and venous thromboembolism. 
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Hart- en vaatziektes vormen één van de meest voorkomende doodsoorzaken in de 
westerse  landen.  Hart-  en  vaatziekte  zoals  hartinfarct,  herseninfarct  en 
etalagebenen zijn meestal het gevolg van afsluiting of vernauwing van de slagaders 
(arteriën)  ten  gevolge  van  vaatwandverkalking  (atherosclerosis).  Wanneer  een 
dergelijke  vaatwandverkalking  loslaat  of  doorbreekt  in  de  vaatwand  kan  dit  tot 
lokale stolselvorming leiden. Afsluiting van de aders (venen) veroorzaakt vooral 
diep  veneuze  trombose  van  de  beenvaten,  overigens  zonder  echt 
vaatwandafwijkingen en vernauwing. De stolsels hierin kunnen vervolgens loslaten 
en verstopping in de longen geven (longembolie). Het ontstaansmechanisme van 
trombose in arteriën is anders dan van venen en de risicofactoren zijn ook niet 
dezelfde. Althans, dat werd van oudsher verondersteld. In de laatste 10 jaar hebben 
verschillende onderzoeken echter uitgewezen dat sommige risicofactoren voor de 
arteriële en veneuze trombose overlap vertonen. Ook is in meerdere onderzoeken 
waargenomen dat mensen met veneuze trombose een hoger risico hebben op het 
krijgen van arteriële trombose. Dat bij elkaar suggereert dat veneuze en arteriële 
trombose mogelijk met elkaar verbonden zijn of zelfs twee verschillende uitingen 
van dezelfde ziekte zijn.  
In het huidige proefschrift werd deze potentiële relatie tussen veneuze trombose en 
arteriële  trombose  onder  de  loep  genomen.  Dat  werd  bewerkstelligd  door  de 
associatie van arteriële risicofactoren met het optreden van veneuze trombose te 
onderzoeken en andersom de associatie van veneuze trombose risicofactoren met 
het optreden van arteriële trombose te onderzoeken. Nierziektes fungeren als rode 
draad in deze associatie tussen veneuze en arteriële trombose, waarbij de relatie 
van  nierziektes  met  beide  vormen  van  trombose  (veneus  en  arteriëel)  werd 
onderzocht. Daarnaast werd in het huidige proefschrift onderzocht wat het risico 
van arteriële trombose is bij patiënten met eerder doorgemaakte veneuze trombose. 
Associatie  tussen  klassieke  risicofactoren  van  arteriële  trombose  en  het 
optreden van veneuze trombose 
De  associatie  tussen  klassieke  risicofactoren  van  arteriële  trombose  zoals  hoge 
bloeddruk,  verhoogd  cholesterol,  suikerziekte  en  roken  met  het  optreden  van 
veneuze  trombose  werd  de  afgelopen  decennia  in  meerdere  onderzoeken 
beschreven,  maar  de  resultaten  zijn  vaak  inconsistent.  Deze  discrepantie  is 
waarschijnlijk te wijten aan de geselecteerde onderzoekspopulaties, de kwaliteit 
van data en het wel of niet corrigeren voor potentiële vertroebelende factoren zoals 
leeftijd.  Het  exact  verantwoordelijke  mechanisme  voor  deze  associatie  is  nog Appendix I 
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onbekend  maar  wordt  vooral  toegeschreven  aan  de  vaatwandschade,  wat  ook 
centraal staat in het optreden van arteriële trombose. In hoofdstuk 3 hebben wij de 
associatie tussen de klassieke risicofactoren van arteriële trombose en het optreden 
van veneuze trombose in de PREVEND studie onderzocht. De PREVEND studie 
was oorspronkelijk  in 1997 opgezet om de associatie tussen nierziektes en het 
optreden  van  met  name  arteriële  trombose  te  onderzoeken  in  een  grote  groep 
individuen  uit  de  algemene  Groningse  populatie.  In  totaal  hebben  ruim  8500 
individuen  uit  Groningen  in  de  leeftijd  van  28  t/m  75  aan  dit  onderzoek 
meegedaan.  Uit  onze  analyses  in  hoofdstuk  3  bleek  inderdaad  dat  meerdere 
risicofactoren voor arteriële trombose een verband lieten zien met het optreden van 
veneuze  trombose.  Echter,  dat  was  alleen  te  zien  in  ongecorrigeerde  analyses. 
Wanneer  wij  corrigeerden  voor  leeftijd  en  geslacht,  bleken  alleen  (ernstig) 
overgewicht en eiwitverlies in de urine (albuminurie) gerelateerd te zijn aan het 
optreden van veneuze trombose. Deze resultaten verklaren een belangrijke deel van 
de discrepanties in de literatuur. Namelijk dat leeftijdcorrectie zeer essentieel is, 
omdat leeftijd een risicofactor is voor zowel veneuze als arteriële trombose. Zo zijn 
er andere,  minder sterke vertroebelende factoren die in het ene onderzoek wel en 
in het andere niet meegenomen zijn, waardoor de resultaten discrepantie vertonen.   
Op  grond  van  het  huidige  proefschrift  en  de  bestaande  literatuur  kan  er 
geconcludeerd  worden  dat  de  klassieke  risicofactoren  voor  arteriële  trombose 
(hoge bloeddruk, verhoogd cholesterol, suikerziekte en roken) vooralsnog niet als 
bewezen  risicofactoren  voor  veneuze  trombose  beschouwd  kunnen  worden  (zie 
eventueel figuur aan het einde van dit hoofdstuk). Overgewicht daarentegen is in 
het  huidige  proefschrift  en  tevens  in  eerdere  onderzoeken  consistent  een 
risicofactor  voor  veneuze  trombose  gebleken.  Daarnaast  werd  in  het  huidige 
proefschrift voor het eerst gevonden dat albuminurie - een bekende risicofactor 
voor arteriële trombose - ook het  risico op veneuze trombose in dezelfde mate 
verhoogt. Deze nieuwe bevinding nodigt uit tot evaluatie van deze bevinding in 
andere onderzoeksgroepen en wordt later in dit hoofdstuk verder toegelicht. 
Erfelijke stollingsafwijkingen en het risico op arteriële en veneuze trombose 
De risicofactoren van veneuze trombose worden verdeeld in erfelijke en verworven 
risicofactoren. De meest bekende verworven risicofactoren voor veneuze trombose 
zijn immobilisatie, operatie of trauma, gipsen van een been, kanker, pilgebruik en 
zwangerschap. Er zijn vijf relevante erfelijke risicofactoren voor veneuze trombose 
waarvan twee vaak voorkomen en de andere drie relatief zeldzaam zijn. De twee Lay summary in Dutch   
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meest voorkomende erfelijke risicofactoren zijn factor V Leiden dat bij ongeveer 
5% van de Nederlandse populatie voorkomt en factor II mutatie dat bij ongeveer 2-
3% van de Nederlandse populatie voorkomt. De drie minder vaak voorkomende 
risicofactoren  zijn  antitrombine-,  proteïne  C-  en  proteïne  S  deficiëntie,  het 
vóórkomen waarvan tussen 0.1–0.4% varieert. Deze drie erfelijke risicofactoren 
voor  veneuze  trombose  zijn  in  vergelijking  met  de  twee  vaak  voorkomende 
risicofactoren,  namelijk  factor  V  Leiden  en  factor  II  mutatie,  relatief  sterke 
risicofactoren. Vanwege deze sterkere predispositie voor veneuze trombose door 
antitrombine, proteïne C en proteïne S deficiëntie wordt al jaren gediscussieerd 
door experts of gezonde familieleden van patiënten met deze erfelijke afwijkingen 
getest  moeten  worden  om  vroegtijdig  preventieve  maatregelen  te  nemen  bij 
degenen die positief worden getest. Echter, de zeldzaamheid van deze afwijkingen 
maakt dat de discussies over het wel of niet testen van gezonde familieleden zijn 
gebaseerd op expertopinies en niet op goed uitgevoerd onderzoek.  
In  hoofdstuk  6  hebben  we  in  een  grote  studie  84  families  met  erfelijke 
antitrombine, proteïne C of proteïne S deficiënties onderzocht. In dit onderzoek 
werd gekeken naar het risico van veneuze trombose in familieleden die ten tijde 
van testen op deze afwijkingen nog geen veneuze trombose hadden. Familieleden 
die  -  wat  deze  erfelijke  afwijkingen  betreft  -    positief  waren  getest  hebben 
vervolgens  adviezen  gekregen  om  tijdens  verhoogde  risicomomenten  zoals 
operaties,  trauma’s,  immobilisatie  en  gips  antistollingsmedicatie  te  gebruiken; 
vrouwelijke  familieleden  kregen  daarnaast  het  advies  om  geen  hormonale 
anticonceptie (de pil) te gebruiken. Ondanks deze maatregelen hebben in de loop 
van gemiddeld 9 jaar observatie toch nog 21 van de 149 familieleden met deze 
afwijkingen een veneuze trombose ontwikkeld. In de 233 familieleden zonder deze 
afwijkingen  hebben  slechts  6  mensen  veneuze  trombose  ontwikkeld.  Ter 
vergelijking, in ons eerder gepubliceerd onderzoek in dezelfde families was het 
risico op veneuze trombose voordat ze getest waren net zo groot als in het huidige 
onderzoek. Op grond hiervan kan men concluderen dat testen op deze afwijkingen 
geen gunstige effect heeft op het voorkómen van veneuze trombose. Echter, bij 
nadere  analyse  bleek  dat  de  voorzorgmaatregelen  en  preventieve  adviezen  in 
slechts 51% van de gevallen opgevolgd waren. Uit onze eerdere analyse in deze 
families bleek dat ongeveer de helft van het totaal aantal veneuze tromboses tijdens 
externe  hoog  risicomomenten  optraden.  Het  risico  op  veneuze  trombose  in 
aanwezigheid van externe hoog risicomomenten was nihil in de huidige analyse als 
de voorzorgsmaatregelen goed opgevolgd waren. Dit geeft aan dat het testen van Appendix I 
 
  185 
deze  individuen  wel  het  risico  op  veneuze  trombose  kan  verlagen  bij  positief 
geteste individuen, mits de voorzorgsmaatregelen goed opgevolgd worden. Echter, 
voorzorgsmaatregelen  in  de  vorm  van  antistollingstherapie  gedurende  hoge 
risicomomenten  zoals  chirurgie,  trauma,  gips  en  immobilisatie  worden 
tegenwoordig bij mensen zónder deze afwijkingen ook sterk geadviseerd, waardoor 
het testen op antitrombine, proteïne C en S deficiëntie mogelijk toch overbodig is. 
Vrouwen in de fertiele leeftijd die of de pil gebruiken of zwanger worden vormen 
een  uitzondering  want  zij  hebben  waarschijnlijk  baat  bij  staken  van  vooral  het 
“Pil”-gebruik. Dit suggereert dat testen van jonge vrouwelijke familieleden van 
patiënten  met  deze  afwijkingen  overwogen  moet  worden.  Om  hierover  solide 
uitspraken te kunnen doen is verder onderzoek nodig. Het uitvoeren van dergelijk 
onderzoek  is  echter  zeer  moeilijk  vanwege  de  zeldzaamheid  van  beschikbare 
kandidaten  voor  dit  soort  onderzoek.  Mogelijk  kan  een  internationale 
samenwerking een oplossing bieden. 
Het  hoge  risico  op  veneuze  trombose  in  patiënten  met  de  deficiënties  van 
antitrombine, proteïne C en proteïne S is al lang bekend. De associatie van deze 
afwijkingen met het optreden van arteriële trombose is daarentegen veel minder 
bekend en goede onderzoeken daarnaar ontbraken tot op heden. In hoofdstuk 7 
hebben we de associatie tussen antitrombine, proteïne C en proteïne S deficiënties 
met het optreden van arteriële trombose in dezelfde 84 families onderzocht. Terwijl 
het  risico  op  veneuze  trombose  het  hoogst  is  bij  individuen  met  antitrombine 
deficiëntie,  bleken  voor  het  optreden  van  arteriële  trombose  deficiënties  van 
proteine  C  en  S  risicofactoren  te  zijn,  terwijl  antitrombinedeficiëntie  geen 
risicofactor  vormde  voor  arteriële  trombose.  Deze  bevinding  suggereert  dat  de 
gevonden associatie tussen proteïne C of proteïne S deficiënties met het optreden 
van  arteriële  trombose  waarschijnlijk  niet  direct  het  gevolg  is  van  verhoogde 
stollingsneiging  maar  eerder  het  gevolg  is  van  vaatwandschade.  Uit  andere 
onderzoeken is gebleken dat deficiënties van proteïne C en proteïne S mogelijk een 
rol spelen bij vaatwandschade. Het is vermeldenswaardig dat het verhoogde risico 
op  arteriële  trombose  bij  individuen  met  proteïne  C  en  proteïne  S  deficiënties 
vooral duidelijk was vóór de leeftijd van 55 jaar. Het risico op arteriële trombose 
nà 55 jaar werd vooral bepaald door de aanwezigheid van klassieke risicofactoren 
voor arteriële trombose, zoals hoge bloeddruk, verhoogd cholesterol, suikerziekte 
en  roken.  Voor  antitrombinedeficiëntie  was  geen  verschil  voor  de  leeftijd  van 
jonger of ouder dan 55 jaar. Concluderend, het risico op arteriële trombose speelt Lay summary in Dutch   
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in families met proteïne C of proteïne S deficiënties wel een (enige) rol op jonge 
leeftijd. Dat geldt niet voor families met antitrombinedeficiëntie. 
Risico op arteriële trombose in patiënten met eerder doorgemaakte veneuze 
trombose 
Het is bekend dat patiënten met een arteriële trombose vooral herseninfarct, een 
verhoogd risico op veneuze trombose hebben. Een omgekeerde relatie, namelijk 
een verhoogd risico op arteriële trombose in patiënten met veneuze trombose is 
nieuw. Dit laatste werd ook in hoofdstuk 8 bevestigd. Er bleek dat vooral in het 
eerste jaar na veneuze trombose het risico op arteriële trombose het hoogst is. Dat 
is enigszins tegenstrijdig met de verwachtingen, want na veneuze trombose wordt 
standaard  antistollingsmedicatie  gebruikt  voor  de  duur  van  meestal  6  maanden. 
Deze  antistollingsmedicatie  wordt  ook  dikwijls  ingezet  in  de  behandeling  van 
arteriële trombose en is daarmee effectief in de preventie van arteriële trombose. Er 
zijn  meerdere  mogelijkheden  die  deze  onverwachte  bevinding  zouden  kunnen 
verklaren, zoals onbetrouwbare data omtrent de volgorde van veneuze en arteriële 
trombose  als  deze  dicht  bij  elkaar  zijn  op  getreden,  of  het  niet  herstarten  van 
preventieve medicatie zoals aspirine na stoppen van antistolling, gegeven voor de 
veneuze trombose. Daarnaast is het gebruik van vitamine K antagonisten (volgens 
sommige  recente  experimentele  onderzoeken)  met  progressie  van 
vaatwandverkalking gerelateerd. 
Een  ander  zeer  relevant  punt  in  dit  opzicht  is  waarschijnlijk  het  effect  van 
statinentherapie (cholesterolverlagende  medicatie)  op verlaging van het veneuze 
tromboserisico. Uit een aantal onderzoeken is gebleken dat het gebruik van statinen 
het risico niet alleen op arteriële trombose waarvoor deze medicamenten gebruikt 
worden verlaagt, maar ook het risico op veneuze trombose kan verlagen. Echter, de 
veneuze  trombose  risicoverlaging  wordt  niet  toegeschreven  aan  de 
cholesterolverlagende  effecten  van  deze  medicatie,  maar  aan  neveneffecten  van 
statinen op de vaatwand en de stolling. Vanwege het zeer gunstige profiel van 
bijwerkingen van statinen, kunnen deze middelen vooral zeer goed ingezet worden 
in de preventie van recidief veneuze trombose nadat antistollingstherapie gestaakt 
wordt. Het risico op recidief veneuze trombose is vooral in het eerste jaar na staken 
van  antistolling  hoog  (ongeveer  5%).  Daarnaast  zal  statinegebruik  preventief 
werken tegen het optreden van arteriële trombose, waarop het risico vooral in het 
eerste jaar na veneuze trombose het hoogst is Appendix I 
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Nierziektes en het risico op veneuze en arteriële trombose 
Sinds meer dan een halve eeuw is bekend dat overmatig eiwitverlies in de urine 
(proteïnurie)  van  meer  dan  3.5  gram  per  24  uur,  ook  wel  nefrotisch-range 
proteïnurie genoemd, het risico op vooral veneuze trombose en waarschijnlijk ook 
op arteriële trombose verhoogt. Vanwege de zeldzaamheid van deze aandoening, 
zijn  de  beschikbare  gegevens  over  dit  onderwerp  gebaseerd  op  kleine  groepen 
patiënten en het is daarom niet bekend in hoeverre precies het risico op veneuze en 
arteriële trombose verhoogd is bij deze patiënten. In hoofdstuk 2 hebben we het 
absolute risico op zowel veneuze als arteriële trombose in een relatief grote groep 
(n=298) patiënten onderzocht. De risico’s op zowel veneuze als arteriële trombose 
waren in dezelfde mate verhoogd (ongeveer 8 keer) in vergelijking tot de algemene 
populatie van dezelfde leeftijd en geslacht. Het risico op zowel veneuze (ongeveer 
140 keer) als arteriële trombose (ongeveer 50 keer) waren het hoogst in de eerste 6 
maanden  na  diagnose  van  nefrotisch-range  proteïnurie.  Op  grond  van  deze 
resultaten  kan  het  gebruik  van  antistollingsmedicatie  overwogen  worden  in  de 
eerste  6  maanden  na  diagnose.  Echter,  gebruik  van  antistollingsmedicatie  is 
geassocieerd  met  hoge  risico’s  op  ernstige  bloedingen.  Daarom  zal  er  gezocht 
moeten worden naar meer veilige alternatieven. Te denken valt aan statinengebruik 
en behandeling van de proteïnurie zelf door middel van vooral renine-angiotensine-
aldosteron  systeem  remmers.  In  dit  opzicht  hebben  we  in  deze  zelfde  groep 
patiënten  de  invloed  van  statinengebruik  op  veneuze  trombose  onderzocht.  Het 
bleek dat statinengebruik inderdaad ongeveer 50% veneuze trombose risicoreductie 
bewerkstelligde (data niet opgenomen in het huidige proefschrift). Verder hebben 
we  in  hoofdstuk  5  de  invloed  van  losartan  (een  renine-angiotensine-aldosteron 
systeem remmer) op de tromboseneiging (protrombotische staat) bij een groep van 
32  patiënten  met  overmatige  proteïnurie  geëvalueerd.  Zoals  verwacht  werd  de 
protrombotische staat gedeeltelijk hersteld door reductie van proteïnurie middels 
losartan.  Het  pathofysiologische  mechanisme  van  de  protrombotische  staat  bij 
patiënten  met  overmatige  proteïnurie  wordt  toegeschreven  aan  de  daling  van 
albuminespiegels in het bloed, waardoor de lever meer stollingseiwitten aanmaakt. 
Verder wordt één van de belangrijkste antistollingseiwitten, namelijk antitrombine, 
verondersteld  verloren  te  gaan  in  de  urine  omdat  dit  eiwit  even  groot  is  als 
albumine. In dit kader hebben we urine van drie willekeurige patiënten onderzocht 
op  verlies  van  antitrombine.  Alle  drie  patiënten  bleken  inderdaad  meetbaar 
antitrombineverlies te hebben in de urine. Lay summary in Dutch   
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In vergelijking tot overmatige proteïnurie of nefrotisch-range proteïnurie, hebben 
microalbuminurie  (kleine  hoeveelheid  albumine  in  de  urine)  en/of  verminderde 
nierfunctie  een  veel  groter  belang  op  populatieniveau  omdat  dit  veel  vaker 
voorkomt. Ongeveer 10-12% van de algemene populatie heeft microalbuminurie 
en/of  een  verminderde  nierfunctie.  De  relatie  van  microalbuminurie  en 
verminderde nierfunctie met arteriële trombose is relatief goed bekend, maar of 
deze ook met veneuze trombose gerelateerd zijn was tot recent onbekend. Zelf 
hebben wij dit voor het eerst onderzocht voor de microalbuminurie; eerder werd 
deze relatie voor het eerst door Amerikaanse onderzoekers onderzocht voor de rol 
van  de  verminderde  nierfunctie.  Zowel  microalbuminurie  in  ons  PREVEND 
onderzoek  (hoofdstuk  3)  als  een  verminderde  nierfunctie  in  het  Amerikaanse 
onderzoek waren gerelateerd aan het optreden van veneuze trombose. Wij hebben 
tevens gekeken naar de verminderde nierfunctie in ons onderzoek in hoofdstuk 4. 
Wij  vonden  vergelijkbare  resultaten  in  ons  onderzoek  als  in  het  Amerikaanse 
onderzoek over nierfunctie. Daarnaast vonden wij dat een verminderde nierfunctie 
vooral  een  risicofactor  voor  veneuze  trombose  was    in  aanwezigheid  van 
microalbuminurie. Dat laatste was niet het geval in het  Amerikaanse onderzoek. 
Deze verschillen kunnen meerdere oorzaken hebben. Het beste kan dit verklaard 
worden  door  verschillen  in  de  onderzochte  populatie.  Aan  het  Amerikaanse 
onderzoek hebben bijvoorbeeld veel suikerziektepatiënten deelgenomen en deze 
patiënten  hebben  heel  vaak  microalbuminurie,  maar  worden  behandeld  met 
statinen. Zoals eerder beschreven kunnen statinen het risico op veneuze trombose 
reduceren en hierdoor zou het risico van microalbuminurie op veneuze trombose 
mogelijk  tenietgedaan  zijn.  Daarentegen,  in  ons  onderzoek  waren 
suikerziektepatiënten die insuline gebruikten buiten de studie gebleven. Om deze 
nader  te  onderzoeken  hebben  we  de  Amerikaanse  onderzoekers  en  een  aantal 
andere  onderzoekers  die  over  dergelijke  gegevens  beschikken  voor  een 
samenwerking  uitgenodigd.  Na  het  samenvoegen  van  meerdere  deelnemende 
onderzoeken zal het mogelijk zijn om de verschillen en de effecten van vooral 
suikerziektepatiënten nader te onderzoeken betreffende  dit onderwerp. Tot slot, het 
pathofysiologische mechanisme van het verhoogde tromboserisico in patiënten met 
microalbuminurie  en  verminderde  nierfunctie  wordt  toegeschreven  aan 
gegeneraliseerde vaatwandschade. 
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Conclusies: 
Concluderend,  niet  alle  maar  sommige  risicofactoren  zoals  nierziektes  en 
overgewicht lijden tot zowel veneuze als arteriële trombose welke samengevat zijn 
in  bovenstaande  Figuur.  Op  grond  van  het  huidige  proefschrift  en  eerder 
gepubliceerde  gegevens,  zijn  veneuze  trombose  en  arteriële  trombose  geen 
verschillende uitingen van dezelfde ziekte maar twee multifactoriële ziektes die 
sommige  risicofactoren  gemeenschappelijk  hebben.  Desalniettemin,  een 
gemeenschappelijke  interventie  om  zowel  veneuze  als  arteriële  trombose  te 
voorkómen zal waarschijnlijk resulteren in effectieve preventie van beide soorten 
trombose  in  een  geselecteerde  groep  patiënten.  Dit  zal  vooral  nierpatiënten  en 
patiënten met eerder doorgemaakte veneuze trombose betreffen, waar het effect 
van statinen hopelijk veelbelovende resultaten zal geven in de preventie van zowel 
recidief veneuze trombose als het optreden van arteriële trombose. 
Figuur.  Associatie  van  verschillende  risicofactoren  met  arteriële  (AT)  en 
veneuze trombose (VT).  
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Wat ik vandaag ben, wat ik bereikt heb, schrijf ik toe aan mijn naasten, met name 
mijn ouders. Als mijn ouders niet naar Nederland waren geëmigreerd, had ik nooit 
de vele kansen die hier in Nederland beschikbaar zijn, kunnen benutten. Ik denk 
dat velen, die hier geboren en getogen zijn, dat helaas niet beseffen. Ik ben mijn 
ouders zeer dankbaar voor de opvoeding en steun. 
 
Mijn research inspiratie heb ik te danken aan wijlen professor Jan van der Meer. 
Zijn  enthousiasme,  energie  en  plezierige  manier  van  omgang  met  patiënten, 
collega´s en vrienden maakten hem een zeer uniek persoon. Toen hij nog mijn 
begeleider was ging ik vaak na mijn coschappen nog naar het UMCG om aan mijn 
onderzoek te werken, ook al was het 20:00 uur. Zelfs dan was hij vaak aanwezig, 
en we voerden dan lange discussies over onderzoek, over verleden en heden. Hij 
was  niet  alleen  mijn  begeleider  maar  ook  een  goede  vriend.  Zijn  plotselinge 
overlijden in januari 2009 heeft op mij veel impact gehad. Ik zou nog in 2009 mijn 
promotie afronden, maar helaas werd dat pas eind 2010. Ik kan niet in genoeg 
woorden beschrijven hoe dankbaar ik ben voor zijn hulp, niet alleen op het gebied 
van onderzoek, maar ook voor mijn verblijfsvergunning. Hij is speciaal voor mij 
twee keer naar de Tweede Kamer gegaan. Ook al heeft dat geen effect gehad, hij 
heeft alles gedaan wat hij kon zodat ik en mijn familie een verblijfsvergunning 
zouden kunnen krijgen. Normaliter noem ik professoren nooit bij hun voornaam, 
maar hem moest ik, op eigen verzoek, 'Jan' noemen. Jan, heel erg bedankt voor 
alles wat je voor mij gedaan hebt! Deze thesis was nooit tot stand gekomen zonder 
jou! 
 
Na het verlies van Jan heeft professor Hanneke Kluin-Nelemans mijn begeleiding 
overgenomen.  Professor  Kluin-Nelemans,  ik  ben  u  zeer  dankbaar  voor  de 
overname van mijn begeleiding. Uw manier van begeleiding was anders dan van 
Jan, namelijk meer formeel. Ik herkende toch  ook veel van Jan in uw begeleiding, 
namelijk  de  snelheid  van  nakijken  en  de  manier  van  commentaar,  vooral  de 
tekstuele bewoording. Zonder uw begeleiding was mijn promotie zeker in gevaar 
gekomen. Andere begeleiders die ik graag van harte wil bedanken zijn professor 
Gerjan Navis, ook al had ik mijn promotie primair bij hematologie, u heeft in de 
combinatie met nefrologie een onmisbare rol gespeeld. Ik heb regelmatig van u 
zeer  waardevol  commentaar  gekregen,  met  name  bij  de  totstandkoming  van  de 
introductie en de discussie van de huidige thesis.  Dr. Ron Gansevoort, hartelijk 
dank voor de PREVEND data en uw begeleiding en waardevolle commentaren op 
de PREVEND data stukken, mijn introductie en discussie. Tevens heel erg bedankt Appendix II 
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voor het regelen van mijn post-doctoraal-plaats in Baltimore, VS. Zonder uw hulp 
was  ik  nooit  bij  de  nummer  1  epidemiologieschool  ter  wereld  binnengekomen. 
Zowel  Dr.  Gansevoort  als  professor  de  Jong  hartelijk  dank  voor  u  hulp  bij  de 
subsidieaanvragen.  Dr.  Nic  Veeger,  van  u  heb  ik  veel  over  statistiek  geleerd 
waarvoor ik zeer dankbaar ben. We hadden weleens meningsverschillen over de 
anlysemethodes waarbij Jan als tussenpersoon kwam. Voor ons JAMA stuk hebben 
we zelfs externe expertise gevraagd bij professor Hillege, professor Roosendaal 
(Leiden) en professor Prins (Maastricht). Aan het einde had iedereen gelijk! Dat is 
de wereld van onderzoek en epidemiologie. In het kader van wetenschappelijke 
betrokkenheid  bij  mijn  proefschrift  wil  ik  ook  alle  andere  co-auteurs  van  mijn 
stukken  bedanken,  te  beginnen  bij  degene  met  wie  ik  dagelijks  ook  op  de 
werkvloer  contact  had,  namelijk  Min  Ki  ten  Kate,  Mohammad  Resh,  Inge  van 
Schouwenburg, René Mulder en Willem Lijfering. Andere co-auteurs met wie ik 
op afstand met veel plezier samengewerkt heb zijn: Andre Mulder, Jan-Leendert 
Brouwer,  Femke Waanders, Gozewijn Laverman, Maartje Slagman, Liffert Vogt,  
Professor  Hillege,  dr.  Spronk  (Maastricht),  professor  ten  Cate    (Maastricht), 
Gurbey  Ocak  (Leiden),  dr.  Verduijn  (Leiden),  dr.  Vossen  (Leiden),    professor 
Dekker (Leiden), professor Rosendaal (Leiden) en dr. Matthews (New York). Jan-
Leendert tevens bedankt voor het DESCARTES database waarop 2 hoofdstuken 
van de huidige thesis gebaseerd zijn. 
 
De leden van de beoordelingcommissie, professor F.R. Rosendaal, professor H. ten 
Cate en professor P.M. ter Wee, heel erg bedankt voor het beoordelen van mijn 
proefschrift. Tevens wil ik de leden van de oppositie van harte bedanken voor hun 
deelname en beoordeling. 
 
Ik  vind  het  zeer  belangrijk  om  alle  mensen  op  het  werkvloer  van  de  afdeling 
stolling  te  bedanken.  Allereerst  Ina,  heel  erg  bedankt  voor  al  jouw  hulp  met 
logistieke dingen rondom mijn verdediging, voor het nakijken van mijn Nederlands 
geschreven teksten op potentiële taalfouten en voor de gezellige sfeer. Zonder jouw 
hulp  bij  de  laatste  loodjes  was  de  logistiek  van  mijn  verdediging  zeker  in 
problemen gekomen. Heel erg bedankt voor je to do lists! I very much appreciated 
that! Verder wil ik al mijn nog niet genoemde kamergenoten bedanken voor de 
goede tijden: Marja, Pyteke, Lucia, Inge, Patricia, Femke, Greetje en Jan Blauw, 
bedankt voor de  leuke tijd en voor de vele koppen thee die jullie voor mij hebben 
opgehaald. Stollingsartsen: Marieke, Vladimir, Anja en Marjan, heel erg bedankt 
voor  de  leuke  discussies  en  gezellige  tijd  op  congressen,  looking  forward  naar Acknowledgment 
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jullie eigen promotie. En sorry voor het regelmatig komen buurten bij jullie. Ik heb 
jullie vast regelmatig afgeleid. Karina Meijer, de huidige leider van de afdeling wil 
ik  niet  alleen  bedanken,  maar  ook  complimenteren  met  het  zeer  succesvol 
voortzetten van het werk van Jan. Alle personeel van de stollingslab bedankt voor 
de uitgevoerde bepalingen voor mijn onderzoek. In het bijzonder, Victor bedankt 
voor de hevige discussies over onderwerpen op gebied van stolling en proteinurie.  
 
Beste Inge en Min Ki, heel erg bedankt voor jullie hulp bij de logistiek van mijn 
verdediging. Heel erg bedankt voor het paranimfschap bij mijn verdediging en voor 
de  organisatie  ervan.  Zoals  eerder  genoemd  Ina  is  onmisbaar  geweest  in  de 
organisatie  proces.  In  het  geregel  rondom  mijn  verdediging  heeft  mijn  broertje 
Moswar ook heel veel tijd gestoken. Heel erg bedankt “workia”! Mijn goede vriend 
Mohammad, heel erg bedankt voor de hulp bij de opmaak van de cover van mijn 
proefschrift en voor de leuke tijd op het werk en op de ACLO. Blijf trainen! 
 
Verder  wil  ik  mijn  zusjes  bedanken  voor  het  lekkere  koken  elke  avond.  Mijn 
oudste zusje, jij hebt het meest gekookt. Ook al had je het druk met jouw studie, 
voor  koken  heb  je  altijd  tijd  gemaakt.  Zonder  jou  was  het  een  stuk  zwaarder 
geweest, dat heb ik inmiddels in Baltimore wel gemerkt!  
 
Als laatste, maar niet minste, beste oom en tante, mijn verloofde, alle vrienden en 
kennissen, mijn docenten van het Noorderpoortcollege en begeleiders tijdens mijn 
geneeskundestudie, heel erg bedankt voor de kennis en/of plezier. Alle aanwezigen 
bij de verdediging en het feest, bedankt voor jullie komst.  
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Bakhtawar Khan Mahmoodi werd op 14 april 1983 in Khost, Afghanistan, geboren.  
Aldaar  volgde  hij  het  lager  onderwijs  en  een  deel  van  zijn  middelbare 
schoolonderwijs. In 2001, op de leeftijd van 18 jaar emigreerde hij, samen met zijn 
ouders, broertjes en zusjes naar Nederland. In 2002 werd hij toegelaten tot het 
voorbereidend  jaar  van  het  Noorderpoortcollege  te    Groningen,  om  de  1-jarige 
voorbereiding voor het Nederlands hoger onderwijs, inclusief de Nederlandse taal 
te  volgen.  Na  een  succesvolle  afronding  van  dit  voorbereidend  jaar  werd  hij 
ingeloot voor de studie geneeskunde aan de Rijksuniversiteit Groningen. Om de 
opleiding geneeskunde enigszins uitdagender te  maken is hij vanaf zijn tweede 
studiejaar begonnen met wetenschappelijk onderzoek. In 2007 werd hij toegelaten 
tot  het  MD/PhD  traject  van  de  Junior  Scientific  Masterclass.  In  een  dergelijke 
traject wordt de studie geneeskunde verlengd met 2 jaar, wat fulltime onderzoek 
inhoudt.  In  zijn  geval  werd  de  studie  geneeskunde  voor  slechts  8  maanden 
verlengd. Hij heeft in mei 2010 zijn artsexamen met cum laude gehaald. Vanaf 
oktober  2010  is  hij  begonnen  als  post-doctoraal  fellow  bij  de  afdeling 
epidemiologie  van  de  prestigieuze  Johns  Hopkins  School  of  Public  Health  in 
Baltimore, VS. Na afloop van zijn fellowship in de VS, dat in totaal 2 jaar zal 
duren,  is  hij  voornemens  om  terug  te  keren  naar  Nederland.  Daar  zal  hij  de 
opleiding tot medisch specialist gaan volgen. Hij is er nog niet helemaal uit wat 
betreft de keuze van de vervolgopleiding, maar interne geneeskunde, cardiologie en 
chirurgie staan op zijn lijst. 
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Bakhatwar Khan Mahmoodi was born on 14 april 1983 in Khost, Afghanistan. In 
2001 at the age of 18 he immigrated together with his parents to the Netherlands, as 
a refugee. He went for about 3 years to secondary and 6 years to primary school. 
He did not attend secondary school in the Netherlands. After extensive self study 
and  learning  of  the  Dutch  language,  he  passed  the  state  admission  exams  for 
Medical School in 2003 and was admitted for Medicine at the State University of 
Groningen.  From  2005,  his  second  year  of  Medicine,  he  started  research  as  a 
student-assistant and in October 2007 he was selected for the PhD program. The 
official MD/PhD program is 8 years in total, with 2 years of full-time research. In 
his case, he was able to combine the research for his PhD thesis with his training 
for the MD degree. Consequently only about 1/2 year of his PhD activities were 
conducted  full-time.  His  remaining  PhD  activities  were  combined  with 
internships/rotations. He graduated cum laude from Medical School in May 2010. 
Starting from October 2010 he will be doing a total of two years postdoctoral 
fellowships at the department of epidemiology of the prestigious Johns Hopkins 
school  of  Public  Health.  After  his  fellowships  in  Baltimore,  he  is  planning  to 
specialize in either internal medicine, cardiology, or surgery. 